


INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁵ : C07C 233/81, C07D 327/06 C07D 319/12, 339/08, 307/68 C07C 333/08, 275/34 C07D 333/38, C07F 9/24 A61K 31/38</p>	A1	<p>(11) International Publication Number: WO 91/05761</p> <p>(43) International Publication Date: 2 May 1991 (02.05.91)</p>									
<p>(21) International Application Number: PCT/US90/05760</p> <p>(22) International Filing Date: 9 October 1990 (09.10.90)</p> <p>(30) Priority data:</p> <table border="0"> <tr> <td>421,155</td> <td>16 October 1989 (16.10.89)</td> <td>US</td> </tr> <tr> <td>567,982</td> <td>15 August 1990 (15.08.90)</td> <td>US</td> </tr> <tr> <td>588,208</td> <td>26 September 1990 (26.09.90)</td> <td>US</td> </tr> </table> <p>(71) Applicants: UNIROYAL CHEMICAL LTD./UNIROYAL CHEMICAL LTEE [CA/CA]; 25 Erb Street, Elmira, Ontario N3B 3A3 (CA). UNIROYAL CHEMICAL COMPANY, INC. [US/US]; World Headquarters, Middlebury, CT 06749 (US).</p> <p>(72) Inventors: HARRISON, William, A. ; 38 Arthur Street N., Guelph, Ontario N1E 4T8 (CA). JEWELL, Gary, E. ; 206 Alma Street N., Guelph, Ontario N1H 5X5 (CA). FELAUER, Ethel, E. ; RR #1, Puslinch, Ontario N0B 2J0 (CA). DEKEYSER, Mark, A. ; 333 Boxbury Drive, Waterloo, Ontario N2K 1W3 (CA). CONG, Dong, D. ; 318 Paisley Road, Guelph, Ontario N1H 2P9 (CA). McGUINNESS, James, A. ; 38 Highland Avenue, Apt. #210, Naugatuck, CT 06770 (US). MISHRA, Anupama ; 28 Kendrick Avenue, Guelph, Ontario N1G 2P7 (CA). BROUWER, Walter, G. ; 15 Hickory Street, Guelph, Ontario N1G 2X2 (CA). McPHEE, Derek, J. ; 109-252 Stone Road West, Guelph, Ontario (CA).</p>		421,155	16 October 1989 (16.10.89)	US	567,982	15 August 1990 (15.08.90)	US	588,208	26 September 1990 (26.09.90)	US	<p>(74) Agents: SHEDDEN, John, A. et al.; Uniroyal Chemical Company, Inc., World Headquarters, Middlebury, CT 06749 (US).</p> <p>(81) Designated States: AT (European patent), AU, BE (European patent), BR, CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FI, FR (European patent), GB (European patent), GR (European patent), HU, IT (European patent), JP, KR, LU (European patent), NL (European patent), NO, SE (European patent), SU.</p> <p>Published With international search report.</p>
421,155	16 October 1989 (16.10.89)	US									
567,982	15 August 1990 (15.08.90)	US									
588,208	26 September 1990 (26.09.90)	US									

(54) Title: TREATMENT OF HIV INFECTIONS AND COMPOUNDS USEFUL THEREIN



(57) Abstract

A method of inhibiting the growth or replication of viruses of the HIV group is disclosed. Also disclosed are compounds useful in the method and pharmaceutical formulations incorporating such compounds. The method involves the use of compounds having general formula (I), wherein the substituent groups are as defined in the specification.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MR	Mauritania
BE	Belgium	GA	Gabon	MW	Malawi
BF	Burkina Faso	GB	United Kingdom	NL	Netherlands
BG	Bulgaria	GR	Greece	NO	Norway
BJ	Benin	HU	Hungary	PL	Poland
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	SD	Sudan
CF	Central African Republic	KP	Democratic People's Republic of Korea	SE	Sweden
CG	Congo	KR	Republic of Korea	SN	Senegal
CH	Switzerland	LI	Liechtenstein	SU	Soviet Union
CI	Côte d'Ivoire	LK	Sri Lanka	TD	Chad
CM	Cameroon	LU	Luxembourg	TC	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark				

5

TREATMENT OF HIV INFECTIONS AND COMPOUNDS USEFUL THEREINBACKGROUND OF THE INVENTION

This is a Continuation-In-Part of U.S. Serial No.
10 567,982 filed August 15, 1990 which is a Continuation-In-
Part of U.S. Serial No. 421,155 filed 16 October, 1989.

1. Field of the Invention

This invention relates to treatment for inhibiting
15 the growth or replication of viruses of the Human
Immunodeficiency Virus (HIV) group, to compounds useful
therein, and to pharmaceutical formulations
incorporating such compounds.

20 2. Background of the Invention

Viruses are the smallest known infectious agents.
They are made up of a nucleic acid (either
Deoxyribonucleic Acid (DNA) or Ribonucleic Acid (RNA))
and viral proteins which are encased in a protein shell.

25 Viral infections, as a group, are among the most
difficult infections to treat because of the way viruses
replicate and interact with the cells which they
infect. Thus current methods of treatment directed
towards preventing the growth or replication of viruses
30 often result in some degree of disturbance to the host
cell's metabolism, with resultant toxicity to the host
cells.

Generally, viruses first bind to the outer membrane of a particular host cell. After binding occurs, the viral nucleic acids (DNA or RNA) along with selected viral proteins enter into the host cell.

5 The viral nucleic acids then take over the metabolic machinery of the host cell and force the host cell to produce viral nucleic acid and proteins, which then assemble and are eventually released from the cell. Since release of the virus causes the cell membrane to
10 rupture, a completed viral replication cycle results in the death of the host cell.

Viruses are generally divided into DNA or RNA viruses (depending on the type of nucleic acid they contain) and are further subdivided into various
15 families.

Retroviruses are RNA viruses which contain high molecular weight RNA, traces of DNA, and various enzymes, including reverse transcriptase and nucleases enclosed by a protein coating. This type of virus first
20 binds to the outer membrane of an appropriate cell, followed by injection of viral RNA and reverse transcriptase into the host cell.

Reverse transcriptase uses the viral RNA as a template to produce a complimentary DNA strand. This
25 DNA becomes incorporated into the host's DNA and causes the host cell to produce viral RNA and viral proteins.

A subgroup of viruses in the Retrovirus family comprises human immunodeficiency viruses (HIV), which

are known to preferentially attack cells of the human immune and nervous systems. HIV-I is the designation of the virus that is one of the etiologic agents for the development of Acquired Immune Deficiency Syndrome

5 ("AIDS") in humans. It is known that HIV is transmitted by the exchange of bodily fluids, such as sexual secretions and blood, e.g., as a result of sexual contact, transfusions, or sharing of needles, for instance by intravenous drug users.

10 The HIV group infects and destroys the CD-4-T-lymphocytes (helper T-lymphocytes) and cells of the central nervous system.

Helper-T lymphocytes are vital to the immune system and are necessary for the immune system to be able to
15 fight off opportunistic organisms such as Pneumocystis carinii (which causes pneumonia), Toxoplasma gondii (Toxoplasmosis), viral infections caused by Herpes and Varicella viruses and also to prevent the formation of certain cancers, the most notable being Kaposi's Sarcoma.

20 Loss of these cells by HIV infection, either quantitatively or functionally, eventually leads to the loss of ability of the human immune system to fight off these diseases. Helper T-lymphocytes are also needed to fight HIV infection. It is the loss of helper T-cells
25 which results in the severe immune deficiency that is one characteristic of AIDS. HIV infections of the central nervous system result in progressive loss of

cerebral function, which culminates in AIDS dementia complex.

As of this date, AIDS caused by HIV has reached epidemic proportions in various parts of the world,
5 including the United States.

Various known antiviral drugs have been tested for the prevention or treatment of HIV infections including alpha interferon, gamma interferon, azimezon, isopinosine, and Azidothymidine (or AZT). To date, the
10 only substance which has achieved some clinical success is AZT. This substance is a synthetic thymidine analog that is incorporated into DNA and causes the premature termination of the synthesis of DNA. This results in the inhibition of viral replication, since DNA needed to
15 produce the viral RNA is not produced.

However, DNA synthesis is also necessary for the continued normal functioning of the host cell. Consequently, administration of AZT results in the inhibition of host DNA synthesis with concomitant severe
20 side effects, e.g., anemia, granulocytopenia, and thrombocytopenia.

Thus, there is a continuing need for better anti-HIV treatments and for better anti-HIV drugs.

25

SUMMARY OF THE INVENTION


Treatments and drugs that satisfy this need have now been developed.

In accordance with one aspect of the present

invention, a method for inhibiting the growth or replication of HIV is provided, which comprises administering an effective amount of a compound having the formula I:

5

(I)



10 wherein:


R^1 is hydrogen, halogen, C_1 - C_4 alkyl or C_1 - C_4 alkoxy;

R^2 is hydrogen, halogen, C_1 - C_4 alkyl, C_1 - C_4 alkoxy, mono-, di- or tri-halomethyl, trifluoromethoxy, methylthio, nitro, cyano, acetoxy or dimethylamino;

R^3 is i) $-SO_2NR^aR^b$, ii) CO_2R^5 , iii) $-(CH_2)_n-Y-R^d$, iv) $-G-CO_2R^5$, v) $-CH=NOR^a$, vi) $-CS_2R^5$, vii) $-COSR^5$, viii) $-O(CH_2)_n-P(O)(OR^a)(OR^b)$, ix) $-COR^a$ or

20


x)




R^4 is hydrogen, halogen, methyl or mono-, di- or tri-halomethyl; and

25

R is



5



wherein the substituent groups are defined in more detail in the Detailed Description.

10

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 is a graph illustrating inhibition of the viral cytopathic effect of HIV-I with increasing concentration of the compound of Example 1 below.

15

Fig. 2 is a graph showing antiviral activity of the compound of Example 3 versus concentration.


Figure 3 is a graph showing effect on infectious virus and p24 production of the compound of Example 3 versus concentration.

20

DETAILED DESCRIPTION OF THE EMBODIMENTS

The compounds useful in the treatment of this invention are compounds of the formula:

25



30

wherein:

R^1 is hydrogen, halogen, C_1 - C_4 alkyl or C_1 - C_4 alkoxy;

5 R^2 is hydrogen, halogen, C_1 - C_4 alkyl, C_1 - C_4 alkoxy, hydroxy, mono-, di- or tri-halomethyl, trifluoromethoxy, methylthio, nitro, cyano, acetoxy or dimethylamino;

R^3 is

10 i) - $SO_2NR^aR^b$ wherein R^a and R^b are independently hydrogen or C_1 - C_6 alkyl or together form a heterocycle wherein the heterocyclic moiety is morpholinyl, piperidinyl, pyrrolidinyl or piperazinyl;

ii) - CO_2R^5 wherein

15 R^5 is an alkyl, a C_3 - C_6 alkenyl or alkynyl, a one to six haloalkyl, an alkoxyalkyl, an alkylthioalkyl, a carboxyalkyl, an alkylcarboxyalkyl, a C_6 - C_{12} arylcarboxyalkyl, an
20 alkylaminoalkyl or dialkylaminoalkyl, a trialkylsilylalkyl, each of the aforementioned alkyl moieties having from one to eight carbon atoms; a phenyl, a naphthyl, a C_1 - C_6
25 alkylphenyl, a C_7 - C_{12} arylalkyl or alkarylalkyl, a C_3 - C_8 carbocyclyl, a C_1 - C_4 alkyl C_3 - C_8 carbocyclyl, or a heterocyclylalkyl, wherein the hetero

cyclic moiety is morpholinyl,
piperidinyl, pyrrolidinyl, piperazinyl,
oxiranyl, oxetanyl, furanyl or
tetrahydrofuranlyl;

5 iii) $-(CH_2)_{n^3}-Y-R^d$ wherein
 n^3 is 0 or 1;

 Y is O, S, SO, SO₂ or NH; and

R^d is C₁-C₆ alkyl, C₃-C₆ cycloalkyl,
C₂-C₆ alkenyl, C₂-C₆ alkynyl,

10 $-CH_2CO_2R^5$, $-CO_2R^5$ with the proviso that
 Y cannot be SO₂, or $-COR^a$ wherein

R^5 and R^a are as defined above;

 iv) $-G-CO_2R^5$ wherein

 G is $-CH_2-$, $-CH_2CH_2-$ or $-CH=CH-$, and

15 R^5 is as defined above;

 v) $-CH=NOR^a$ wherein R^a is as defined above;

 vi) $-CS_2R^5$ wherein R^5 is as defined above;

 vii) $-COSR^5$ wherein R^5 is as defined above;

20 viii) $-O(CH_2)_n - \begin{matrix} O \\ || \\ P \\ | \\ OR^b \end{matrix} OR^a$ wherein


 n is 1 or 2,

R^a and R^b are independently hydrogen

25 or C₁-C₆ alkyl;

 ix) $-COR^a$ wherein R^a is defined above; or

x)




5

R^4 is hydrogen, halo, methyl or mono-, di- or tri-halomethyl;

R is

10

i)



wherein

Y^1 is O, S, NH or NR^a wherein R^a is as defined above;

15

ii) $R^{18} - Y^3 - C \begin{smallmatrix} SR^a \\ | \end{smallmatrix} = N -$ wherein

20

R^{18} is linear or branched C_1-C_6 alkyl or alkoxyalkyl wherein the alkyl groups are C_1-C_6 , C_3-C_8 cycloalkyl or mono-, di- or tri-halo C_1-C_6 alkyl;


Y^3 is O or S; and

R^a is as defined above; or

iii) R^Z-NH- wherein R^Z is

25

a)




wherein

R^a and R^b are independently hydrogen
or C_1-C_6 alkyl; and
 Z^1 is O or S;

b) cyano;

5




wherein

Y^1 is as defined above;

10

or




Z^2 is O, S, NH, NR^a or $NC\equiv N$;

15

wherein R^a is as defined above; and

R^A is



wherein

20


R^7 , R^8 and R^9 are

independently hydrogen or C_1-C_6

alkyl, or R^7 and R^8 together with

the N form a C_2-C_6 heterocyclic ring;

25



wherein

R^7 , R^8 and R^9 are independently hydrogen or C_1-C_6 alkyl, or R^7 and R^8 together with the carbon atom form a C_3-C_7 carbocyclic ring;

5 3) a) fully unsaturated, partially or fully reduced or substituted oxathiinyl; furanyl; dithiinyl; dioxinyl; thienyl; thiazolyl; oxazolyl; isoxazolyl; thiadiazolyl; 10 pyrazolyl; pyrrolyl; pyranyl; oxathiazinyl; oxadiazolyl; or indolyl;

b) substituted or unsubstituted, linear or branched C_1-C_8 alkyl; 15 C_2-C_8 alkenyl; C_2-C_8 alkynyl; C_1-C_8 mono- or di-alkylamino; C_3-C_7 cycloalkyl; C_3-C_7 cycloalkyl C_1-C_6 alkyl; C_3-C_7 cycloalkenyl unsubstituted or substituted by 20 C_1-C_6 alkyl; or C_7-C_8 phenylalkyl; or

c) aryl, C^7-C^{10} aralkyl or aryloxyalkyl or C_3-C_8 cycloalkyl-aryloxy wherein the aryl moiety of this group is naphthyl, phenyl or 25 phenyl substituted by one or more halo, C_1-C_8 alkyl, carboxyl, C_1-C_8 haloalkyl, C_1-C_8 alkylthio, phenyl,

nitro, amino, C₁-C₈ alkylcarbonyl-
amino, hydroxyl, acetyl, acetyloxy,
phenoxy; C₁-C₈ alkoxy carbonyl or
C₁-C₈ alkylcarbonyl;

5

4) R¹⁰-W- wherein

W is O, NH or NR^f wherein R^f is
C₁-C₄ alkyl; and

R¹⁰ is

10

i) a linear or branched, unsubsti-
tuted or halo-substituted C₁-C₈
alkyl, C₂-C₈ alkenyl, C₂-C₈
alkynyl; a C₃-C₇ cycloalkyl,
C₃-C₇ cycloalkyl C₁-C₆ alkyl,
C₃-C₇ cycloalkenyl unsubsti-
tuted or substituted by C₁-C₆
alkyl; an unsubstituted phenyl
or phenyl substituted by halo,
C₁-C₆ alkyl, C₁-C₆ alkoxy,
carboxyl, C₁-C₈ haloalkyl,
C₃-C₇ cycloalkyl, C₁-C₈
alkylthio, phenyl, nitro,
amino, hydroxyl, acetyl
acetyloxy, phenoxy, C₁-C₈
alkoxy carbonyl, C₁-C₈ alkyl-
carbonyl; furanylalkyl,
tetrahydrofuranylalkyl,
oxetanylalkyl, or oxiranylalkyl;

15

20

25

ii) R¹¹-W¹-R^e wherein

R^e is a linear or branched
 C_1-C_6 alkylidene;

W^1 is O or S; and

R^{11} is linear or branched

C_1-C_4 alkyl;


iii) $R^{13}R^{12}-N-R^e$ wherein

R^e is as defined above; and

R^{12} and R^{13} are

independently linear or

branched C_1-C_4 alkyl;



wherein

R^e is as defined above;

W^2 is O, S, NH, NR^{14} or
 $CR^{15}R^{16}$; wherein

R^{14} is linear or branched

C_1-C_4 alkyl;

R^{15} and R^{16} are

independently, hydrogen,

linear or branched C_1-C_4

alkyl; and

n^1 and m are

independently 1, 2 or 3;

v) $R^{17}O_2C-R^e$ wherein

R^e is as defined above;

and

R^{17} is linear or branched

C_1-C_6 alkyl, C_2-C_6 alkenyl,

C_2-C_6 alkynyl or C_3-C_7

cycloalkyl; C_3-C_7

cycloalkyl C_1-C_6 alkyl;

C_3-C_7 cycloalkenyl

unsubstituted or

substituted by C_1-C_6 alkyl;

vi) $U-R^e$ - wherein

R^e is as defined above;

U is hydroxyl, acyloxy,

aroyloxy, arylsulphonyloxy,

NO_2 , CN or $Si(CH_3)_3$;

vii) 1-adamantyl, 2-adamantyl

or bornyl moieties;

viii) Ar^1-R^e - wherein

R^e is as defined above;

and

Ar^1 is phenyl or phenyl

substituted independently

with one to three halogen,

mono-, di- or tri-halo-


methyl, nitro, C_1-C_4 alkyl,

C_2-C_4 alkenyl, C_1-C_4

alkyloxy, C₂-C₄ alkenyloxy,
or C₂-C₄ alkynyloxy; or

5) a C₃-C₆ sugar derivative.

Preferred among the compounds useful in the
5 treatment of this invention are compounds of the formula:



10

Z is O or S;

R^A is

a) a fully unsaturated, partially or fully reduced
or substituted oxathiinyl; a furanyl; a dithiinyl; a
15 dioxinyl; a thienyl; a thiazolyl; an oxazolyl; an
isoxazolyl; a thiadiazolyl; a pyrazolyl; a pyrrolyl; a
pyranyl; an oxathiazinyl; or an oxadiazolyl;

(b) linear or branched C₁-C₈ alkyl; a C₂-C₈
alkenyl; a C₂-C₈ alkynyl; a C₁-C₈ alkoxy; a C₂-C₈
20 alkenyloxy; a C₂-C₈ alkynyloxy; a C₃-C₈ cycloalkyloxy; a
C₃-C₈ cycloalkyl-alkoxy; a C₁-C₈ alkylamino; a C₃-C₆
cycloalkyl; a C₃-C₆ cycloalkenyl; a C₇-C₈ phenylalkyl; a
C₇-C₈ phenoxyalkyl or a phenoxy; or

(c) phenyl or phenyl substituted by one or more
25 halo, a C₁-C₈ alkyl, a C₁-C₈ alkoxy, a carboxyl, a C₁-C₈
haloalkyl, a C₁-C₈ alkylthio, a phenyl, an amino, an
acetamido, a hydroxyl, an acetyl, an acetyloxy, a

phenoxy; a C₁-C₈ alkoxy carbonyl or a C₁-C₈ alkyl carbonyl;

R¹, R², R³ and R⁴ are as defined in formula I.

More preferred among the compounds useful in the treatment of this invention are compounds of the formula

5 II wherein

Z is O or S;

R^A is


(a) a dihydro-3-oxathiinyl; a furanyl; a dihydro-furanyl, a thienyl, a dihydro-2-dithiinyl; or a
10 dihydro-2-dioxinyl; which can be substituted by one to three alkyl or alkoxyalkyl groups wherein the alkyl group is C₁-C₄;

(b) a phenyl; or a phenyl substituted by a group selected from a C₁-C₈ alkyl; a halogen; a C₁-C₈
15 haloalkyl; a C₁-C₈ alkylthio; a C₁-C₈ alkylthio; a carboxyl; an amino; an acetamido; a C₁-C₈ alkoxy; a C₁-C₈ alkoxy carbonyl; a hydroxyl; a C₁-C₈ alkyl carboxyl; a phenyl or a phenoxy group;

(c) a linear or branched C₁-C₈ alkyl; a C₂-C₈
20 alkenyl; a C₂-C₈ alkynyl; a C₁-C₈ alkoxy; a C₂-C₈ alkenyloxy; a C₂-C₈ alkynyloxy; a C₃-C₈ cycloalkyloxy; a C₃-C₈ cycloalkylalkoxy; a C₁-C₈ alkylamino; C₃-C₇ cycloalkyl; C₃-C₇ cycloalkyl C₁-C₆ alkyl; C₃-C₇ cycloalkenyl unsubstituted or substituted by C₁-C₆ alkyl
25 or a phenoxy group; and wherein R¹, R², R³, and R⁴, have the meanings given above in formula I.

In particular, the preferred group of oxathiin derivatives comprise those of formula III:

(III)



5

wherein

Z is O or S;


R⁶ is an alkyl or alkoxyalkyl wherein the alkyl groups are independently C₁-C₄; and

10 R¹, R², R³ and R⁴ have the meanings given above in formula I.

A particularly preferred group of compounds has the formula IV

15

(IV)



wherein

20 Z is O or S;


R¹ is a hydrogen, a fluoro or a methyl group;

R² is a hydrogen, a chloro, a fluoro or a methyl group;


25 R³ is COOR⁵ wherein R⁵ is an alkyl group of 1 to 6 carbon atoms;

R⁴ is hydrogen; andR⁶ is a methyl, ethyl or propyl group.

Furan derivatives found useful in the method of the invention comprise compounds of formula V a and V b:




OR



wherein Z is O or S; R⁷ and R⁸ are independently hydrogen or a methyl; R¹⁸ is hydrogen, methyl or ethyl; and R¹, R², R³, and R⁴ have the meanings given above in formula I.

Preferred compounds of this group comprise those of the above formulas Va and Vb wherein R¹ and R⁴ are hydrogen; R² is a halogen; and R³ is COOR⁵ wherein R⁵ is an alkyl group of 1 to 6 carbon atoms.

Another group of effective compounds has the formula VI:



5


wherein Z, R¹, R², R³ and R⁴ have the meanings given above in formula I and

R¹⁰, R¹¹, R¹², and R¹³ are independently hydrogen or halogen; and

10 R¹⁴ is hydrogen; a halogen; a C₁-C₄ alkyl; a C₁-C₄ alkoxy; a C₁-C₄ haloalkyl; a C₁-C₄ alkylthio; an amino; a C₁-C₈ alkylcarbonylamino; a hydroxyl; an acetyl; an acetyloxy; or acetylamino.

More preferred compounds of formula VI are those
15 wherein R¹ is hydrogen or fluoro; R¹⁰, R¹¹, R¹², and R¹³ are hydrogen; R¹⁴ is hydrogen, methyl, ethyl, a chloro, an iodo, an amino, a bromo, a fluoro, a methylthio, a methoxy, or a hydroxyl.

Dioxin derivatives that may be utilized in the
20 method for inhibiting the growth or replication of HIV comprise compounds of formula VII:




25

wherein Z, R¹, R², R³ and R⁴ have the meanings given above in formula I.

More preferred dioxin compounds are those wherein R¹ and R⁴ are hydrogen; and R³ is a COOR⁵ group in which R⁵ has the meaning given above in formula I.

Preferred derivatives of acyclic carboxamides or carbamates useful in the method hereof comprise compounds of formula VIII:

10



wherein R¹⁵ is a linear or branched C₃-C₆ alkyl; a C₂-C₆ alkenyl or alkynyl; a C₇-C₈ aralkyl or aryloxyalkyl; a C₁-C₈ alkoxy; a C₂-C₈ alkenyloxy or alkynyloxy; a C₁-C₈ aryloxy; C₃-C₇ cycloalkyl; C₃-C₇ cycloalkyl C₁-C₆ alkyl; C₃-C₇ cycloalkenyl unsubstituted or substituted by C₁-C₆ alkyl; a C₃-C₈ cycloalkyloxy, cycloalkylalkyloxy, cycloalkylaryloxy or alkylamino; and Z, R¹, R², R³ and R⁴ have the meanings given above in formula I.


More preferred compounds are those wherein R¹ is a hydrogen or a fluoro; R² has the meaning given above in formula I; R³ is a COOR⁵ wherein R⁵ has the meaning given above in formula I; R⁴ is a hydrogen and R¹⁵ can be a C₃-C₆ alkyl; a C₂-C₆ alkenyl or alkynyl; a C₇-C₈ phenylalkyl or phenoxyalkyl; a C₁-C₈ alkoxy; a C₂-C₈ alkenyloxy or alkynyloxy; phenoxy; C₃-C₇ cycloalkyl;

C₃-C₇ cycloalkyl C₁-C₆ alkyl; C₃-C₇ cycloalkenyl unsubstituted or substituted by C₁-C₆ alkyl; C₃-C₈ cycloalkoxy or cycloalkylalkyloxy; cycloalkyl- phenoxy or alkylamino.

5 Effective compounds are those compounds of formula VIII wherein R¹⁵ is a C₃-C₆ cycloalkyl or cycloalkenyl group and R¹-R⁴ have the meanings of formula I.

A subgroup of compounds of formula VIII are those wherein R¹ and R⁴ are hydrogen and R³ is a COOR⁵ group
10 wherein R⁵ has the meaning given above.

Dithiin derivatives found most useful in the method hereof comprise compounds of formula IX:



wherein Z and R¹-R⁴ have the meanings given above in formula I.

20 The preferred compounds of formula IX are those wherein R¹ and R⁴ are hydrogen; R² is a hydrogen or a chloro; and R³ is a C₂-C₆ alkoxy carbonyl group.

Various carbonylamino derivatives of oxathiins are known. Thus, the preparation and use of various
25 5,6-dihydro-2-methyl-1,4-oxathiin-3-carboxamides (which may also be termed 2,3-dihydro-5-carboxamido-6-methyl-1,4-oxathiins) as bactericides, fungicides and plant viricides, particularly for agricultural purposes, is

disclosed in U.S. Patent Nos. 3,249,499; 3,402,241;
3,454,391; 3,657,449; 3,806,332; 4,182,716; 4,247,707;
and 4,359,579.

One such compound, carboxin, viz. 5,6-dihydro-2-
5 methyl-N-phenyl-1,4-oxathiin-3-carboxamide (previously
termed 5,6-dihydro-2-methyl-1,4-oxathiin-3-carbox-
anilide), is commercially marketed as a systemic plant
fungicide providing control by seed treatment of various
fungi that cause seed and seedling diseases in a variety
10 of crops.

Certain of the particular oxathiin derivatives
useful in the present method are also disclosed in White
et al., Pesticide Biochemistry and Physiology, 9, 165
(1978). In particular, White et al. discloses that
15 methyl 3-[[[(5,6-dihydro-2-methyl-1,4-oxathiin-3-yl)
carbonyl]amino]benzoate and ethyl 3-[[[(5,6-dihydro-2-
methyl-1,4-oxathiin-3-yl)carbonyl]amino]benzoate
(Example 8 below) are inhibitors of succinate
dehydrogenase complex in mitochondria from Ustilago
20 maydis, the corn smut fungus.

This publication neither discloses nor suggests
that either of the noted compounds is useful in
inhibiting the growth or replication of viruses of the
HIV class.

25 In accordance with a further aspect of the present
invention, there is provided a class of novel compounds
useful in inhibiting the growth or replication of HIV,
which compounds have not previously been described in

the literature. The subset of novel compounds which may be so utilized comprises the furanyl-, phenyl-, dithiiny-, dioxiny-, alkoxy-, and alkyl-carbonylamino derivatives of Formula (I) above, and the oxathiiny-
5 derivative of Formula (II) other than those in which the carboalkoxy moiety on the aryl nucleus is carbomethoxy or carboethoxy and R_1 , R_2 and R_4 are all hydrogen.


The compounds useful in accordance with the present invention may be prepared by the methods described in
10 von Schmeling et al, see U.S. Patent No. 3,249,499, at col. 2, line 34 to col. 3 line 73; or Znotins et al, see U.S. Patent No. 4,182,716, at col. 2, line 3 to col. 2, line 68.

When R^A is a C_3 to C_6 sugar derivative, it is one
15 of the following:


A) A C_3 sugar derivative of the general structure $CH_2OP^I-CHOP^{II}-CH_2-$, where P^I and P^{II} are both H or a combination of H and a suitable protecting group (i.e. a mono-protected sugar) or two such protecting groups.
20 Suitable protecting groups are an alkyl or aryl ether, an alkyl or aryl ester, an alkyl or aryl silyl ether or a cyclic protecting group (i.e. P^I and P^{II} are connected to each other) such as acetal, a ketal, an ortho ester or a cyclic ester. The sugar is of either the D
25 configuration, the L configuration or a racemic mixture of both configurations.

B) A C_4 sugar derivative of the general structure $CH_2OP^I-CHOP^{II}-CHOP^{III}-CH_2$ where P^I , P^{II} and P^{III} are

defined as above. Also considered are the five-membered (furanose) cyclic forms of the parent aldoses, as indicated in the figure below. These sugars are of the stereochemical configurations corresponding to the structures designated by the names erythritol (erythrose) or threitol (threose), in either their D, L or racemic forms. In the case of the cyclic forms, both the α and β anomers are included.




10 C) A C_5 sugar aldose or ketose derivative in either one of the following forms: i) a suitably protected linear form of the corresponding sugar alcohols, analogous to that described in (B); ii) their five-membered (furanose) or six-membered (pyranose; see 15 below for an example) cyclic forms, which are attached to Y through either a primary or secondary carbon and where protecting groups are as described above. These sugars are the D, L or racemic forms (plus the α and β anomers, if applicable) of the structures corresponding 20 to the configurations described by the common names ribose, arabinose, xylose and lyxose (aldoses) or xylulose and ribulose (ketoses). Also considered are the distinct desoxy forms of these sugars where one of the O-protecting groups is missing and is replaced by H 25 or CH_3 .



D) A C6 sugar aldose or ketose in either one of the following forms: i) a suitably protected linear form of the corresponding sugar alcohols, analogous to that described in (C); ii) five-membered (furanose) or six-membered (pyranose) cyclic forms. The sugar is attached to Y through either a primary or secondary carbon and the protecting groups are those described above. The sugars are the D, L, or racemic forms (plus the α and β anomers, where applicable) of the structures corresponding to the stereochemical configurations described by the common names allose, altrose, glucose, gulose, mannose, idose, galactose, talose (aldohexoses) and fructose, sorbose, psicose and tagatose (2-ketohexoses). Also considered are the known desoxy forms of the aforementioned sugars as described in (C) that are distinct from previously mentioned compounds.

GENERAL SYNTHETIC METHODS FOR PREPARING
EACH CLASS OF COMPOUNDS

Compounds of formula II, wherein Z is O and R^A is oxathiinyl, furanyl, dithiinyl, dioxinyl, other heterocyclyl, substituted phenyl or alkyl, may be prepared from the appropriate carboxylic acid, $R^A\text{COOH}$, and an aniline derivative, i.e.,



5

by employing one of the conventional methods of amide bond formation. For example, the carboxylic acid may be converted to an acid halide, such as the acid chloride, R^ACOCl, which may then be reacted with the aniline derivative to form the amide (I). The amide-forming reaction is carried out in an appropriate solvent, such as methylene chloride, toluene, methyl ethyl ketone, tetrahydrofuran, dimethylformamide or acetonitrile, at a temperature of about 0°C to about 100°C. It is usually preferable to carry out the reaction in the presence of a base, such as triethylamine or pyridine. Other reactive derivatives of the carboxylic acid may be employed: for example the anhydride of the carboxylic acid or a mixed anhydride, such as an alkoxy-carbonyloxy derivative, may be reacted with the aniline derivative. Alternatively, the carboxylic acid and aniline derivative may be reacted directly in the presence of a condensing agent, such as dicyclohexylcarbodiimide, to form the amide.


25

The aniline derivatives may be prepared by reduction of the corresponding nitro compounds by

well-known methods, for example with hydrogen and a catalyst, such as Raney nickel or platinum, or with a metal-acid combination, such as iron or tin and hydrochloric or acetic acid. Where R^3 is $COOR^5$, the R^5 group
5 may be introduced by esterification of the corresponding aminobenzoic acid or nitrobenzoic acid by conventional methods.

Other compounds of formula II wherein R^A is an alkoxy may be prepared by reacting the appropriate
10 aniline derivative with an alkoxycarbonyl chloride under conditions essentially similar to those used for reaction of an acid chloride with the aniline derivative. They may also be prepared by reacting the appropriate isocyanate derivative with an alcohol. The
15 isocyanate may be prepared by reacting the aniline derivative or a suitable salt thereof, such as the hydrochloride, with phosgene or a phosgene substitute, such as trichloromethyl chloroformate.

Compounds of formula II, wherein R^3 is $COOR^5$ or
20 $COSR^5$, may also be prepared from the appropriate carbonylaminobenzoic acid i.e.,




25

or a corresponding derivative thereof, such as the acid chloride, by using a conventional esterification

method. For example, the acid may be reacted with the alcohol, R^5OH , or thiol, R^5SH , in the presence of one of the common esterification catalysts, such as hydrogen chloride, sulfuric acid, methanesulfonic acid, p-toluenesulfonic acid, thionyl chloride or phosphorus pentachloride. The alcohol itself may serve as the solvent, or the esterification can be carried out in a compatible solvent such as toluene, methylene chloride or tetrahydrofuran. Esterification may also be accomplished by reacting the acid chloride with the above alcohol or thiol, in which case the presence of a base, such as triethylamine or pyridine, may be advantageous. Esters may also be obtained by reacting an alkali metal salt of the acid with the halide, R^5Hal .

The carbonylaminobenzoic acid derivatives may be prepared by reacting the corresponding aminobenzoic acid with an acid chloride, $R^A COCl$, or by hydrolyzing a compound of formula II, wherein R^3 is $COOR^5$ and R^5 is preferably a lower alkyl group (such as methyl or ethyl), for example by reaction with sodium or potassium hydroxide followed by acidification.


Oxathiin derivatives of formula II may be prepared by reacting a 5,6-dihydro-1,4-oxathiin-3-carbonyl chloride derivative with an aniline compound in a suitable solvent, such as methylene chloride or toluene, in the presence of a base, such as triethylamine or pyridine:



The acid chloride may be made by conventional methods from the 5,6-dihydro-1,4-oxathiazine-3-carboxylic acid, which is made in turn from the appropriate


5 mercaptoethanol derivative and methyl or ethyl 2-chloro-3-oxoalkanoate by the method described in US 3,249,499 (col 3, lines 46-66) for the preparation of 5,6-dihydro-2-methyl-1,4-oxathiazine-3-carboxylic acid (named 2,3-dihydro-6-methyl-1,4-oxathiazine-5-carboxylic

10 acid or 2,3-dihydro-5-carboxy-6-methyl-1,4-oxathiazine in the reference), as illustrated below:




Certain compounds of formula II may also be prepared by reacting the aniline derivative with diketene to form the 1,3-dioxobutylamino derivative.

- 5 This may be converted to the oxathiin by chlorination and reaction with mercaptoethanol by the method described in U.S. 3,249,499 (col 1, line 54 to col 2, line 67), as illustrated below:




Alternatively, the 1,3-dioxobutylamino derivative may be converted to the oxathiin by the method described in U.S. 4,182,716 (col 2, line 3 to col 2, line 68) as

5 illustrated below:



Oxathiins of formula II, wherein R^3 is COOR^5 or COSR^5 , may also be prepared from the appropriate oxathiincarbonylaminobenzoic acid compound, i.e.,

5



or a reactive derivative thereof, such as the acid chloride, by using a conventional esterification method. For example, the acid may be reacted with the alcohol, $R^5\text{OH}$, or thiol, $R^5\text{SH}$, in the presence of one of
10 the common esterification catalysts, or by reacting the

acid chloride with the alcohol or thiol, if necessary, in the presence of a base such as triethylamine or pyridine. Esterification may also be accomplished by reacting an alkali metal salt of the acid with the



5 halide, $R^5\text{Hal}$.

The oxathiincarbonylaminobenzoic acid derivatives may be prepared by reacting the appropriate 5,6-dihydro-1,4-oxathiin-3-carbonyl chloride and aminobenzoic acid derivatives, or by hydrolyzing an oxathiin of

10 formula II, wherein R^3 is OR^5 and R^5 is preferably a lower alkyl group (such as methyl or ethyl), for example by reaction with sodium or potassium hydroxide followed by acidification.


Thiocarbamates, thioureas and thiocarboxanilides

15 are important and active compounds of the invention. Thiocarbamates and thioureas are made by taking alcohols and amines and reacting them with the appropriate isothiocyanate. Thus to make compounds of the formula II type:




The isothiocyanate is made using the appropriate aniline derivative or suitable salt thereof, such as the hydrochloride, with thiophosgene.

- 5 Alternatively, esters of these thiocarbamates can be made using a carboxylic acid and appropriate alcohol in the presence of dicyclohexylcarbodiimide (DCC) and a base catalyst such as 4-dimethylaminopyridine (DMAP). A preferred carboxylic acid is 2-chloro-5-[[[1-methyl-
- 10 ethoxy)thioxomethyl]amino]benzoic acid.



Thiocarboxanilides can be prepared starting from the corresponding amide and reacting it with a sulfurating agent such as Lawesson's reagent or
 5 phosphorus pentasulphide.



The compounds of this invention, as noted herein-above, are useful for inhibiting the growth or replication of viruses of the HIV group, at present known to
 10 include HIV-I and HIV-II. The present compounds also may be used in those individuals who have been exposed to HIV but have not been infected, as a prophylactic measure to prevent infection by HIV. They may be used alone or in combination with other chemotherapeutic

agents either prophylactically or to combat an active infection.

The dosage levels at which the compounds of the invention are employed in human therapy may, of course, be adjusted to provide optimum therapeutic response. For example, several divided doses may be administered daily or the dose may be proportionally reduced, as indicated by the exigencies of the therapeutic situation.

It may be advantageous to formulate the compositions in unit dosage forms for ease of administration and uniformity of dosage. "Unit dosage form," as that term is used herein, refers to a physically discrete unit suitable for use as a unitary dosage for mammalian subjects to be treated. Each unit contains a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with the required pharmaceutically acceptable carrier. Specifications for unit dosage forms are dictated by and directly depend on (a) the unique characteristics of the active material and the particular therapeutic effect to be achieved and (b) the limitations inherent in the art of compounding such an active material for the treatment of HIV infections in living subjects without excessive cytotoxic side effects.

The active compounds may suitably be administered parenterally, intraperitoneally, intrathecally, intravenously, orally, or as an aerosol. Solutions or dispersions of the active compounds can be prepared,

e.g., in glycerol, liquid polyethylene glycols, and mixtures thereof, and in oils. For ordinary conditions of storage and use, these preparations usually contain a preservative to prevent the growth of microorganisms.

5 The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. For such uses the form must be sterile and must be fluid to the
10 extent necessary to provide easy syringeability. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi.

 The carrier can be a solvent or dispersing medium
15 containing, for example, water, ethanol, a polyol (glycerol, propylene glycol, liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by
20 the maintenance of the required particle size in the case of a dispersion, and by the use of surfactants. Prevention of the action of microorganisms can be insured by various anti-bacterial and antifungal agents, for example, paraben, chlorobutanol, phenol, sorbic
25 acid, and thimerosal. Other agents may be used. In many cases it may be preferable to include isotonic agents, for example, sugars or sodium chloride, in the dosage form. Prolonged absorption of the injectable

formulations can be effected by incorporating therein agents delaying absorption, for example, aluminum monostearate and gelatin.

Sterile injectable solutions are prepared by incorporating the active compound in the appropriate solvent, in admixture with various of the other ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the sterilized active ingredient in a sterile vehicle that contains the dispersing medium and any other required ingredients. When, on the other hand, sterile powders are used to prepare sterile injectable solutions, it is preferred to subject a sterile, filtered solution of the desired ingredients to vacuum drying or freeze-drying, yielding a powder of the active ingredient plus any additional desired ingredients.

As used herein, a "pharmaceutically acceptable" carrier or excipient includes solvents, dispersing media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. The use of such media and agents as carriers or excipients for pharmaceutically active substances is well known in the art. Except insofar as any conventional medium or agent is incompatible with the active ingredients of the present invention or toxic, its use in the therapeutic formulations of the invention is

contemplated. Supplementary active ingredients can also be incorporated in the present formulation.


The invention will be further described with reference to the following Examples, but the invention
5 is not meant to be limited to the details described therein.

In the Examples, percent (%) is by weight. Nuclear magnetic resonance data is shown as NMR.

Table I and Tables IA through IE below summarize
10 the structures of the compounds of the Examples having reference to the preceding general formulas.

TABLE I

Compounds Prepared

5					
	Oxathiins				
10	Compound	R ¹	R ²	R ³	R ⁴
	-----	--	--	--	--
15	1	H	Cl	CO ₂ iPr	H
	1-Methylethyl 2-chloro-5-[[[(5,6-dihydro-2-methyl-1,4-oxathiin-3-yl)carbonyl]amino]benzoate				
	2	F	Cl	CO ₂ iPr	H
25	1-Methylethyl 2-chloro-5-[[[(5,6-dihydro-2-methyl-1,4-oxathiin-3-yl)carbonyl]amino]-4-fluorobenzoate				
30	3	H	Cl	CO ₂ Me	H
	Methyl 2-chloro-5-[[[(5,6-dihydro-2-methyl-1,4-oxathiin-3-yl)carbonyl]amino]benzoate				
35	4	H	Cl	CO ₂ Et	H
	Ethyl 2-chloro-5-[[[(5,6-dihydro-2-methyl-1,4-oxathiin-3-yl)carbonyl]amino]benzoate				
45	5	H	Cl	CO ₂ Pr	H
	Propyl 2-chloro-5-[[[(5,6-dihydro-2-methyl-1,4-oxathiin-3-yl)carbonyl]amino]benzoate				
50	6	H	Cl	CO ₂ Bu	H
	Butyl 2-chloro-5-[[[(5,6-dihydro-2-methyl-1,4-oxathiin-3-yl)carbonyl]amino]benzoate				
55					

7	H	Cl	CO2iPr	H	Et
---	---	----	--------	---	----

1-Methylethyl 2-chloro-5-[[(2-ethyl-5,6-dihydro-1,4-oxathiin-3-yl)carbonyl]amino]benzoate

8	H	H	CO2Et	H	Me
---	---	---	-------	---	----

10 Ethyl 3-[[(5,6-dihydro-2-methyl-1,4-oxathiin-3-yl)carbonyl]amino]benzoate

15	9	H	H	CN	H	Me
----	---	---	---	----	---	----

N-(3-Cyanophenyl)-5,6-dihydro-2-methyl-1,4-oxathiin-3-carboxamide

20

10	H	H	CO2iPr	H	Me
----	---	---	--------	---	----

25 1-Methylethyl 3-[[(5,6-dihydro-2-methyl-1,4-oxathiin-3-yl)carbonyl]amino]benzoate

11	H	Cl	CO2Et	H	Et
----	---	----	-------	---	----

30

Ethyl 2-chloro-5-[[(2-ethyl-5,6-dihydro-1,4-oxathiin-3-yl)carbonyl]amino]benzoate

12	F	Me	CO2iPr	H	Me
----	---	----	--------	---	----

35

1-Methylethyl 5-[[(5,6-dihydro-2-methyl-1,4-oxathiin-3-yl)carbonyl]amino]-4-fluoro-2-methylbenzoate

40

13	F	H	CO2iPr	H	Me
----	---	---	--------	---	----

45 1-Methylethyl 3-[[(5,6-dihydro-2-methyl-1,4-oxathiin-3-yl)carbonyl]amino]-4-fluorobenzoate

50	14	Me	H	CO2Et	H	Me
----	----	----	---	-------	---	----

Ethyl 3-[[(5,6-dihydro-2-methyl-1,4-oxathiin-3-yl)carbonyl]amino]-4-methylbenzoate

55

- 15 H Cl CO₂n-Pentyl H Me
- 5 Pentyl 2-chloro-5-[[[(5,6-dihydro-2-methyl-1,4-oxathiin-3-yl)carbonyl]amino]benzoate
- 10 69 H Cl CO₂(CH₂)₂-OCH₃ H CH₃
- 2-Methoxyethyl 2-chloro-5-[[[5,6-dihydro-2-methyl-1,4-oxathiin-3-yl)carbonyl]amino]benzoate
- 15 M.P.°C: syrup
- 20 70 H Cl CO₂Et H nPr
- Ethyl 2-chloro-5-[[[(5,6-dihydro-2-propyl-1,4-oxathiin-3-yl)carbonyl]amino]benzoate
- 25 M.P.°C: 66-66.5
- 30 71 H Cl CO₂CH₃ H nPr
- Methyl 2-chloro-5-[[[(5,6-dihydro-2-propyl-1,4-oxathiin-3-yl)-carbonyl]amino]benzoate
- 35 72 H F CO₂iPr H Me
- 1-Methylethyl 5-[[[5,6-dihydro-2-methyl-1,4-oxathiin-3-yl)carbonyl]amino]-2-fluorobenzoate
- 40 M.P.°C: 123-125
- 45 73 H Me CO₂iPr H Me
- 1-Methylethyl 5-[[[5,6-dihydro-2-methyl-1,4-oxathiin-3-yl)carbonyl]amino]-2-methylbenzoate
- 50 M.P.°C: 95-97

74 H Cl CO₂CH₂iPr H Et

2-Methylpropyl 2-chloro-5-[[[(2-ethyl-5,6-dihydro-1,4-
5 oxathiin-3-yl)carbonyl]amino]benzoate

M.P.°C: 78-80

10 75 Me H CO₂nPr H Me

Propyl 3-[[[(5,6-dihydro-2-methyl-1,4-oxathiin-3-
yl)carbonyl]amino]-4-methylbenzoate

15

M.P.°C: 87-88

20 76 H H CO₂nBu H Me

Butyl 3-[[[5,6-dihydro-2-methyl-1,4-oxathiin-3-
yl)carbonyl]amino]benzoate

25 M.P.°C: 112-113

77 F F CO₂iPr H Me

30

1-Methylethyl 5[[[(5,6-dihydro-2-methyl-1,4-oxathiin-3-
yl)carbonyl]amino]-2,4-difluorobenzoate

M.P.°C: 132-133

35

78 H Cl CO₂(CH₂)₂O- H Me
(CH₂)₂OCH₃

40

2-(2-Methoxyethoxy)ethyl 2-chloro-5-[[[(5,6-dihydro-2-methyl-
1,4-oxathiin-3-yl)carbonyl]amino]benzoate

M.P.°C: syrup

45

110 H Cl CO₂C₆H₁₁(CYCLO) H CH₃

Cyclohexyl 2-chloro-5-[[[5,6-dihydro-2-methyl-1,4-oxathiin-3-yl)
50 carbonyl]amino]benzoate

Oil
111 H Cl CO₂C₅H₉ (CYCLO) H CH₃

Cyclopentyl 2-chloro-5-[[[(5,6-dihydro-2-methyl-1,4-oxathiin-3-yl)carbonyl]amino]benzoate

M.P.°C: 112-113

10 112 H OH CO₂iPr H CH₃

1-Methylethyl 5-[[[(5,6-dihydro-2-methyl-1,4-oxathiin-3-yl)-carbonyl]amino]-2-hydroxybenzoate

15
147 H H H CONHR^H CH₃
M.P.°C: 202-203


20 157 H OC(O)CH₃ CO₂iPr H CH₃
M.P.°C: 99-101

158 H OC(O)ET CO₂iPr H CH₃
25 M.P.°C: 135-137

Furans


30
Compound

35 16



1-Methylethyl 2-chloro-5-[[[(2,4,5-trimethyl-3-furanyl)carbonyl]amino]benzoate

17



45
1-Methylethyl 2-chloro-5-[[[(3-methyl-2-furanyl)carbonyl]amino]benzoate

50 79 1-Methylethyl 2-chloro-5-[[[(2-methyl-3-furanyl)carbonyl]amino]benzoate

M.P.°C: 90-91

55

80 1-Methylethyl 2-chloro-5-[[[(2,4-dimethyl-3-furanyl)carbonyl]amino]benzoate

M.P.°C: 126-127

5


81 1-Methylethyl 2-chloro-5-[[[(2,5-dimethyl-3-furanyl)carbonyl]amino]benzoate

10 M.P.°C: 132-134

113 1-Methylethyl 2-chloro-5-[(2-furanylcarbonyl)-amino]benzoate
M.P.°C: 141-142

15

Aromatics



20

Compound	R ¹	R ²	R ³	R ¹⁰	R ¹¹	R ¹²	R ¹³	R ¹⁴
18	F	Cl	CO ₂ iPr	H	H	H	H	H
19	H	Cl	CO ₂ iPr	H	H	H	H	OMe
20	F	Cl	CO ₂ iPr	Br	Br	Br	Br	CO ₂ H
21	H	Cl	CO ₂ iPr	Br	Br	Br	Br	CO ₂ H
22	H	Cl	CO ₂ iPr	Cl	Cl	Cl	Cl	CO ₂ H

25

18 F Cl CO₂iPr H H H H H

1-Methylethyl 5-(benzoylamino)-2-chloro-4-fluorobenzoate

30

19 H Cl CO₂iPr H H H H OMe

1-Methylethyl 2-chloro-5-[(2-methoxybenzoyl)amino]benzoate

35

20 F Cl CO₂iPr Br Br Br Br CO₂H

2,3,4,5-Tetrabromo-6-[[[4-chloro-2-fluoro-5-[(1-methylethoxy)carbonyl]phenyl]amino]carbonyl]benzoic acid

40

21 H Cl CO₂iPr Br Br Br Br CO₂H


2,3,4,5-Tetrabromo-6-[[[4-chloro-3-[(1-methylethoxy)carbonyl]phenyl]amino]carbonyl]benzoic acid

45

22 H Cl CO₂iPr Cl Cl Cl Cl CO₂H

50

2,3,4,5-Tetrachloro-6-[[[4-chloro-3-[(1-methylethoxy)carbonyl]phenyl]amino]carbonyl]benzoic acid

- 23 H Cl CO₂iPr H H H H Me
1-Methylethyl 2-chloro-5-[(2-methylbenzoyl)amino]benzoate
- 5 24 H Cl CO₂nPr H H H H Me
Propyl 2-chloro-5-[(2-methylbenzoyl)amino]benzoate
- 10 25 H Cl CO₂iPr H H H H F
1-Methylethyl 2-chloro-5-[(2-fluorobenzoyl)amino]benzoate
M.P.°C: 53-56
- 15 82 H Cl CO₂iPr H H H H I
1-Methylethyl 2-chloro-5-[(2-iodobenzoyl)amino]benzoate
20 M.P.°C: 120-120.5
- 83 H Cl CO₂CH₂  H H H H OCH₃
25 Tetrahydro-2-furanylmethyl 2-chloro-5-[(2-methoxybenzoyl)-
amino]benzoate
M.P.°C: 75-77
- 30 84 H Cl CO₂(CH₂)₂ H H H H H
OCH₃
2-Methoxyethyl 5-[benzoylamino]-2-chlorobenzoate
M.P.°C: syrup
- 35 85 H Cl CO₂iPr H H H H Br
1-Methylethyl 5-[(2-bromobenzoyl)amino]-2-chlorobenzoate
40 M.P.°C: 123-140
- 86 H Cl CO₂ET H H H H OCH₃
45 Ethyl 2-chloro-5-[(2-methoxybenzoyl)amino]benzoate
M.P.°C: 56-57
- 50 87 H Cl CO₂Et H H H H H
Ethyl 5-(benzoylamino)-2-chlorobenzoate
M.P.°C: 140-142

88 H Cl CO₂iPr H H H H NH₂

Ethyl 5-[(2-aminobenzoyl)amino]-2-chlorobenzoate
M.P. °C: 150-152

5

89 H Cl CO₂iPr H H H H H

1-Methylethyl 5-(benzoylamino)-2-chlorobenzoate
10 M.P. °C: 105-107

90 H Cl CO₂iPr H H H H Cl

15 1-Methylethyl 2-chloro-5-[(2-chlorobenzoyl)amino]benzoate
M.P. °C: 100-101

114 H Cl CO₂iPr H H H H NH COCN₃

20

1-Methylethyl 5-[(2-acetamidobenzoyl)amino]-2-chlorobenzoate
M.P. °C: 130-132


146 H Cl CO₂iPr H H H H NH CO₂ET
25 M.P. °C: 150-151

159 H Cl CO₂iPr H H H H NH₂HCL
M.P. °C: 226-229

30

Dithiins

35



Compound	R ²	R ³
26	Cl	H

40

N-(4-Chlorophenyl)-5,6-dihydro-3-methyl-1,4-dithiin-2-carboxamide

45


27 Cl CO₂iPr

1-Methylethyl 2-chloro-5-[(5,6-dihydro-3-methyl-1,4-dithiin-2-yl)carbonyl]amino]benzoate
50

-48-

Dioxins

5


Compound

10

28 1-Methylethyl 2-chloro-5-[[5,6-dihydro-3-methyl-1,4-dioxin-2-yl]carbonyl]amino]benzoate

Pyrans

15




20

115 1-Methylethyl 2-chloro-5-[[3,4-dihydro-6-methyl-2H-pyran-5-yl]carbonyl]amino]benzoate
M.P.°C: 147-148

25

Acyclic Derivatives

30



35

CompoundR¹R¹⁵

40

91 H (CH₃)₂C=CH-
1-Methylethyl 2-chloro-5-[(3-methyl-1-oxo-2-butenyl)amino]-
benzoate
M.P.°C: 98-99

45

92 H CHEC-CH₂-
1-Methylethyl
2-chloro-5-[(2-propynyloxy)carbonyl]amino]benzoate
M.P.°C: 120-122

50

93 H nBuO-
1-Methylethyl 5-[(butoxycarbonyl)amino]-2-chlorobenzoate
M.P.°C: 85-87

55

29 H iPrO

1-Methylethyl 2-chloro-5-[[1-methylethoxycarbonyl]amino]benzoate
M.P. °C: 108-109

5


30 F t-Bu

1-Methylethyl 2-chloro-5-[(2,2-dimethyl-1-oxopropyl)
10 amino]-4-fluorobenzoate
M.P. °C: 81-83

The following supplemental Table I's list additional
15 compounds that were prepared and are within the scope of this
invention. Specific examples following the Tables describe in
detail the exact procedures for the preparation of certain of
the compounds in the Tables; the balance being prepared by
similar processes.

20

TABLE IA
PREPARED COMPOUNDS







	COMPOUND	W	R ¹⁰	M.P. °C
10	---	---	-----	-----
	31	0	CH ₃	108-110
	32	0	CH(CH ₃) ₂	89-90
	33	0	CH ₂ CH ₃	65-66
	34	0	CH ₂ (CH ₂) ₂ CH ₃	OIL
15	35	0	CH ₂ (CH ₂)CH ₃	78-80
	36	0	CH ₂ (CH ₂) ₃ CH ₃	OIL
	37	0	CH ₂ CH=CH ₂	OIL
20	39	0		OIL
	42	0		66-68
25	43	0		OIL
	44	0	C ₆ H ₁₁ (CYCLO)	94-95
	46	0	CH ₂ C ₃ H ₅ (CYCLO)	77-78
30	47	0	CH ₂ CH ₂ OCH ₃	OIL
	48	NCH ₃	CH ₃	72-74
	49	NH CH(CH ₃) ₂	130-132	
	116	0	CH ₂ CF ₃	97-99
	117	0	CH ₂ C ₆ H ₅	74-76
35	118	0	2-ADAMANTYL	138-142
	119	0	1-ADAMANTYL	168-169

TABLE IA (Cont'd)

5

120

0




108-110

10

121

0




95-96

15

20 122

0




OIL

TABLE IB

PREPARED COMPOUNDS

5




10	COMPOUND	R ⁵	M.P. °C
		-----	-----
	132	CH ₂ OCOC(CH ₃) ₃	OIL
	133	CH(CF ₃) ₂	109-110
15	134	C(CH ₃) ₃	OIL
	135	CH ₂ OCOC ₆ H ₄ -2-CH ₃	88-89
	136	CH ₂ CF ₃	87-90
	137	CH ₂ CH ₂ OCOCH ₃	OIL
	138	CH ₂ C≡CH	75-83
20	139	C ₆ H ₅	106-107
	140	C ₆ H ₄ -2-CH ₃	93-94
	141	CH ₂ CH ₂ Si(CH ₃) ₃	89-92
	142	CH ₂ C ₃ H ₅ (CYCLO)	62-64
	143	CH ₂ CH C ₄ H ₉	OIL
25		I	
		C ₂ H ₅	
	144	CH ₂ C ₆ H ₅	88-89
	148	CH ₂ CH ₃	72-73
	149	CH ₂ iPr	OIL
30	151	CH(ET) ₂	85-86
	152	CH(CH ₃)ET	60-62
	153	nBu	OIL
	154	nPr	57-58
	155	CH ₂ CH(ET) ₂	OIL
35			

TABLE IC

PREPARED COMPOUNDS

5

10



15

COMPOUND	Y ³	R ¹⁸	R ^a	M.P. °C
50	0	CH(CH ₃) ₂	CH ₃	OIL
51	0	CH(CH ₃) ₂	CH ₂ CH ₃	OIL
52	0	CH(CH ₃) ₂	CH ₂ CH ₂ CH ₃	OIL


20

TABLE ID

PREPARED COMPOUNDS

25

30



35

COMPOUND	R ⁷	R ⁸	M.P. °C
58	CH ₃	CH ₃	109-110
59	H	H	83-85
60	H	CH ₃	125-126


40

TABLE IE

PREPARED COMPOUNDS

5

10



15

20

25


COMPOUND	R ^a	R ¹⁴	R ²	R ⁴	M.P. °C
-----	-----	---	--	--	-----
61	CH(CH ₃) ₂	H	Cl	H	93-94
62	CH ₂ CH ₃	H	Cl	H	125-127
63	CH(CH ₃) ₂	H	F	F	92-93
64	CH(CH ₃) ₂	CH ₃	Cl	H	110-111
65	CH(CH ₃) ₂	OCH ₃	Cl	H	79-80
123	C ₆ H ₁₁ (CYCLO)	OCH ₃	Cl	H	82-84
124	C ₅ H ₉ (CYCLO)	OCH ₃	Cl	H	85-86
125	C ₆ H ₁₁ (CYCLO)	Cl	Cl	H	105-106
126	C ₅ H ₉ (CYCLO)	H	Cl	H	114-115
127	C ₆ H ₁₁ (CYCLO)	H	Cl	H	90-91

TABLE IF


PREPARED COMPOUNDS

m p. C


87



85 - 86


R^H in the following is

94




115 - 117

98



172 - 173

99



175 - 177


-56-

TABLE IF

PREPARED COMPOUNDS


m p. C

102




145 - 146

103




117 - 119

104




207 - 210

105



131 - 132

106




102 - 104

TABLE IF (CONT.)

PREPARED COMPOUNDS


m p. °C

107




90 - 91

108




110 - 112

109




120 - 121

128



117 - 118

129






110 - 111

TABLE IF (CONT.)

PREPARED COMPOUNDS

M P. °C



EXAMPLE 1A. Preparation of 1-Methylethyl 5-amino-2-chloro-benzoate

5 Methanesulfonic acid (99%, 318 g, 3.3 mole) was added slowly to a stirred mixture of 5-amino-2-chloro-benzoic acid (85%, 215g, 1.1 mole) in 2-propanol (about 1100 ml). The mixture was heated under reflux with stirring for 6 hours, then the excess 2-propanol was
10 evaporated under reduced pressure. Water (about 1000 ml) was added to the residue and the mixture was neutralized with solid sodium bicarbonate and extracted with methylene chloride (about 1200 ml). The extract was washed twice with water, dried over magnesium
15 sulfate and evaporated to give a purple oil, which crystallized on seeding. The product was reprecipitated from dilute hydrochloric acid solution by slowly basifying with concentrated ammonium hydroxide and seeding. The resulting crystals after drying melted at
20 50.5-52°C (170 g, 75% yield).

B. Preparation of 1-Methylethyl 2-chloro-5[[[5,6-dihydro-2-methyl-1,4-oxathiin-3-yl)carbonyl]aminolbenzoate (Compound 1)

25 Ethyl 5,6-dihydro-2-methyl-1,4-oxathiin-3-carboxylate was prepared by the method of U.S. 3,249,499 (col. 5, lines 36-55), with the following modifications: toluene was used as the solvent instead of benzene, sodium bicarbonate was used as the base instead of

potassium hydroxide, and the azeotropic removal of water was carried out under reduced pressure at about 65°C.

5,6-Dihydro-2-methyl-1,4-oxathiin-3-carboxylic acid was prepared by hydrolysis of the ester as described in the same patent (col. 5, lines 56-68, where the acid is
5 named 2,3-dihydro-5-carboxy-6-methyl-1,4-oxathiin).

Thionyl chloride (6.5 g, 0.055 mole) was added to a stirring slurry of 5,6-dihydro-2-methyl-1,4-oxathiin-3-carboxylic acid (8.0 g, 0.050 mole) in methylene
10 chloride (50 ml). The mixture was stirred at 35-40°C for 4 hours, during which the solid completely dissolved. The solution was then evaporated under reduced pressure at about 35°C to remove hydrogen chloride, sulfur dioxide and unreacted thionyl
15 chloride. The residue, crude 5,6-dihydro-2-methyl-1,4-oxathiin-3-carbonyl chloride, which solidified, was dissolved in methylene chloride (50 ml). The solution was chilled in ice and treated dropwise with a solution of 1-methylethyl 5-amino-2-chlorobenzoate (10.7 g, 0.050
20 mole) and triethylamine (5.5 g, 0.055 mole) in methylene chloride (50 ml). The addition was carried out over about 2 hours, after which the reaction mixture was left stirring overnight at room temperature.

The reaction mixture was worked up by washing the
25 methylene chloride solution with water (50 ml), dilute hydrochloric acid (3.5%, 50 ml), water (50 ml), dilute sodium hydroxide (2%, 25 ml) and water (50 ml). The

methylene chloride solution was then filtered through anhydrous sodium sulfate (about 5 g) and evaporated. The residue solidified. The crude product (17.0 g, m.p. 123-128°C) was recrystallized from 95% ethanol (175 ml) to give light tan crystals, m.p. 130-132°C (12.9 g, 72.5% yield).

Analysis:	Calc.	C 54.01	H 5.10	N 3.94
	Found	C 53.96	H 4.98	N 3.94

NMR (CDCl₃): 1.4(6H,d), 2.3(3H,s), 2.95 (2H,m), 4.35 (2H,m), 5.2 (1H,m), 7.2-8.0 (3H,m), 8.2 (1H,bs)

C. Alternate Preparation

A solution of diketene (4.0 g, 0.048 mole) in toluene (20 ml) was added dropwise over 1.5 hours to a cooled (8-12°C) solution of 1-methylethyl 5-amino-2-chlorobenzoate (9.9 g, 0.046 mole) in toluene (20 ml). The reaction mixture was warmed slowly to 40°C, then to 60-65°C for 4 hours. The reaction mixture was washed with dilute hydrochloric acid and twice with water, filtered and evaporated. The residue, a viscous purple oil, slowly solidified. The product, crude 1-methylethyl 2-chloro-5-[(1,3-dioxobutyl)amino]benzoate (11.7 g), melted at about 72-75°C. Recrystallization of a sample (1.0 g) from toluene (5 ml) gave an off white solid, m.p. 89-91°C (0.5 g).

Crude 1-methylethyl 2-chloro-5-[(1,3-dioxobutyl)amino]benzoate (10.0 g, 0.034 mole) was stirred in

toluene (50 ml) and treated dropwise at room temperature with a solution of sulfuryl chloride (4.6 g, 0.034 mole) in toluene (20 ml). Stirring was continued overnight, then the mixture was evaporated under reduced pressure.

- 5 The residue failed to crystallize, but its NMR spectrum was consistent with 1-methylethyl 2-chloro-5-[(2-chloro-1,3-dioxobutyl)amino]benzoate, about half in the enol form.

- 2-Mercaptoethanol (2.6 g, 0.033 mole) was added
10 to a solution of crude 1-methylethyl 2-chloro-5-[(2-chloro-1,3-dioxobutyl)amino]benzoate (11 g) in toluene (75 ml). Sodium bicarbonate (5.0 g, 0.06 mole), incompletely dissolved in water (40 ml), was added over 30 minutes with rapid stirring. Stirring was continued
15 for another hour, then the toluene layer was separated, washed with water, and filtered. p-Toluenesulfonic acid (0.2 g, dehydration catalyst) was added to the toluene solution, which was heated to reflux at 60-70°C under reduced pressure, using a Dean-Stark trap to remove
20 water. After water ceased being formed, the toluene solution was cooled and washed first with water, then with 2% aqueous sodium bicarbonate and again with water. Evaporation of the toluene gave a viscous oil. Crystallization from 90% ethanol (30ml) gave an
25 off-white solid, m.p. 127-130°C (1.2 g, 10% yield), which was identified (mixed m.p., NMR spectra) as 1-methylethyl 2-chloro-5-[[[5,6-dihydro-2-methyl-1,4-oxathiin-3-yl)carbonyl]amino]benzoate.

EXAMPLE 2

5 1-Methylethyl 2-chloro-5-[[[5,6-dihydro-2-methyl-1,4-oxathiin-3-yl)carbonyl]aminol-4-fluorobenzoate
 (Compound 2)

Thionyl chloride (4.2 g, 0.035 mole) was added to a stirring slurry of 5,6-dihydro-2-methyl-1,4-oxathiin-3-carboxylic acid (4.8 g, 0.030 mole) in methylene chloride (40 ml). The mixture was warmed to 35°C for 3
10 hours, then left stirring overnight at room temperature. The solution was then evaporated under reduced pressure at about 35°C. The solid residue, crude 5,6-dihydro-2-methyl-1,4-oxathiin-3-carbonyl chloride, was dissolved in methylene chloride (50 ml)
15 and the solution chilled in ice and treated dropwise with a solution of 1-methylethyl 5-amino-2-chloro-4-fluorobenzoate (7.0 g, 0.030 mole) and triethylamine (3.5 g, 0.035 mole) in methylene chloride (50 ml). The addition was carried out over 2 hours, after which
20 the reaction mixture was stirred at 20-35°C for 3 hours.

The reaction mixture was worked up by washing the methylene chloride solution first with water (50 ml), then with dilute hydrochloric acid (3.5%, 50 ml), again with water (50 ml), then with dilute sodium hydroxide
25 (2%, 25 ml) and a final wash with water (50 ml). The methylene chloride solution was then evaporated to give an oil, which solidified. The crude product was recrystallized from ethanol (100 ml) to give crystals, m.p. 123-125°C (8.2 g, 73% yield).

30 Analysis: Calc. C 51.41 H 4.58 N 3.75
 Found C 50.91 H 4.45 N 3.43

NMR: (CDCl₃) : 1.35 (6H,d), 2.3 (3H,s), 3.0 (2H,m), 4.4 (2H,m), 5.2 (1H,m), 7.2 (1H,d), 8.2 (1H,bs), 8.8 (1H,d)

5

EXAMPLE 3

10 Methyl 2-chloro-5[[5,6-dihydro-2-methyl-1,4-oxathiin-3-yl)carbonyl]aminolbenzoate (Compound 3)

Thionyl chloride (4.1 g, 0.034 mole) was added to a stirred mixture of 5,6-dihydro-2-methyl-1,4-oxathiin-3-carboxylic acid (4.3 g, 0.027 mole) and methylene chloride (35 ml). The mixture was warmed to a gentle reflux for about 3.5 hours, left stirring overnight at room temperature, and then evaporated under reduced pressure. The solid residue, crude 5,6-dihydro-2-methyl-1,4-oxathiin-3-carbonyl chloride, was dissolved in methylene chloride (50 ml) and the solution treated dropwise at 5-10°C over 2 hours with a solution of methyl 5-amino-2-chlorobenzoate (5.1 g, 0.027 mole) and triethylamine (3.1 g, 0.031 mole) in methylene chloride (35 ml). The reaction mixture was stirred at room temperature for a further 3 hours and worked up by washing in sequence with water (50 ml), dilute hydrochloric acid (3.5%, 50 ml), water (50ml), dilute sodium hydroxide (2%, 25 ml) and water (50 ml). The methylene chloride was then evaporated to leave an oil (8.2 g), which slowly solidified. Recrystallization from methanol (75 ml) gave a beige solid, m.p. 115-117°C (5.5 g, 62.5% yield).

30

Analysis:	Calc.	C 51.30	H 4.31	N 4.27
	Found	C 50.96	H 4.25	N 4.23

-65-

NMR: (CDCl₃) : 2.3 (3H,s), 3.0 (2H,m), 3.9 (3H,s), 4.4 (2H,m), 7.2-8.2 (4H,m)

5

EXAMPLE 4

Ethyl 2-chloro-5-[[[5,6-dihydro-2-methyl-1,4-oxathiin-3-yl)-carbonyl]aminolbenzoate (Compound 4)

10

Thionyl chloride (7.3 g, 0.055 mole) was added to a stirred mixture of 5,6-dihydro-2-methyl-1,4-oxathiin-3-carboxylic acid (8.0 g, 0.050 mole) and methylene chloride (50 ml). The mixture was warmed to 35°C for 15 4.5 hours, then evaporated under reduced pressure. The solid residue, crude 5,6-dihydro-2-methyl-1,4-oxathiin-3-carbonyl chloride, was dissolved in methylene chloride (50 ml) and the solution treated dropwise at 5-10°C over 5 hours with a solution of ethyl 5-amino-2-chlorobenzoate (10.0 g, 0.050 mole) and triethylamine (5.5 g, 20 0.054 mole) in methylene chloride (50 ml). The reaction mixture was left stirring overnight at room temperature.

The reaction mixture was worked up by washing the methylene chloride solution in sequence with water (50 25 ml), dilute hydrochloric acid (3.5%, 50 ml), water (50 ml), dilute sodium hydroxide (2%, 25 ml) and water (50 ml). The methylene chloride solution was filtered through anhydrous sodium sulfate and evaporated. The residual brown oil, which slowly crystallized, was 30 recrystallized from 95% ethanol (80 ml) to give a tan product, m.p. 86-88°C (10.6 g, 62% yield).

Analysis:	Calc.	C 52.71	H 4.72	N 4.10
	Found	C 53.10	H 4.97	N 4.05

NMR: (CDCl₃) : 1.4 (3H,t), 2.3 (3H,s), 3.0 (2H,m),
4.2-4.6 (4H,m), 7.2-7.95 (3H,m), 8.05 (1H,bs)

5

Example 5

Propyl 2-chloro-5-[[5,6-dihydro-2-methyl-1,4-oxathiin-3-yl)-carbonyl]aminobenzoate (Compound 5)

10

Thionyl chloride (4.4 g, 0.037 mole) was added to a stirred mixture of 5,6-dihydro-2-methyl-1,4-oxathiin-3-carboxylic acid (5.25 g, 0.033 mole) and methylene chloride (50 ml). The mixture was warmed to a gentle reflux for 3 hours, stirred overnight at room temperature, and evaporated under reduced pressure. The solid residue, crude 5,6-dihydro-2-methyl-1,4-oxathiin-3-carbonyl chloride, was dissolved in methylene chloride (50 ml), chilled, and treated dropwise over about 2 hours with a solution of propyl 5-amino-2-chlorobenzoate (7.0 g, 0.033 mole) and triethylamine (3.5 g, 0.035 mole) in methylene chloride (50 ml).

The reaction mixture was stirred overnight at room temperature, and worked up by washing in sequence with water (50 ml), dilute hydrochloric acid (3.5%, 50 ml), water (50 ml), dilute sodium hydroxide (2%, 25 ml) and water (50 ml). The methylene chloride was then evaporated to give a brown oil (8.2 g), which crystallized slowly. Recrystallization from 100% ethanol (60 ml) gave tan crystals, m.p. 76-78°C (6.2 g, 53% yield).

Analysis:	Calc.	C 54.01	H 5.10	N 3.94
	Found	C 53.99	H 5.06	N 3.59

NMR: (CDCl₃) : 1.0 (3H,t), 1.8 (2H,m), 2.3 (3H,s),
3.0 (2H,m), 4.15-4.55 (4H,m), 7.2-8.0 (3H,m), 8.1
(1H,bs)

5

EXAMPLE 6

Butyl 2-chloro-5-[[[5,6-dihydro-2-methyl-1,4-oxathiin-3-yl]carbonyl]aminolbenzoate (Compound 6)

10 Thionyl chloride (4.4 g, 0.037 mole) was added to a stirred mixture of 5,6-dihydro-2-methyl-1,4-oxathiin-3-carboxylic acid (5.0 g, 0.031 mole) and methylene chloride (50 ml). The mixture was warmed to 35-40°C for about 3 hours, left stirring overnight at room
15 temperature, and evaporated under reduced pressure. The solid residue, crude 5,6-dihydro-2-methyl-1,4-oxathiin-3-carbonyl chloride, was dissolved in methylene chloride (50 ml) and the solution treated dropwise at 5-10°C over 2 hours with a solution of butyl 5-amino-2-chloroben-
20 zoate (6.1 g, 0.031 mole) and triethylamine (3.6g, 0.036 mole) in methylene chloride (50 ml). The reaction mixture was stirred at room temperature for a further 3 hours and then worked up by washing in sequence with water (50 ml), dilute hydrochloric acid (3.5%, 50 ml),
25 water (50 ml), dilute sodium hydroxide (2%, 25 ml) and water (50ml). Evaporation of the solvent left an oil, which slowly solidified. Recrystallization from methanol (50 ml) gave beige crystals, m.p. 71-73°C (4.7 g, 41% yield).

30 Analysis: Calc. C 55.21 H 5.45 N 3.79
Found C 55.10 H 5.42 N 3.51

NMR: (CDCl₃) : 1.0 (3H,m), 1.2-2.0 (4H,m), 3.0 (2H,m),
4.15-4.55 (4H,m), 7.2-7.95 (3H,m), 8.1 (1H,bs)

35

EXAMPLE 7

1-Methylethyl 2-chloro-5-[[(2-ethyl-5,6-dihydro-1,4-oxathiin-3-yl)carbonyl]aminolbenzoate (Compound 7)

5 Thionyl chloride (3.7 g, 0.031 mole, was added to a stirred mixture of 2-ethyl-5,6-dihydro-1,4-oxathiin-3-carboxylic acid (5.0 g, 0.029 mole) and methylene chloride (35 ml). The mixture was warmed to about 35°C for 4 hours and then evaporated under reduced pressure.

10 The dark residue, crude 2-ethyl-5,6-dihydro-1,4-oxathiin-3-carbonyl chloride, was dissolved in methylene chloride (50 ml) and treated dropwise at about 10°C over 2.5 hours with a solution of 1-methylethyl 5-amino-2-chloro benzoate (6.1 g, 0.029 mole) and triethylamine

15 (3.3 g, 0.033 mole) in methylene chloride (50 ml). The reaction mixture was stirred overnight at room temperature and worked up by washing in sequence with water (50 ml), dilute hydrochloric acid (3.5%, 50 ml), water (50 ml), dilute sodium hydroxide (2%, 25 ml) and

20 water (50 ml). The methylene chloride was then evaporated to give a solid residue (10.5 g). Recrystallization from 100% ethanol (40 ml) gave a grey-brown solid, m.p. 90-92°C (5.0 g, 47% yield).

25 NMR: (CDCl₃) : 1.15 (3H,t), 1.37 (6H,d), 2.6 (2H,quartet), 3.0 (2H,m), 4.4 (2H,m), 5.25 (1H,m), 7.25-7.95 (3H,m), 8.1 (1H,bs)

EXAMPLE 8

30 Ethyl 3-[[(5,6-dihydro-2-methyl-1,4-oxathiin-3-yl)carbonyl]aminolbenzoate (Compound 8)

Thionyl chloride (6.5 g, 0.055 mole) was added to a stirred mixture of 5,6-dihydro-2-methyl-1,4-oxathiin-3-

carboxylic acid (8.0 g, 0.050 mole) and methylene chloride (50 ml). The mixture was warmed to 35-40°C for 4 hours and the resulting dark solution evaporated under reduced pressure. The solid residue, crude 5,6-dihydro-2-methyl-1,4-oxathiin-3-carbonyl chloride, was dissolved in methylene chloride (50 ml). On the following day, the solution was treated dropwise at 15-20°C over 2 hours with a solution of ethyl 3-aminobenzoate (8.2 g, 0.050 mole) and triethylamine (5.5 g, 0.054 mole) in methylene chloride (50 ml). The reaction mixture was stirred at room temperature for a further 5 hours and worked up by washing in sequence with water (50 ml), dilute hydrochloric acid (3.5%, 50 ml), water (50 ml), dilute sodium hydroxide (2%, 25 ml) and water (50 ml). Evaporation of the solvent left an oil, which slowly solidified. Recrystallization from ethanol (75 ml) gave yellow-tan crystals, m.p. 100-102°C (11.2 g, 73% yield).

20	Analysis:	Calc.	C 58.62	H 5.57	N 4.56
		Found	C 58.46	H 5.74	N 4.72

NMR: (CDCl₃) : 1.4 (3H,t), 2.3 (3H,s), 3.0 (2H,m),
4.15-4.6 (4H,m), 7.2-8.3 (5H,m)

25

EXAMPLE 9

N-(3-Cyanophenyl)-5,6-dihydro-2-methyl-1,4-oxathiin-3-carboxamide (Compound 9)

30 5,6-Dihydro-2-methyl-1,4-oxathiin-3-carboxylic acid (5.0 g, 0.031 mole) and thionyl chloride (4.1 g, 0.034 mole) were heated under reflux in methylene chloride for

about 2 hours, then evaporated under reduced pressure. The solid residue, crude 5,6-dihydro-2-methyl-1,4-oxathiin-3-carbonyl chloride, was dissolved in methylene chloride and the chilled solution treated dropwise with a solution of 3-aminobenzonitrile (3.7 g, 0.031 mole) and triethylamine (3.2 g, 0.032 mole) in methylene chloride. The reaction mixture was stirred at room temperature for a further 3 hours and then worked up by washing with dilute hydrochloric acid and dilute sodium hydroxide. Evaporation of the solvent gave a solid residue, which was recrystallized from methanol to give a white solid, m.p. 119-121°C (5.5 g, 67% yield).

NMR: (CDCl₃) : 2.3 (3H,s), 3.0 (2H,m), 4.4 (2H,m), 7.2-8.2 (5H,m)

EXAMPLE 10

1-Methylethyl 5-[[5,6-dihydro-2-methyl-1,4-oxathiin-3-yl]carbonyl]aminobenzoate (Compound 10)

Thionyl chloride (3.5 g, 0.029 mole) was added to a stirred mixture of 5,6-dihydro-2-methyl-1,4-oxathiin-3-carboxylic acid (4.7 g, 0.029 mole) and methylene chloride (100 ml). The mixture was warmed to 30-35°C for 4 hours, then evaporated under reduced pressure. The residue, crude 5,6-dihydro-2-methyl-1,4-oxathiin-3-carbonyl chloride, was dissolved in methylene chloride (100 ml), and the ice-chilled solution treated dropwise with a solution of 1-methylethyl 3-aminobenzoate (5.2 g, 0.029 mole) and triethylamine (2.9 g, 0.029 mole) in methylene chloride (50 ml). The reaction mixture was

stirred overnight at room temperature and then worked up by washing in sequence with water, dilute hydrochloric acid, water, 2% sodium hydroxide and water. Evaporation of the solvent left an oil, which solidified. After
5 recrystallization from ethanol (30 ml) the product (4.0 g, 42% yield) melted at 92-94°C.

Analysis:	Calc.	C 59.79	H 5.96	N 4.36
	Found	C 59.46	H 6.21	N 4.51

10 NMR: (CDCl₃) : 1.35 (6H,d), 2.3 (3H,s) 3.0 (2H,m), 4.4 (2H,m), 4.4 (2H,m), 5.25 (1H,m), 7.2-8.2 (5H,m)

EXAMPLE 11

15

Ethyl 2-chloro-5-[[[2-ethyl-5,6-dihydro-1,4-oxathiin-3-yl]carbonyl]aminolbenzoate (Compound 11)

Thionyl chloride (4.0 g, 0.034 mole) was added to a
20 stirred mixture of 2-ethyl-5,6-dihydro-1,4-oxathiin-3-carboxylic acid (5.9 g, 0.034 mole) and methylene chloride (100 ml). The mixture was warmed to about 35°C for 3 hours, then evaporated under reduced pressure. The residue, crude 2-ethyl-5,6-dihydro-1,4-oxathiin-3-
25 carbonyl chloride, was dissolved in methylene chloride (100 ml), and the ice-chilled solution treated dropwise with a solution of ethyl 5-amino-2-chlorobenzoate (6.8 g, 0.034 mole) and triethylamine (3.7 g, 0.037 mole) in methylene chloride (100 ml). The reaction mixture was
30 stirred overnight at room temperature and then worked up by washing in sequence with water, dilute hydrochloric acid, water, 2% sodium hydroxide and water. Evaporation of the solvent left an oil, which solidified. After

recrystallization from ethanol (30 ml) the product (7.0 g, 58% yield) melted at 86-88°C.

Analysis:	Calc.	C 54.01	H 5.10	N 3.94
	Found	C 53.60	H 5.03	N 4.04

5

NMR: (CDCl₃) : 1.0-1.6 (6H,m) 2.6 (2H,quartet), 3.0 (2H,m), 4.15-4.6 (4H,m), 7.2-7.9 (3H,m), 8.05 (1H,bs)

10

EXAMPLE 12

1-Methylethyl 5-[[[5,6-dihydro-2-methyl-1,4-oxathiin-3-yl)carbonyl]amino]-4-fluoro-2-methylbenzoate (Compound 12)

15

Thionyl chloride (4.7 g, 0.040 mole) was added to a stirred mixture of 5,6-dihydro-2-methyl-1,4-oxathiin-3-carboxylic acid (6.0 g, 0.037 mole) and methylene chloride (50 ml). The mixture was stirred overnight at room temperature, then evaporated under reduced pressure. The solid residue, crude 5,6-dihydro-2-methyl-1,4-oxathiin-3-carbonyl chloride, was dissolved in methylene chloride (50 ml) and the chilled solution treated dropwise over about 1 hour with a solution of 1-methylethyl 5-amino-4-fluoro-2-methylbenzoate (7.9 g, 0.037 mole) and triethylamine (3.9 g, 0.039 mole) in methylene chloride (50 ml). The reaction mixture was left stirring overnight at room temperature and worked up by washing in sequence with water (50 ml), dilute hydrochloric acid (3.5%, 50 ml), water (50 ml), dilute sodium hydroxide (2%, 25 ml) and water (50 ml). Evaporation of the solvent left a solid residue. Recrystallization from 100% ethanol (60 ml) gave yellow-tan crystals, m.p. 119-122°C (7.6 g, 57% yield).

Analysis: Calc. C 57.78 H 5.70 N 3.96
Found C 57.75 H 5.79 N 3.99

5 NMR: (CDCl₃) : 1.35 (6H,d), 2.3 (3H,s),
2.55 (3H,s), 3.0 (2H,m), 4.4 (2H,m), 5.2 (1H,s),
6.95 (1H,d), 8.1 (1H,bs), 8.75 (1H,d)

EXAMPLE 13

10

1-Methylethyl 3-[[[(5,6-dihydro-2-methyl-1,4-oxathiin-3-yl)carbonyl]amino]-4-fluorobenzoate (Compound 13)

Thionyl chloride (4.6 g, 0.039 mole) was added to a
15 stirred mixture of 5,6-dihydro-2-methyl-1,4-oxathiin-3-
carboxylic acid (6.0 g, 0.037 mole) and methylene
chloride (50 ml). The mixture was warmed to 35-40°C for
about 3 hours, then evaporated under reduced pressure.
The residue, crude 5,6-dihydro-2-methyl-1,4-oxathiin-
20 3-carbonyl chloride, was dissolved in methylene chloride
(50 ml) and the ice-cooled solution treated dropwise
with a solution of 1-methylethyl 3-amino-4-fluoroben-
zoate (7.4 g, 0.037 mole) and triethylamine (3.9 g,
0.039 mole) in methylene chloride (50 ml). The reaction
25 mixture was stirred overnight at room temperature, and
then washed in sequence with water (50 ml), dilute
hydrochloric acid (3.5%, 50 ml), water (50 ml), dilute
sodium hydroxide (2%, 25 ml) and water (50 ml), dried
with anhydrous sodium sulfate and evaporated.
30 Recrystallization of the solid residue from 100% ethanol
(100 ml) gave light brown crystals, m.p. 132-135°C
(7.8 g, 61% yield).

Analysis: Calc. C 56.63 H 5.35 N 4.13
Found C 56.40 H 5.26 N 4.25

35

NMR: (CDCl₃) : 1.35 (6H,d), 2.3 (3H,s),
3.0 (2H,m), 4.4 (2H,m), 5.25 (1H,m), 7.1
(1H,m), 7.8 (1H,m) 8.2 (1H,bs), 8.9 (1H,m)

EXAMPLE 14

Ethyl 3-[[[5,6-dihydro-2-methyl-1,4-oxathiin-3-yl]
carbonyllaminol-4-methylbenzoate (Compound 14)

Thionyl chloride (4.5 g, 0.038 mole) was added to a
5 stirred mixture of 5,6-dihydro-2-methyl-1,4-oxathiin-3-
carboxylic acid (6.0 g, 0.037 mole) and methylene
chloride (100 ml). The mixture was warmed to 30-35° C.
for 3 hours, then evaporated under reduced pressure.
The residue, crude 5,6-dihydro-2-methyl-1,4-oxathiin-3-
10 carbonyl chloride, was dissolved in methylene chloride
(100 ml), and the ice-chilled solution treated dropwise
with a solution of ethyl 3-amino-4-methylbenzoate (6.7
g, 0.037 mole) and triethylamine (4.0 g, 0.040 mole) in
methylene chloride (100 ml). The reaction mixture was
15 stirred overnight at room temperature and then worked up
by washing in sequence with water, dilute hydrochloric
acid, water, 2% sodium hydroxide and water. Evaporation
of the solvent gave an oil, which solidified. After
recrystallization from ethanol (30 ml), the product (7.1
20 g, 59% yield) melted at 105-107°C.

Analysis:	Calc.	C 59.79	H 5.96	N 4.36
	Found	C 59.87	H 5.73	N 4.52

25 NMR: (CDCl₃) : 1.35 (3H,t), 2.25 (3H,s),
2.3 (3H,s) 2.3 (3H,s), 3.0 (2H,m), 4.15-4.55
(4H,m), 7.1-7.3 (1H,m), 7.55-7.95 (2H,m), 8.45
(1H,d)

EXAMPLE 15

Pentyl 2-chloro-5-[[[5,6-dihydro-2-methyl-1,4-oxathiin-
3-yl]carbonyllaminolbenzoate (Compound 15)

Thionyl chloride (3.9 g, 0.033 mole) was added to a

stirred mixture of 5,6-dihydro-2-methyl-1,4-oxathiin-3-carboxylic acid (5.2 g, 0.032 mole) and methylene chloride (100 ml). The mixture was stirred overnight at room temperature, then evaporated under reduced pressure. The residue, crude 5,6-dihydro-2-methyl-1,4-oxathiin-3-carbonyl chloride, was dissolved in methylene chloride (100 ml), and the ice-chilled solution treated dropwise with a solution of pentyl 5-amino-2-chlorobenzoate (7.9 g, 0.033 mole) and triethylamine (3.3 g, 0.033 mole) in methylene chloride (100 ml). The reaction mixture was stirred at room temperature for 4 hours, then worked up by washing in sequence with water, dilute hydrochloric acid, water, 2% sodium hydroxide and water. Evaporation of the solvent left an oil, which solidified very slowly. After recrystallization from ethanol (30 ml) the product (5.9 g, 47% yield) melted at 65-68°C. A second recrystallization raised the melting point to 70-71°C.

20	Analysis:	Calc.	C 56.32	H 5.78	N 3.65
		Found	C 56.29	H 5.66	N 3.67

NMR: (CDCl₃) : 0.7-1.9 (9H,m) 2.3 (3H,s),
3.0 (2H,m) 4.15-4.55 (4H,m), 7.15-8.1 (4H,m)

EXAMPLE 16

1-Methylethyl 2-chloro-5-[[(2,4,5-trimethyl-3-furanyl)carbonyl]aminolbenzoate (Compound 16)

2,4,5-Trimethyl-3-furancarboxylic acid was prepared by the method of Hanson et al., J. Chem Soc. (1965), 5984.

2,4,5-Trimethyl-3-furancarbonyl chloride was prepared by refluxing 2,4,5-trimethyl-3-furancarboxylic acid (20.0 g) with thionyl chloride (20 ml) in toluene (75 ml) for 3 hours. The toluene and excess thionyl chloride were removed on a rotary evaporator and the residue distilled (b.p. 95 - 97°C. at ca. 12 mm).

A solution of 2,4,5-trimethyl-3-furancarbonyl chloride (7.8 g, 0.045 mole) in toluene (25 ml) was added to 1-methylethyl 5-amino-2-chlorobenzoate (10.6 g, 0.050 mole) and triethylamine (6 g) in toluene (25 ml). The mixture was warmed to 60°C for about 1 hour, then washed in sequence with dilute hydrochloric acid, water, aqueous 5% sodium bicarbonate and water. The solution was dried with magnesium sulfate, filtered and evaporated. The residue was crystallized from toluene/petroleum ether to give 6.7 g of a pale yellow solid, m.p. 83 - 85°C.

Analysis:	Calc.	C 61.89	H 5.73	N 4.01
	Found	C 61.78	H 5.83	N 4.10

NMR: (DMSO-d₆): 1.35 (6H,d), 1.98 (3H,s), 2.20 (3H,s), 2.42 (3H,s), 5.2 (1H,m), 7.4-8.2 (3H,m), 10.1 (1H,s)

EXAMPLE 17

1-Methylethyl 2-chloro-5-[(3-methyl-2-furanyl)carbonyl]aminobenzoate (Compound 17)

3-Methyl-2-furancarboxylic acid (41 g, m.p. 136 - 138°C) was prepared by refluxing methyl 3-methyl-2-furancarboxylate 54g, (Organic Synthesis, Coll. Vol. IV,

p. 649), sodium hydroxide (20 g), water (100 ml) and ethanol (100 ml), then cooling and acidifying with concentrated hydrochloric acid.

3-Methyl-2-furancarbonyl chloride was prepared by
5 refluxing 3-methyl-2-furancarboxylic acid (20.0 g) with thionyl chloride (25 ml) in toluene (75 ml) for 3 hours. After removal of the solvent, the acid chloride was distilled (b.p. 74-76°C at ca. 12 mm).

A solution of 3-methyl-2-furancarbonyl chloride
10 (9.5 g, 0.066 mole) in toluene (20 ml) was added to 1-methylethyl 5-amino-2-chlorobenzoate (14 g, 0.066 mole) and triethylamine (10 g) in toluene (20 ml). After about three hours at ambient temperature, the mixture was washed with dilute hydrochloric acid, water,
15 aqueous 5% sodium bicarbonate and finally water. With cooling, the product (m.p. 99 - 100°C., 10 g, 47% yield) was crystallized from toluene.

Analysis:	Calc.	C 59.81	H 4.98	N 4.36
	Found	C 59.11	H 5.00	N 4.02

20 NMR: (DMSO-d₆): 1.35 (6H,d), 2.37 (3H,s), 5.2 (1H,m), 6.6 (1H,d), 7.44-8.29 (4H,m), 10.35 (1H,s)

25 EXAMPLE 18

1-Methylethyl 5-(benzoylamino)-2-chloro-4-fluorobenzoate
(Compound 18)

A solution of benzoyl chloride (2.94 g, 0.021 mole)
30 and 1-methylethyl 5-amino-2-chloro-4-fluorobenzoate (4.62 g, 0.020 mole) in methyl ethyl ketone (50 ml) was stirred at room temperature for 3 days. Evaporation of the solvent and crystallization of the solid residue

from ethyl ether gave colorless needles, m.p. 117-119°C (6 g, 90% yield).

5 Analysis: Calc. C 60.81 H 4.50 N 4.17
 Found C 60.89 H 4.72 N 4.08

NMR: (CDC13) : 1.37 (6H,d), 5.25 (1H,m), 7.20 (1H,d),
 7.4-7.6 (3H,m), 7.75-8.0 (2H,m), 8.15 (1H,bs), 8.83
 (1H,d)

10

EXAMPLE 19

1-Methylethyl 2-chloro-5-[(2-methoxybenzoyl)
aminolbenzoate (Compound 19)

15 2-Methoxybenzoyl chloride (8.8 g, 0.05 mole) was
added at room temperature under a dry nitrogen
atmosphere to a stirred mixture of 1-methylethyl
5-amino-2-chlorobenzoate (10.7 g, 0.05 mole),
triethylamine (5.6 g, 0.055 mole) and 4-(N,N,-
20 dimethylamino)pyridine (catalyst, 0.2 g) dissolved in
dry p-dioxane (100 ml). A solid precipitate formed.
Following the initial exothermic reaction (temperature
increased to about 45°C), the reaction mixture was
stirred under nitrogen at room temperature for 20
25 hours. Next, the reaction mixture was added to water
(500 ml), resulting in the precipitation of a solid
product, which was collected by vacuum filtration,
washed with water (500 ml), and dried to yield 16.2 g of
the title compound, m.p. 94-96°C.

30 NMR: (CDC13) : 1.40 (6H,d) 4.05 (3H,s) 5.28 (1H,m), 7.02
 (1H,d), 7.11 (1H,m), 7.38 (1H,d), 7.49 (1H,m), 7.87
 (1H,m), 7.95 (1H,d), 8.25 (1H,m), 9.86 (1H,s)

EXAMPLE 20

5 2,3,4,5-Tetrabromo-6-[[[4-chloro-2-fluoro-5-(1-methylethoxycarbonyl)phenyllaminolcarbonyl]benzoic acid (Compound 20)

Tetrabromophthalic anhydride (6.67 g, 0.014 mole) and 1-methylethyl 5-amino-2-chloro-4-fluorobenzoate (3.33 g, 0.014 mole) were heated to reflux with stirring
10 in about 150 ml of toluene, then left overnight at room temperature. Filtration of the reaction mixture gave the title compound, m.p. 160-165°C (decomp.).

Analysis: Calc. C 31.09 H 1.60 N 2.01
Found C 31.27 H 1.57 N 2.12
15 NMR (DMSO-d₆): 1.35 (6H,d), 5.2 (1H,m),
7.7 (1H,d), 8.45 (1H,d), 9.9 (1H,bs), 10.9 (1H,s)

20

EXAMPLE 21

2,3,4,5-Tetrabromo-6-[[[4-chloro-3-(1-methylethoxycarbonyl)phenyllaminolcarbonyl]benzoic acid (Compound 21)

25

Tetrabromophthalic anhydride (7.03 g, 0.015 mole), 1-methylethyl 5-amino-2-chlorobenzoate (3.24 g, 0.015 mole) and toluene (about 150 ml) were heated almost to reflux over 30 minutes. The reaction mixture was cooled
30 and filtered to give the title compound, m.p. 169-171°C (decomp.) (8.92 g, 87% yield).

Analysis: Calc. C 31.92 H 1.79 N 2.07
Found C 33.00 H 2.00 N 2.12
35 NMR: (DMSO-d₆): 1.35 (6H,d), 5.2 (1H,m)
7.4-8.2 (3H,m), 11.0 (1H,s), 12.0 (1H,bs)

40

EXAMPLE 22

2,3,4,5-Tetrachloro-6-[[[4-chloro-3-(1-methylethoxycarbonyl)phenyllaminolcarbonyl]benzoic acid (Compound 22)

A mixture of tetrachlorophthalic anhydride (2.97 g, 0.010 mole), 1-methylethyl 5-amino-2-chlorobenzoate (2.22 g, 0.010 mole) and toluene (100 ml) was heated slowly to reflux with stirring, then left overnight at room temperature. Filtration of the reaction mixture gave the title compound, m.p. 178-179°C (3.45 g, 70% yield).

Analysis: Calc. C 43.28 H 2.42 N 2.80
 Found C 42.99 H 2.31 N 2.91

NMR: (DMSO-d₆): 1.35 (6H,d), 5.2 (1H,m)
 7.4-8.2 (3H,m), 11.2 (1H,s), 11.5 (1H,bs)

EXAMPLE 23

1-Methylethyl 2-chloro-5-[(2-methylbenzoyl)aminobenzoate (Compound 23)

A solution of 1-methylethyl 5-amino-2-chlorobenzoate (5.3 g, 0.025 mole) and triethylamine (3 g, 0.030 mole) in methylene chloride (50 ml) was added dropwise over 1 hour to an ice-cooled solution of o-toluy chloride (4 g, 0.026 mole) in methylene chloride (50 ml). The mixture was then stirred at room temperature for 2 hours and worked up by sequential washing with water, dilute hydrochloric acid, water, 2% aqueous sodium hydroxide and water. The residue from evaporation of the methylene chloride was recrystallized from isopropyl alcohol (50 ml) to give the title compound, m.p. 137-138°C (4 g, 49% yield).

Analysis: Calc. C 65.16 H 5.47 N 4.22
 Found C 64.75 H 5.01 N 3.95

NMR: (CDCl₃) : 1.4 (6H,d), 2.5 (3H,s),
 5.25 (1H,m), 7.2-7.55 (5H,m), 7.7-8.0 (3H,m)

EXAMPLE 24Propyl 2-chloro-5-[(2-methylbenzoyl)aminolbenzoate
(Compound 24)

A solution of propyl 5-amino-2-chlorobenzoate (10.7
5 g, 0.050 mole) and triethylamine (6 g, 0.059 mole) in
methylene chloride (50 ml) was added dropwise over 1
hour to an ice-cooled solution of o-toluoyl chloride
(7.8 g, 0.50 mole) in methylene chloride (50 ml). The
mixture was then stirred at room temperature for 3 hours
10 and worked up by washing sequentially with water, dilute
hydrochloric acid, water, 2% aqueous sodium hydroxide
and water. The residue from evaporation of the
methylene chloride was recrystallized from ethanol (100
ml) to give the title compound, m.p. 103-105°C (7.5 g,
15 45% yield).

Analysis:	Calc.	C 65.16	H 5.47	N 4.22
	Found	C 64.79	H 4.91	N 4.11

20 NMR: (CDCl₃) : 1.0 (3H,t), 1.7 (2H,m), 2.5 (3H,s), 4.25
(2H,t), 7.2-7.55 (5H,m), 7.65-8.0 (3H,m)

EXAMPLE 25N-(4-Chlorophenyl)-5,6-dihydro-3-methyl-1,4-dithiin-2-
carboxamide (Compound 26)

2-Chloro-N-(4-chlorophenyl)-3-oxobutanamide (24.7
g, 0.1 mole), 1,2-ethanedithiol (9.4 g, 0.1 mole) and a
small amount of p-toluenesulfonic acid were heated under
30 reflux in benzene (150 ml), using a Dean-Stark trap to
remove water (1.9 ml collected). The reaction mixture
was filtered, treated with triethylamine (8 ml), and
refluxed for a further 30 minutes. The mixture was then

washed with water, dilute hydrochloric acid, and water. Evaporation of the benzene gave a white solid, which was recrystallized from absolute ethanol. The product melted at 115 - 117°C (24 g, 84% yield).

5	Analysis:	Calc.	C 50.43	H 4.20
		Found	C 50.18	H 4.15

EXAMPLE 26

10

1-Methylethyl 2-chloro-5-[[[5,6-dihydro-3-methyl-1,4-dithiin-2-yl]carbonyl]aminolbenzoate (Compound 27)

5,6-Dihydro-3-methyl-1,4-dithiin-2-carboxylic acid
15 was prepared by the method of U.S. patent 4,004,018, col. 11, lines 24-38.

Thionyl chloride (6.5 g, 0.055 mole) was added slowly to a stirred solution of 5,6-dihydro-3-methyl-1,4-dithiin-2-carboxylic acid (3 g, 0.017 mole) in toluene
20 (15 ml) at room temperature. The mixture was heated under reflux for 4 hours. The excess toluene and thionyl chloride were removed in a rotary evaporator, yielding the crude acid chloride. 1-Methylethyl 5-amino-2-chlorobenzoate (3 g, 0.014 mole) in pyridine (20
25 ml) was added slowly to a stirred solution of the crude acid chloride (3 g) in methylene chloride (20 ml) at 20°C. The mixture was stirred for 24 hours, poured onto ice and concentrated hydrochloric acid, washed twice with water, dried with magnesium sulfate, and the
30 methylene chloride evaporated. Recrystallization from 95% ethanol yielded the title compound, m.p. 122 - 124°C. (3 g, 57% yield).

Analysis: Calc. C 51.67 H 4.88 N 3.77
Found C 51.43 H 4.70 N 3.72

5 NMR: (DMSO-d₆): 1.4 (6H,d), 2.1 (3H,s),
3.3 (4H,bs), 5.2 (1H,m), 7.4-8.25 (3H,m)

EXAMPLE 27

10 1-Methylethyl 2-chloro-5-[[5,6-dihydro-3-methyl-1,4-dioxin-2-yl)carbonyl]aminobenzoate (Compound 28)

Trifluoroacetic anhydride (100 g, 0.5 mole) was added dropwise to an ice-cooled solution of
15 2,3-dihydro-5-methyl-1,4-dioxin (30 g, 0.30 mole) in methylene chloride (50 ml) and pyridine (40 g, 0.50 mole). The mixture was stirred overnight and then evaporated under reduced pressure. To the residue was added ether (150 ml) and 10% sodium carbonate solution.
20 The ether phase was separated, washed with dilute hydrochloric acid and water, dried over anhydrous sodium sulfate, filtered and evaporated to leave an oil, 1-(5,6-dihydro-3-methyl-1,4-dioxin-2-yl)-2,2,2-trifluoroethanone (12 g, 20% yield).

25 A mixture of 1-(5,6-dihydro-3-methyl-1,4-dioxin-2-yl)-2,2,2-trifluoroethanone (12 g, 0.06 mole) and powdered potassium hydroxide (6 g, 0.1 mole) was refluxed in toluene (200 ml) for 7 hours. The mixture was cooled, acidified with 6N hydrochloric acid, and the
30 solid precipitate, crude 5,6-dihydro-3-methyl-1,4-dioxin-2-carboxylic acid (6 g, 60% yield) collected.

A mixture of thionyl chloride (1.3 g, 0.011 mole) and 5,6-dihydro-3-methyl-1,4-dioxin-2-carboxylic acid

(0.57 g, 0.004 mole) was refluxed on a steam bath for 3 hours and the excess thionyl chloride was evaporated at atmospheric pressure. The resulting liquid was added dropwise to a stirred solution of 1-methylethyl

5 5-amino-2-chlorobenzoate (1.6 g, 0.008 mole) in diethyl ether (30 ml), cooled in an ice-water bath. The mixture was worked up by diluting with diethyl ether (120 ml), washing with dilute hydrochloric acid (50 ml), and then with water (50 ml). The diethyl ether solution was

10 dried over anhydrous sodium sulfate, filtered and evaporated under reduced pressure, leaving a solid residue. The crude product was washed with isopropyl alcohol (30 ml), leaving a brown solid, m.p. 103-105°C (1.2 g, 95.8% yield).

15 NMR: (CDCl₃) : 1.4 (6H,d), 2.3 (3H,s), 4.2 (4H,s), 5.3 (1H,m), 7.3-8.0 (3H,m), 8.3 (1H,bs)

EXAMPLE 28

20 1-Methylethyl 2-chloro-5-[[1-methylethoxycarbonyl]aminolbenzoate (Compound 29)

Hydrogen chloride was bubbled into a solution of

25 1-methylethyl 5-amino-2-chlorobenzoate (35 g, 0.16 mole) in dry diethyl ether (500 ml). The resulting precipitate was filtered off, washed with ether and dried overnight in a vacuum desiccator. It was then suspended in ethyl acetate and excess phosgene bubbled

30 into the stirred, refluxing mixture over 45 minutes. Part of the ethyl acetate was distilled off to remove excess phosgene, then the rest of the solvent was

removed under reduced pressure and the residual
1-methylethyl 2-chloro-5-isocyanatobenzoate distilled at
114°C./0.1 mm (28 g, 71% yield).

5 NMR (CDCl₃): 1.39 (6H,d), 5.26 (1H,m), 6.98-7.52 (3H,m)

1-Methylethyl 2-chloro-5-isocyanatobenzoate (3 g,
0.013 mole) in tetrahydrofuran (5 ml) was added to
isopropyl alcohol (5 ml) in tetrahydrofuran (5 ml). A
10 few drops of triethylamine were added and the reaction
mixture left at ambient temperature overnight. Removal
of the solvent and crystallization from isopropyl
alcohol gave the title compound, m.p. 108 - 109°C (2.7
g).

15 Analysis: Cal. C 56.18 H 6.02 N 4.68
Found C 55.66 H 5.93 N 4.51

NMR: (DMSO-d₆): 1.27 (6H,d), 1.35 (6H,d),
20 4.7-5.38 (2H,m), 7.38-8.0 (3H,m), 9.9 (1H,s)

EXAMPLE 29

25 1-Methylethyl 2-chloro-5-[(2,2-dimethyl-1-oxopropyl)
aminol-4-fluorobenzoate (Compound 30)

A solution of trimethylacetyl chloride (2.53 g,
0.021 mole) and 1-methylethyl 5-amino-2-chloro-4-
fluorobenzoate (4.62 g, 0.020 mole) in methyl ethyl
30 ketone was stirred at room temperature for 16 hours and
then refluxed for 2 hours. The solvent was removed and
the residue triturated with diethyl ether to give a tan
solid, m.p. 81-83°C (5.0 g, 79% yield).

Analysis:	Calc.	C 57.06	H 6.06	N 4.44
	Found	C 56.83	H 6.08	N 4.38

5 NMR: (CDCl₃) : 1.33 (9H,s), 1.38 (6H,d),
(5.25 (1H,m), 5.25 (1H,m), 7.18 (1H,d), 7.60
(1H,bs), 8.77 (1H,d)

EXAMPLE 30

10

Preparation of 1-methylethyl 2-chloro-5-[(2-methyl-3-furanyl)thioxomethyl]amino benzoate (Compound 59).

A mixture of 3.5g 1-methylethyl 2-chloro-5-[(2-methyl-3-furanyl)carbonyl]amino]benzoate, 4.0g

15

Lawesson's reagent was refluxed in toluene for seven hours. The solvent was removed and the residue eluted from a silica gel column with a 40:60 mixture of ethyl acetate: hexane. An oil was obtained from the first fraction which on crystallization from toluene/petroleum

20

ether gave a yellow solid (0.9g) m.p. 83-85°C.

Analysis:	Calc.	C 56.97	H 4.75	N 4.15
	Found	C 56.86	H 4.69	N 3.83

25

NMR spectrum (CDCl₃) gave ppm values 1.30 (3H,s) 1.40 (3H,s) 2.65(3H,s) 5.0-5.5 (1H,quartet) 6.55-6.62 (1H,d) 7.15-8.0(4H,m) 8.7-9.05(1H,s)

EXAMPLE 31

30

1-Methylethyl 2-chloro-5-[(2,5-diethyl-3-furanyl)thioxomethyl]aminolbenzoate (Compound 60)

was prepared in a manner similar to Example 30.

NMR spectrum (CDCl₃) gave ppm values 1.40 (3H,s)

1.50(3H,s) 2.69(3H,s) 5.0-5.6 (1H,quartet) 6.25

35

(1H,s) 7.38-8.1 (2H,m) 8.78-9.05 (1H,s)

EXAMPLE 32

1-Methylethyl 2-chloro-5-[[2,4,5-trimethyl
3-furanyl]thioxomethyl]aminobenzoate (Compound 58)

5 was prepared in a manner similar to Example 30.

Analysis: Calc. C:59.18 H:5.48 N:3.84

Found C:58.94 H:5.49 N:4.40

EXAMPLE 33

10

Benzoic acid, 2-chloro-5-[(phenylthioxomethyl)
aminoethyl ester (Compound 62)

A solution of benzoic acid, 5-(benzoylamino)-2-chloro-, ethyl ester (3.0g, 10m moles) and 4.12 (10m
15 moles) of Lawesson's reagent in 100 ml of dry toluene was stirred and refluxed for nine hours. The solution was concentrated then purified through a short column of silica gel (70-230 mesh) using ethyl ether: hexane (1:1) as eluent. A bright amber solid was obtained m.p.

20 125-127°C, yield 2.6g (80%)

Analysis: Calc. C 60.9 H 4.41 N 4.38
Found C 59.88 H 4.43 N 4.28

25 NMR: δ (CDCl₃) 1.36(3H,t), 4.34(2H,m), 7.3-8.1 (8H,m),
9.23(1H,bs)

EXAMPLE 34

30 Benzoic acid, 2-chloro-5-(phenylthioxomethyl)
amino-, 1-methylethyl ester (Compound 61)

A solution of benzoic acid, 5-(benzoylamino)-2-chloro-, 1-methylethyl ester (3.2g, 10mmoles) and 4.04g
of Lawesson's reagent in 150 ml of dry toluene was
stirred and refluxed for 40 hours. The solution was
35 concentrated then purified through a short column of

aluminum oxide using ethyl ether: hexane (1.3) as eluents. The amber solution was concentrated to give bright amber solid m.p. 93-94°C yield, 1.5g (44.6%).

5 NMR δ (CDCl₃) 1.30-1.40(d, 6H), 5.23(m, 1H)
7.2-8.1(m, 8H) 9.30 (bs, 1H)

Analysis:	Calc.	C 61.16	H 4.83	N 4.20
	Found	C 61.24	H 4.84	N 4.52

10

EXAMPLE 35

Benzoic Acid, 2-chloro-5-(3-methyl-1-thioxo-2-butenyl)amino-, 1-methylethyl ester (Compound 67)

15 A solution of benzoic acid, 2-chloro-(3-methyl-1-oxo-2-butenyl)amino-, 1-methylethyl ester (3.7g, 12.5 mmoles) and Lawesson's reagent (5.1g, 12.5 mmoles) in 100ml of dry toluene was stirred and refluxed for 40 hours. The final solution was concentrated then
20 purified through a short column of silica gel (70-230 mesh) using ethyl ether as eluent. An orange oil (5g) was obtained. This crude product was purified further with a column of aluminum oxide using ethyl ether: hexane (1:3) as eluent. A light amber solution was
25 obtained which was concentrated to give a light amber solid m.p. 85-86°C, yield 2.8g, (72%)

Analysis:	Calc.	C 57.78	H 5.82	N 4.49
	Found	C 57.05	H 5.54	N 5.70

30 NMR: δ (CDCl₃) 1.33, 1.40 (d, 6H); 1.83-2.03 (dd, 6H)
5.26(m, 1H), 6.13(unresolved m, 1H), 7.23-7.8 (m, 3H)
7.9 (bs, 1H)

35

EXAMPLE 361-Methylethyl 2-chloro-5-[[(1-methylethoxy)thioxo-methyl]amino]benzoate (Compound 32)

5 This is the preparation of compound 32 using
1,3-dicyclohexylcarbodiimide. A mixture of
2-chloro-5-[[(1-methylethoxy)thioxomethyl]amino]benzoic
acid (2g, 0.007 mol), isopropyl alcohol (1.3g, 0.02
mol), 4-dimethylaminopyridine (0.85g, 0.007 mol) in 25
10 ml methylene chloride was stirred in an ice bath and
1,3-dicyclohexylcarbodiimide (1.7g 0.008 mol) added.
The mixture was allowed to come to ambient temperature
and stirred overnight. The precipitated solid was
filtered off and the filtrate washed with dilute
15 hydrochloric acid and aqueous 5% sodium bicarbonate.
After drying over magnesium sulfate, filtering and
removing the methylene chloride, the product was
crystallized from toluene/petroleum ether. Yield 1.2g
m.p. 89°C. A mixed m.p. with authentic compound 32 also
20 gave m.p. 89-90°C. The N.M.R. spectrum was identical
with that of authentic compound 32.

Analysis:	Calc.	C 53.33	H 5.71	N 4.44
	Found	C 53.44	H 5.62	N 4.42

25 NMR: δ (CDCl₃) 1.35(6H,d), 1.45 (6H,d); 5.0-5.8 (2H,m)
7.28-7.80(3H,m), 8.43(1H,s)

IN VITRO SCREENING RESULTS

The compounds of Examples were tested for
30 anti-AIDS activity by subjecting them to standard
National Cancer Institute ("NCI") in vitro screening

procedures. In carrying out each test, two blanks were run. In the first blank, HIV and a culture of a standard human cell line were incubated together to measure the infectivity of the virus. The viability of the cells was measured after holding for six or seven days. In an "effective" test, most cells were infected before the holding period was complete.

In the second blank, the cell line culture and the compound being tested (but not virus) were incubated together to measure the toxicity of the drug to the cellline. The viability of the cells was measured as a function of concentration of the compound, after holding for seven days. Typically, the cells survive at low compound concentrations, but at some higher concentration, toxicity of the compound is manifested and the cells die. The concentration of the test compound that results in 50% inhibition of cell growth is defined as the IC50.

Finally, the protective effects of the test compounds were measured. Each cell culture and test compound were incubated with the virus and the viability of the cells was measured as a function of compound concentration after holding for six or seven days. If the compound is active in protecting the cells against the virus, there is typically low cell viability until an effective concentration of the test compound is reached. At this point, cell viability increases steadily toward 100% unless the toxic effect of the

compound (as measured in the second blank) takes effect. The concentration of the test compound that results in 50% "control," i.e., a 50% reduction of the viral cytopathic effect, is defined as the EC 50. The
5 therapeutic index TI50 is calculated as IC_{50}/EC_{50} .

Values of test compound concentrations required for between 20 and 50% reduction of the viral cytopathic effect can also be determined. Such compounds are classified as moderately active. Compounds with less
10 than 20% control are considered inactive.

The compounds were tested to determine their reduction of HIV cytopathic effect on the human cell lines CEM and MT2. Tests were done by innoculating these cell lines either with free HIV (V) or with a
15 virus previously cultured with host cells (C). Thus, in Table III the designation CEMV means CEM line cells innoculated with free virus and MT2C means MT2 cells innoculated with cultured viral infected MT2 cells. In some cases the compound was also tested on a cell line
20 together with a sub-effective amount of the known HIV viricide AZT. This is done to test possible synergistic effects. Such a test on the CEM line is denoted CEMZ.

The Test Procedure

25 1) T4 lymphocytes (CEM cell line) are exposed to HIV at a virus to cell ratio of approximately 0.05 and plated along with non-infected control cells in 96-well microtiter plates.

- 2) Each candidate agent is dissolved in dimethyl sulfoxide (unless otherwise indicated), then diluted 1:200 in cell culture medium. Further dilutions (five-fold) are prepared before adding to an equal
5 volume of medium containing either infected or noninfected cells.
- 3) Cultures are incubated at 37°C in a 5% carbon dioxide atmosphere for seven days (if six days the CEMV test is identified as CEM-6).
- 10 The aforementioned identifiers are used when a batch was prepared and samples inserted into the wells. In procedures calling for the addition of the drug (or no drug) and the CEM uninfected cells to each well, followed by the subsequent addition of the HIV virus,
15 the protocol is designated as CEM-IW.
- 4) The tetrazolium salt, XTT, is added to all wells, and cultures are incubated to allow formazan color development by viable cells.
- 5) Individual wells are analyzed spectrophotometri-
20 cally to quantity formazan production, and in addition are viewed microscopically for detection of viable cells and confirmation of protective activity.
- 6) Drug-treated virus-infected cells are compared with drug-treated non-infected cells and with other
25 appropriate controls (untreated infected and untreated non-infected cells, drug-containing wells without cells, etc.) on the same plate.
- 7) A determination of activity is made.

Screening Data for Test CompoundsExhibiting Inhibition of HIV

The preceding protocol was carried out with the
5 compounds of the examples all of which showed some
significant activity in at least one of the tests. All
test results (molar) for all compounds exhibiting
greater than 50% inhibition of the virus in any of the
tests are shown in Table II as EC50's. Also shown are
10 results for compounds exhibiting moderate activity (MA),
that is, inhibition between approximately 20 and 50%.
Tests in which a compound was inactive (less than 20%
inhibition) are denoted as I.

TABLE II

Activity of Anti-HIV Compounds (EC50)
Concentration (moles/liter x 10⁻⁶)

5	COMPOUND	MT2C	MT2V	CEMC	CEMV	CEMZ
	1	1.2	2.6	1.2	0.2	
		0.9		0.7	0.3	
10		4.2		39.2	8.8	
		0.009		0.6	11.8	
		0.4		0.4	1.0	
					0.05	
15	2	3.2	14.4	3.5	1.3	1.8
					1.5	
					0.9	
					4.3	
					6.3	
20					1.3	
					0.2	
	3				6.1	
					4.6	
25					1.4	
					1.9	
	4				0.4	
					0.3	
30					0.2	
	5				.07	
					.06	
35	6				0.1	
	7				0.84	
					0.70	
40	8			MA		
				MA		
	9				MA	
					MA	
45					MA	
	10				3.0	
					2.9	
50	11				0.15	
					0.07	
					(CEM-6)	
					0.258	
					0.280	

5

0.172
0.143
0.236
0.076
0.067

TABLE II (Cont'd)

5		<u>Activity of Anti-HIV Compounds (EC50)</u>				
		<u>Concentration (moles/liter x 10-6)</u>				
	<u>COMPOUND</u>	<u>MT2C</u>	<u>MT2V</u>	<u>CEMC</u>	<u>CEMV</u>	<u>CEMZ</u>
10	12				1.2 3.3	
15	13				15.2 13.2	
	14				7.6 5.2	
20	15				0.82 0.61	
	16				3.0 9.6	0.9
25					8.4 0.4 1.6 1.2	
30	17				3.3	7.9
	18				8.1 7.8 2.5 6.7	
35						
	19				3.1 2.3 0.4 0.8	
40						
	20				69.5 58.7 69.4	
45	21				54.5 58.2 36.2	
50	22				88.6 75.4 32.7	

TABLE II (Cont'd)

Activity of Anti-HIV Compounds (EC50)
Concentration (moles/liter x 10⁻⁶)

5	COMPOUND	MT2C	MT2V	CEMC	CEMV	CEMZ
	23				5.8 5.6	1.1
10	24				11.1 0.9	12.0
15	25				466 228	34.4 39.4
	26	MA MA		35.5	MA I	
20	27				1.38 0.81	
	28				11.6 28.5 7.7	
25	29				5.6 11.9 7.8	
30					1.4 1.5	
	30				I I MA MA 42.7	
35						
	31*				2.84 2.14 5.43 5.85	
40						
	32				0.035 0.059 0.030	
45						
	33*				(* CEM-IW) 0.66 0.68 0.68 0.73	
50						

55 Asterisks indicate the CEM-IW protocol.

TABLE II (Cont'd)

Activity of Anti-HIV Compounds (EC50)
Concentration (moles/liter x 10⁻⁶)

5	COMPOUND	MT2C	MT2V	CEMC	CEM-6	CEMZ
					<u>CEM-6</u>	
	34				0.13	
10					0.073	
					0.46	
	35*				0.24	
					0.24	
15					0.18	
					0.20	
	36*				1.04	
					1.38	
20					1.32	
					0.89	
	37*				0.32	
					0.32	
25					0.32	
					0.20	
	39*				1.75	
					1.46	
30					1.09	
					1.47	
	43*				MA	
	44				0.76	
35					1.34	
	46				0.21	
					0.053	
40					0.45	
	47*				0.41	
					1.33	
					1.44	
45					MA	
	48				MA	
	49				MA	
50	50*				1.06	
					1.78	
					0.74	
					0.83	

TABLE II (Cont'd)

Activity of Anti-HIV Compounds (EC50)
Concentration (moles/liter x 10⁻⁶)

5	<u>COMPOUND</u>	<u>MT2C</u>	<u>MT2V</u>	<u>CEMC</u>	<u>CEM-6</u>	<u>CEMZ</u>
	52*				2.44	
					2.47	
10					1.94	
	58*				0.87	
					0.75	
					1.06	
15					0.90	
	59*				0.043	
					0.037	
20	60*				0.15	
					0.17	
					0.11	
					0.13	
25	61*				0.39	
					0.62	
					0.42	
					0.45	
30	62*				0.398	
					0.317	
					0.267	
					0.0622	
35	64*				0.0735	
					0.0329	
	65*				0.476	
					0.404	
40					0.588	
					0.509	
	69				0.34	
					0.34	
45	70				0.17	
					0.21	
					0.23	
50	71				0.99	
					1.83	
					1.62	
	72				0.54	
55					0.59	
					0.34	

TABLE II (Cont'd)

Activity of Anti-HIV Compounds (EC50)

5	<u>Concentration (moles/liter x 10⁻⁶)</u>					
	<u>COMPOUND</u>	<u>MT2C</u>	<u>MT2V</u>	<u>CEMC</u>	<u>CEM-6</u>	<u>CEMZ</u>
10	73				0.41	
					0.58	
15	74				38.9	
	75				1060	
					908	
20	76				MA	
	77*				5.06	
					3.12	
					15.1	
25					16.4	
	78				MA	
	78*				MA	
	79				3.3	
30					3.1	
					1.4	
					4.5	
					3.3	
35					3.3	
	80				3.6	
					6.7	
					2.3	
40					2.5	
					2.3	
	81				0.42	
	82*				2.67	
45					2.56	
					2.15	
					2.88	
	83*				MA	
50	84				MA	
	85				0.82	
					1.02	
55					0.42	

TABLE II (Cont'd)

Activity of Anti-HIV Compounds (EC50)
Concentration (moles/liter x 10⁻⁶)

	<u>COMPOUND</u>	<u>MT2C</u>	<u>MT2V</u>	<u>CEMC</u>	<u>CEM-6</u>	<u>CEMZ</u>
5	86				1.74 1.36	
10	87				MA	
	88				5.7 3.1	
15	89				7.5 7.3 2.6 1.8	
20	90				MA	
	91				MA	
25	92				MA	
	93				1.36 2.77	
30	94				MA	
	94*				MA	
	98*				0.89 0.73 0.35 0.51	
35						
	99*				MA	
40	102*				MA	
	103				MA	
45	104				MA	
	105				MA	
	106				5.3 2.3 2.6 2.2 2.2	
50						
	107				MA	
55	108				MA	

TABLE II (Cont'd)

Activity of Anti-HIV Compounds (EC50)
Concentration (moles/liter x 10⁻⁶)

5	<u>COMPOUND</u>	<u>MT2C</u>	<u>MT2V</u>	<u>CEMC</u>	<u>CEM-6</u>	<u>CEMZ</u>
	109				MA	
10	112*				MA	
	114*				MA	
	117*				MA	
15	130*				MA	
	131*				MA	
20	145*				0.260 0.373 0.243 0.422	
25	146*				42.0 3.50 5.29	
	147*				0.590 0.608	
30	148*				MA	
	149*				0.0448 0.0901 0.0677 0.170	
35						
40	150*				0.210 0.230 0.296 0.329	
	151*				0.0954 0.0842 0.0777 0.0537	
45						
50	152*				0.0717 0.0417 0.0368 0.0571	

TABLE II (Cont'd)

Activity of Anti-HIV Compounds (EC50)
Concentration (moles/liter x 10⁻⁶)

5	<u>COMPOUND</u>	<u>MT2C</u>	<u>MT2V</u>	<u>CEMC</u>	<u>CEM-6</u>	<u>CEMZ</u>
	153*				0.0719	
					0.0426	
10					0.0530	
					0.0719	
	154*				0.0443	
15	155*				0.0394	
					0.0607	
					0.0381	
					0.0301	
20	156*				0.486	
					0.632	
					1.19	
					1.04	
25	157*				MA	
	158*				6.10	
					6.77	
					4.49	
30					3.62	
	159*				0.0589	
					0.0839	
					1.07	
35					1.02	

For compounds giving greater than 50% control (i.e., which have a true EC50), the EC50 is given for each test. Compounds giving between 20% and 50% control are listed as moderately active (MA) for each test.

Screening of the Compound of Example 3
with CEM Cell Line

45 The compound of Example 3, viz., methyl 2-chloro-5-[[
 (5,6-dihydro-2-methyl-1,4-oxathiin-3-yl)carbonyl]
 amino]benzoate, was tested against the H9/HTLV-IIIB

(HIV-I) virus employing the CEM line of host cells and using free (HIV-I) virus employing the CEM line of host cells and using free virus inoculation (denoted CEM-V). The concentrations of the test compound that resulted in 50% inhibition of cell growth (IC50), the concentration of the compound that was effective in achieving 50% reduction in the viral cytopathic effect (EC50), and the therapeutic index I50) are shown in Table III below. All concentrations are expressed in moles per liter.

TABLE III

		SUMMARY		
	INDEX			CONCENTRATION
5				
	IC50 (Molar)			1.01 X 10 ⁻⁴
	EC50 (Molar)			1.91 X 10 ⁻⁶
	TI50 (IC/EC)			5.31 X 10 ⁺²
10		<u>CONCLUSION</u>		
		ACTIVE		
		<u>INFECTED CULTURE</u>		<u>UNINFECTED CULTURE</u>
15	Dose (Molar)	Response(%)	Dose (Molar)	Response (%)
	5.47 X 10 ⁻⁸	15.3	5.47 X 10 ⁻⁸	86.8
	1.72 X 10 ⁻⁷	23.3	1.72 X 10 ⁻⁷	86.8
20	5.46 X 10 ⁻⁷	15.7	5.46 X 10 ⁻⁷	84.0
	5.45 X 10 ⁻⁶	78.8	1.72 X 10 ⁻⁶	84.6
	1.72 X 10 ⁻⁵	89.2	5.45 X 10 ⁻⁶	107.9
	5.44 X 10 ⁻⁵	86.1	1.72 X 10 ⁻⁵	95.7
	1.72 X 10 ⁻⁴	10.7	5.44 X 10 ⁻⁵	97.0
25			1.72 X 10 ⁻⁴	10.1

The same data are plotted in Figure I. The number of viable CEM test cells as a percentage of the number of cells in an uninfected, untreated CEM control culture is plotted against the concentration of the test compound in varying cultures of the CEM cell line.

The viral cytopathic effect in this experiment is indicated by a dotted reference line. This line shows the extent of destruction of cells by the virus in the absence of treatment and is used as a quality control parameter. Values of this parameter less than 50% are considered acceptable in the current protocol. This plot represents the first blank test.

The dashed line connecting the square symbols depicts the percentage of surviving uninfected cells treated with the sample relative to the same uninfected, untreated controls. This line expresses the in-vitro growth inhibitory properties of the sample and represents the second blank test. The plot thus shows toxicity of the test compound to the cell line, the uninfected treated culture being viable up to the concentration of the test compound that is toxic to the host cells.

The solid line connecting the square symbols depicts the percentage of surviving HIV-infected cells treated with the sample (at the indicated concentration) relative to the uninfected, untreated control. This line expresses the in vitro anti-HIV activity of the sample.

Up to point 5, low cell viability was obtained. Starting after point 5, an effective concentration of the test compound was obtained, and cell viability rapidly increased to point 6, above which the high concentration of the test compound poisoned the CEM cells.

It may be seen from Figure I that the compound of Example 3 began to show inhibition of the viral cytopathic effect (point 5) at a concentration of about 5.5×10^{-7} molar and shows maximum effect at a concentration of about 1.7×10^{-5} molar (point 6). The compound would thus be expected to be effective and safe to use between

these two values. The compound of Example 3 was also tested in p24 and SFU tests to confirm activity against the HIV virus.

P24 is a specific antibody/antigen test that measures the amount of viral protein in the cell by linking with the virus's core protein. Unlike the previous tests described above, which measured the survival of host cells, this test measures survival of the virus.

The SFU (Syncytia Forming Units) test indicates how extensively the virus has infected the host cell. Normally, protein in the HIV virus combines with a protein in the host cell. This protein is then expressed on the surface of the host cell, which causes that cell to fuse to another cell. Giant conglomerates are formed and can be easily counted.

The activity of the compounds of the invention was confirmed by these tests, as shown in Figs. 2 and 3.

Initial studies on the toxicity of the compound of Example 1 were made on mice. These tests are summarized in Table IV below:

TABLE IV

5	Dosage, mg/Kg per day	Times Administered	Type of	Result,
	<u>for 5 days</u>	<u>Per Day</u>	<u>Test</u>	<u>Toxicity</u>
	10	2	IV	No visible sign
	100	2	IP	"
	750	1	Oral	"

10

In addition it has been found that the compound of Example 3 exhibits full HIV antiviral activity for up to eight hours after infection of the virus, and delays of up to twenty hours will still offer some protection.


15 This is in contrast to AZT which is no longer effective after about four hours after infection.

The preceding is by way of example only and the scope of the invention is to be limited only by the scope of the appended claims.

20

We claim:

1. A process for inhibiting the growth or replication of human immunodeficiency viruses, which comprises administering an effective amount of a
5 compound having the formula:



10

wherein:

R¹ is hydrogen, halogen, C₁-C₄ alkyl or C₁-C₄ alkoxy;

R² is hydrogen, halogen, C₁-C₄ alkyl, C₁-C₄ alkoxy, hydroxy, mono-, di- or tri-halomethyl,

15 trifluoromethoxy, methylthio, nitro, cyano, acetoxy or dimethylamino;

R³ is

i) - SO₂NR^aR^b wherein R^a and R^b are independently hydrogen or C₁-C₆ alkyl or together form a
20 heterocycle wherein the heterocyclic moiety is morpholinyl, piperidinyl, pyrrolidinyl or piperazinyl;

ii) -CO₂R⁵ wherein

25 R⁵ is an alkyl, a C₃-C₆ alkenyl or alkynyl, a one to six haloalkyl, an alkoxyalkyl, an alkylthioalkyl, a carboxyalkyl, an alkylcarboxyalkyl, a C₆-C₁₂ arylcarboxyalkyl, an alkylaminoalkyl

or dialkylaminoalkyl, a trialkylsilylalkyl, each of the aforementioned alkyl moieties having from one to eight carbon atoms; a phenyl, a naphthyl, a C₁-C₆ alkylphenyl, a C₇-C₁₂ arylalkyl or alkarylalkyl, a C₃-C₈ carbocyclyl, a C₁-C₄ alkyl C₃-C₈ carbocyclyl, or a heterocyclylalkyl, wherein the heterocyclic moiety is morpholinyl, piperidinyl, pyrrolidinyl, piperazinyl, oxiranyl, oxetanyl, furanyl or tetrahydrofuranyl;

iii) $-(CH_2)_{n^3}-Y-R^d$ wherein
 n^3 is 0 or 1;
 Y is O, S, SO, SO₂ or NH; and
 R^d is C₁-C₆ alkyl, C₃-C₆ cycloalkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, $-CH_2CO_2R^5$, $-CO_2R^5$ with the proviso that Y cannot be SO₂, or $-COR^a$ wherein

R^5 and R^a are as defined above;

iv) $-G-CO_2R^5$ wherein
 G is $-CH_2-$, $-CH_2CH_2-$ or $-CH=CH-$, and
 R^5 is as defined above;

v) $-CH-NOR^a$ wherein R^a is as defined above;

vi) $-CS_2R^5$ wherein R^5 is as defined above;

vii) $-COSR^5$ wherein R^5 is as defined above;

viii) $-O(CH_2)_n - \begin{matrix} O \\ \parallel \\ P \\ \backslash \\ OR^b \end{matrix} OR^a$ wherein


n is 1 or 2,

R^a and R^b are independently hydrogen or C_1-C_6 alkyl;

ix) $-COR^a$ wherein R^a is defined above; or

5


x)



R^4 is hydrogen, halogen, methyl or mono-, di- or tri-halomethyl; and

R is

1)



wherein

15

Y^1 is O, S, NH or NR^a wherein R^a is as defined above;

ii) $R^{18} - Y^3 - \overset{\overset{SR^a}{|}}{C} = N -$ or iv) $R^Z - NH -$ wherein

20

R^{18} is linear or branched C_1-C_6 alkyl or alkoxyalkyl wherein the alkyl groups are C_1-C_6 , C_3-C_8 cycloalkyl or mono-, di- or tri-halo C_1-C_6 alkyl;

Y^3 is O or S; and

25


R^a is as defined above; or

iii) R^Z-NH- wherein R^Z is





5 R^a and R^b are independently hydrogen or C_1-C_6 alkyl; and
 Z^1 is O or S;


b) cyano;



Y^1 is as defined above; or



25 R^7 , R^8 and R^9 are
 independently hydrogen or C_1-C_6
 alkyl, or R^7 and R^8 together with
 the N form a C_2-C_6 heterocyclic ring;



5

R^7 , R^8 and R^9 are independently hydrogen or C_1 - C_6 alkyl, or R^7 and R^8 together with the carbon atom form a C_3 - C_7 carbocyclic ring;

10

3) a) fully unsaturated, partially or fully reduced or substituted oxathiinyl; furanyl; dithiinyl; dioxinyl; thienyl; thiazolyl; oxazolyl; isoxazolyl; thiadiazolyl; pyrazolyl; pyrrolyl; pyranyl; oxathiazinyl; oxadiazolyl; or indolyl;

15

b) substituted or unsubstituted, linear or branched C_1 - C_8 alkyl; C_2 - C_8 alkenyl; C_2 - C_8 alkynyl; C_1 - C_8 mono- or di-alkylamino; C_3 - C_7 cycloalkyl; C_3 - C_7 cycloalkyl C_1 - C_6 alkyl; C_3 - C_7 cycloalkenyl unsubstituted or substituted by C_1 - C_6 alkyl; or C_7 - C_8 phenylalkyl; or

20

c) aryl, C^7 - C^{10} aralkyl or aryloxyalkyl or C_3 - C_8 cycloalkyl-aryloxy wherein the aryl moiety of this group is naphthyl, phenyl or

25

phenyl substituted by one or more
halo, C₁-C₈ alkyl, carboxyl, C₁-C₈
haloalkyl, C₁-C₈ alkylthio, phenyl,
nitro, amino, C₁-C₈
alkylcarbonylamino, hydroxyl, acetyl,
acetyloxy, phenoxy; C₁-C₈
alkoxycarbonyl or C₁-C₈ alkylcarbonyl;

4) R¹⁰-W- wherein

W is O, NH or NR^f wherein R^f is

C₁-C₄ alkyl; and

R¹⁰ is

- i) a linear or branched,
unsubstituted or halo-
substituted C₁-C₈ alkyl, C₂-C₈
alkenyl, C₂-C₈ alkynyl; a C₃-C₇
cycloalkyl, C₃-C₇ cycloalkyl
C₁-C₆ alkyl, C₃-C₇ cycloalkenyl
unsubstituted or substituted by
C₁-C₆ alkyl; an unsubstituted
phenyl or phenyl substituted by
halo, C₁-C₆ alkyl, C₁-C₆
alkoxy, carboxyl, C₁-C₈
haloalkyl, C₃-C₇ cycloalkyl,
C₁-C₈ alkylthio, phenyl, nitro,
amino, hydroxyl, acetyl
acetyloxy, phenoxy, C₁-C₈
alkoxycarbonyl, C₁-C₈

alkylcarbonyl, furanylalkyl,
 tetrahydrofuranylalkyl,
 oxetanylalkyl or oxiranylalkyl;

ii) $R^{11}-W^1-R^e$ wherein

5

R^e is a linear or

branched C_1-C_6 alkylidene;

W^1 is O or S; and

R^{11} is linear or branched

C_1-C_4 alkyl;

10

iii) $R^{13}R^{12}-N-R^e$ wherein

R^e is as defined above;


and

R^{12} and R^{13} are

independently linear or

15

branched C_1-C_4 alkyl;



20

wherein

R^e is as defined above;

W^2 is O, S, NH, NR^{14} or

$CR^{15}R^{16}$; wherein

R^{14} is linear or

25

branched C_1-C_4 alkyl;

R^{15} and R^{16} are

independently, hydrogen,

linear or branched C_1-C_4

alkyl; and

n^1 and m are

independently 1, 2 or 3;

v) $R^{17}O_2C-R^e$ wherein

R^e is as defined above;

and

R^{17} is linear or branched

C_1-C_6 alkyl, C_2-C_6 alkenyl,

C_2-C_6 alkynyl or C_3-C_7

cycloalkyl; C_3-C_7 cycloalkyl

C_1-C_6 alkyl; C_3-C_7 cyclo-

alkenyl unsubstituted or

substituted by C_1-C_6 alkyl;

vi) $U-R^e$ - wherein

R^e is as defined above;

U is hydroxyl, acyloxy,

aroyloxy, arylsulphonyloxy,

NO_2 , CN or $Si(CH_3)_3$;

vii) 1-adamantyl, 2-adamantyl

or bornyl moieties;

viii) Ar^1-R^e - wherein


R^e is as defined above;

and

Ar¹ is phenyl or phenyl substituted independently with one to three halogen, mono-, di- or tri-halomethyl, nitro, C₁-C₄ alkyl, C₂-C₄ alkenyl, C₁-C₄ alkyloxy, C₂-C₄ alkenyloxy, or C₂-C₄ alkynyloxy; or

5) a C₃-C₆ sugar derivative.

2. A process for inhibiting the growth or replication of human immunodeficiency viruses, which comprises administering an effective amount of a compound having the formula:



20 Z is O or S;

R^A is

a) a fully unsaturated, partially or fully reduced or substituted oxathiinyl; a furanyl; a dithiinyl; a dioxinyl; a thienyl; a thiazolyl; an oxazolyl; an isoxazolyl; a thiadiazolyl; a pyrazolyl; a pyrrolyl; a pyranyl; an oxathiazinyl; or an oxadiazolyl ;

(b) linear or branched C₁-C₈ alkyl; a C₂-C₈ alkenyl; a C₂-C₈ alkynyl; a C₁-C₈ alkoxy; a C₂-C₈ alkenyloxy; a C₂-C₈ alkynyloxy; a C₃-C₈ cycloalkyloxy; a C₃-C₈ cycloalkyl- alkoxy; a C₁-C₈ alkylamino; a C₃-C₆ cycloalkyl; a C₃-C₆ cycloalkenyl; a C₇-C₈ phenylalkyl; a C₇-C₈ phenoxyalkyl or a phenoxy; or

(c) phenyl or phenyl substituted by one or more halo, a C₁-C₈ alkyl, a C₁-C₈ alkoxy, a carboxyl, a C₁-C₈ haloalkyl, a C₁-C₈ alkylthio, a phenyl, a C₁-C₈ alkylcarbonylamino, an amino, a hydroxyl, an acetyl, an acetyloxy, a phenoxy; a C₁-C₈ alkoxycarbonyl or a C₁-C₈ alkylcarbonyl;

R¹ is hydrogen, halogen, C₁-C₄ alkyl or C₁-C₄ alkoxy;

R² is hydrogen, halogen, C₁-C₄ alkyl, C₁-C₄ alkoxy, hydroxy, mono-, di- or tri-halomethyl, trifluoromethoxy, methylthio, nitro, cyano, acetoxy or dimethylamino;


R³ is

i) - SO₂NR^aR^b wherein R^a and R^b are independently hydrogen or C₁-C₆ alkyl or together form a heterocycle wherein the heterocyclic moiety is morpholinyl, piperidinyl, pyrrolidinyl or piperazinyl;

ii) -CO₂R⁵ wherein

R⁵ is an alkyl, a C₃-C₆ alkenyl or alkynyl, a one to six haloalkyl, an alkoxyalkyl, an alkylthioalkyl, a

- carboxyalkyl, an alkylcarboxyalkyl, a
C₆-C₁₂ arylcarboxyalkyl, an alkylaminoalkyl
or dialkylaminoalkyl, a trialkylsilylalkyl,
each of the aforementioned alkyl moieties
5 having from one to eight carbon atoms; a
phenyl, a naphthyl, a C₁-C₆ alkylphenyl, a
C₇-C₁₂ arylalkyl or alkarylalkyl, a C₃-C₈
carbocyclyl, a C₁-C₄ alkyl C₃-C₈
carbocyclyl, or a heterocyclylalkyl,
10 wherein the heterocyclic moiety is
morpholinyl, piperidinyl, pyrrolidinyl,
piperazinyl, oxiranyl, oxetanyl, furanyl or
tetrahydrofuranyl;
- iii) $-(CH_2)_{n^3}-Y-R^d$ wherein
15 n^3 is 0 or 1;
Y is O, S, SO, SO₂ or NH; and
R^d is C₁-C₆ alkyl, C₃-C₆ cycloalkyl,
C₂-C₆ alkenyl, C₂-C₆ alkynyl, -CH₂CO₂R⁵,
-CO₂R⁵ with the proviso that Y cannot be
20 SO₂, or -COR^a wherein
R⁵ and R^a are as defined above;
- iv) -G-CO₂R⁵ wherein
G is -CH₂-, -CH₂CH₂- or -CH=CH-, and
R⁵ is as defined above;
- 25 v) -CH=NOR^a wherein R^a is as defined above;
vi) -CS₂R⁵ wherein R⁵ is as defined above;
vii) -COSR⁵ wherein R⁵ is as defined above;




5

n is 1 or 2,

 R^a and R^b are independently hydrogen or C_1-C_6 alkyl;ix) $-COR^a$ wherein R^a is defined above; or

10

x)



R^4 is hydrogen, halo, methyl or mono-, di- or tri-halomethyl.

15

3. A process according to claim 2 wherein:

Z is O or S;


 R^A is

(a) a dihydro-3-oxathiinyl; a furanyl; a dihydro-furanyl, a thienyl, a dihydro-2-dithiinyl; or a dihydro-2-dioxinyl; which can be substituted by one to three alkyl or alkoxyalkyl groups wherein the alkyl group is C_1-C_4 ;

(b) a phenyl; or a phenyl substituted by a group selected from a C₁-C₈ alkyl; a halogen; a C₁-C₈ haloalkyl; a C₁-C₈ alkylthio; a C₁-C₈ alkylthio; a carboxyl; an amino; a C₁-C₈ alkoxy; a C₁-C₈ alkoxycarbonyl; a hydroxyl; a C₁-C₈ alkylcarboxyl; a phenyl or a phenoxy group;

(c) a linear or branched C₁-C₈ alkyl; a C₂-C₈ alkenyl; a C₂-C₈ alkynyl; a C₁-C₈ alkoxy; a C₂-C₈ alkenyloxy; a C₂-C₈ alkynyloxy; a C₃-C₈ cycloalkyloxy; a C₃-C₈ cycloalkylalkoxy; a C₁-C₈ alkylamino; C₃-C₇ cycloalkyl; C₃-C₇ cycloalkyl C₁-C₆ alkyl; C₃-C₇ cycloalkenyl unsubstituted or substituted by C₁-C₆ alkyl or a phenoxy group.

15 4. A process according to claim 1 wherein said
compound has the formula




wherein

Z is 0 or S;

R⁶ is an alkyl or alkoxyalkyl wherein the alkyl
25 groups are independently C₁-C₄.

5. A process according to claim 4 wherein

(IV)



wherein

Z is O or S;

R¹ is a hydrogen, a fluoro or a methyl group;


10 R² is a hydrogen, a chloro, a fluoro or a methyl group;

R³ is COOR₅ wherein R₅ is an alkyl group of 1 to 6 carbon atoms;


R⁴ is hydrogen; and

15 R⁶ is a methyl, ethyl or propyl group.

6. A process according to claim 1 wherein said compound has the formula:



or



wherein Z is O or S, R⁷ and R⁸ are independently a hydrogen or a methyl; R¹⁸ is hydrogen, methyl or ethyl;

R¹ is hydrogen, halo or C₁-C₄ alkyl or C₁-C₄ alkoxy;

R² is hydrogen, halogen, C₁-C₄ alkyl, C₁-C₄

10 alkoxy, hydroxy, mono-, di- or tri-halomethyl, trifluoromethoxy, methylthio, nitro, cyano, acetoxy or dimethylamino;

R³ is

i) - $\text{SO}_2\text{NR}^{\text{a}}\text{R}^{\text{b}}$ wherein R^{a} and R^{b} are independently hydrogen or $\text{C}_1\text{-C}_6$ alkyl or together form a heterocycle wherein the heterocyclic moiety is morpholinyl, piperidinyl, pyrrolidinyl or piperazinyl;

ii) $-\text{CO}_2\text{R}^5$ wherein

R^5 is an alkyl, a $\text{C}_3\text{-C}_6$ alkenyl or alkynyl, a one to six haloalkyl, an alkoxyalkyl, an alkylthioalkyl, a carboxyalkyl, an alkylcarboxyalkyl, a $\text{C}_6\text{-C}_{12}$ arylcarboxyalkyl, an alkylaminoalkyl or dialkylaminoalkyl, a trialkylsilylalkyl, each of the aforementioned alkyl moieties having from one to eight carbon atoms; a phenyl, a naphthyl, a $\text{C}_1\text{-C}_6$ alkylphenyl, a $\text{C}_7\text{-C}_{12}$ arylalkyl or alkarylalkyl, a $\text{C}_3\text{-C}_8$ carbocyclyl, a $\text{C}_1\text{-C}_4$ alkyl $\text{C}_3\text{-C}_8$ carbocyclyl, or a heterocyclylalkyl, wherein the heterocyclic moiety is morpholinyl, piperidinyl, pyrrolidinyl, piperazinyl, oxiranyl, oxetanyl, furanyl or tetrahydrofuranyl;

iii) $-(\text{CH}_2)_{\text{n}^3}\text{-Y-R}^{\text{d}}$ wherein

n^3 is 0 or 1;

Y is O, S, SO, SO_2 or NH; and

R^d is C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl,
 C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, $-\text{CH}_2\text{CO}_2R^5$,
 $-\text{CO}_2R^5$ with the proviso that Y cannot be
 SO_2 , or $-\text{COR}^a$ wherein

5 R^5 and R^a are as defined above;

iv) $-\text{G}-\text{CO}_2R^5$ wherein

G is $-\text{CH}_2-$, $-\text{CH}_2\text{CH}_2-$ or $-\text{CH}=\text{CH}-$, and

R^5 is as defined above;

v) $-\text{CH}=\text{NOR}^a$ wherein R^a is as defined above;

10 vi) $-\text{CS}_2R^5$ wherein R^5 is as defined above;

vii) $-\text{COSR}^5$ wherein R^5 is as defined above;

viii) $-\text{O}(\text{CH}_2)_n - \text{P} \begin{matrix} \text{O} \\ \parallel \\ \text{OR}^a \\ \text{OR}^b \end{matrix}$ wherein

15


n is 1 or 2,

R^a and R^b are independently hydrogen or
 C_1 - C_6 alkyl;

ix) $-\text{COR}^a$ wherein R^a is defined above; and

20

x)



R^4 is hydrogen, halo, methyl or mono-, di- or
 25 tri-halomethyl.


7. A process according to claim 6 wherein

R^1 and R^4 are hydrogen;

R^2 is halo; and

5 R^3 is COOR^5 in which R^5 is $\text{C}_1\text{-C}_6$ alkyl.

8. A process according to claim 1 wherein said compound has the formula:



wherein

15 Z is O or S ;

R^1 is hydrogen, halo or $\text{C}_1\text{-C}_4$ alkyl or $\text{C}_1\text{-C}_4$ alkoxy;

R^2 is hydrogen, halogen, $\text{C}_1\text{-C}_4$ alkyl, $\text{C}_1\text{-C}_4$ alkoxy, hydroxy, mono-, di- or tri-halomethyl, trifluoromethoxy, methylthio, nitro, cyano, acetoxy

20 or dimethylamino;

R^3 is

i) $-\text{SO}_2\text{NR}^a\text{R}^b$ wherein R^a and R^b are independently hydrogen or $\text{C}_1\text{-C}_6$ alkyl or together form a heterocycle wherein the heterocyclic moiety is morpholinyl, piperidinyl, pyrrolidinyl or

25 piperazinyl;

ii) $-\text{CO}_2\text{R}^5$ wherein

5 R^5 is an alkyl, a $\text{C}_3\text{-C}_6$ alkenyl or alkynyl, a one to six haloalkyl, an alkoxyalkyl, an alkylthioalkyl, a carboxyalkyl, an alkylcarboxyalkyl, a $\text{C}_6\text{-C}_{12}$ arylcarboxyalkyl, an alkylaminoalkyl or dialkylaminoalkyl, a trialkylsilylalkyl, each of the aforementioned alkyl moieties having from one to eight carbon atoms; a
10 phenyl, a naphthyl, a $\text{C}_1\text{-C}_6$ alkylphenyl, a $\text{C}_7\text{-C}_{12}$ arylalkyl or alkarylalkyl, a $\text{C}_3\text{-C}_8$ carbocyclyl, a $\text{C}_1\text{-C}_4$ alkyl $\text{C}_3\text{-C}_8$ carbocyclyl, or a heterocyclylalkyl, wherein the heterocyclic moiety is
15 morpholinyl, piperidinyl, pyrrolidinyl, piperazinyl, oxiranyl, oxetanyl, furanyl or tetrahydrofuranyl;

iii) $-(\text{CH}_2)_{n^3}\text{-Y-R}^d$ wherein

n^3 is 0 or 1;
20 Y is O, S, SO, SO_2 or NH; and
 R^d is $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_3\text{-C}_6$ cycloalkyl, $\text{C}_2\text{-C}_6$ alkenyl, $\text{C}_2\text{-C}_6$ alkynyl, $-\text{CH}_2\text{CO}_2\text{R}^5$, $-\text{CO}_2\text{R}^5$ with the proviso that Y cannot be SO_2 , or $-\text{COR}^a$ wherein


25 R^5 and R^a are as defined above;

iv) $-\text{G-CO}_2\text{R}^5$ wherein

G is $-\text{CH}_2-$, $-\text{CH}_2\text{CH}_2-$ or $-\text{CH}=\text{CH}-$, and
 R^5 is as defined above;

- v) $-\text{CH}=\text{NOR}^a$ wherein R^a is as defined above;
 vi) $-\text{CS}_2\text{R}^5$ wherein R^5 is as defined above;
 vii) $-\text{COSR}^5$ wherein R^5 is as defined above;

5



n is 1 or 2,


10

R^a and R^b are independently hydrogen or $\text{C}_1\text{-C}_6$ alkyl;

- ix) $-\text{COR}^a$ wherein R^a is defined above; and

15

x)



R^4 is hydrogen, halo, methyl or mono-, di- or tri-halomethyl;


R^{10} , R^{11} , R^{12} , and R^{13} are independently hydrogen or halogen; and

R^{14} is hydrogen; a halogen; a $\text{C}_1\text{-C}_4$ alkyl; a $\text{C}_1\text{-C}_4$ alkoxy; a $\text{C}_1\text{-C}_4$ haloalkyl; a $\text{C}_1\text{-C}_4$ alkylthio; an amino; a $\text{C}_1\text{-C}_6$ alkylcarbonylamino, a hydroxyl; an acetyl; an acetyloxy; or acetylamino.

25

9. A process according to claim 8 wherein R^1 is hydrogen or fluoro; R^{10} , R^{11} , R^{12} , and R^{13} are hydrogen; R^{14} is hydrogen, methyl, ethyl, a chloro, an iodo, an amino, an acetamido, a bromo, a fluoro, a methylthio, a methoxy, or a hydroxyl.

10. A process according to claim 1 wherein said compound has the formula:



15

wherein

Z is O or S;

R^1 is hydrogen, halo or C_1 - C_4 alkyl or C_1 - C_4 alkoxy;

20 R^2 is hydrogen, halogen, C_1 - C_4 alkyl, C_1 - C_4 alkoxy, hydroxy, mono-, di- or tri-halomethyl, trifluoromethoxy, methylthio, nitro, cyano, acetoxy or dimethylamino;

R^3 is

25 i) $-SO_2NR^aR^b$ wherein R^a and R^b are independently hydrogen or C_1 - C_6 alkyl or together form a heterocycle wherein the heterocyclic moiety is morpholinyl, piperidinyl, pyrrolidinyl or piperazinyl;

ii) $-\text{CO}_2\text{R}^5$ wherein

R^5 is an alkyl, a $\text{C}_3\text{-C}_6$ alkenyl or
alkynyl, a one to six haloalkyl, an
alkoxyalkyl, an alkylthioalkyl, a
5 carboxyalkyl, an alkylcarboxyalkyl, a
 $\text{C}_6\text{-C}_{12}$ arylcarboxyalkyl, an alkylaminoalkyl
or dialkylaminoalkyl, a trialkylsilylalkyl,
each of the aforementioned alkyl moieties
having from one to eight carbon atoms; a
10 phenyl, a naphthyl, a $\text{C}_1\text{-C}_6$ alkylphenyl, a
 $\text{C}_7\text{-C}_{12}$ arylalkyl or alkarylalkyl, a $\text{C}_3\text{-C}_8$
carbocyclyl, a $\text{C}_1\text{-C}_4$ alkyl $\text{C}_3\text{-C}_8$
carbocyclyl, or a heterocyclylalkyl,
wherein the heterocyclic moiety is
15 morpholinyl, piperidinyl, pyrrolidinyl,
piperazinyl, oxiranyl, oxetanyl, furanyl or
tetrahydrofuranyl;

iii) $-(\text{CH}_2)_n\text{-Y-R}^d$ wherein

n is 0 or 1;
20 Y is O, S, SO, SO_2 or NH; and
 R^d is $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_3\text{-C}_6$ cycloalkyl,
 $\text{C}_2\text{-C}_6$ alkenyl, $\text{C}_2\text{-C}_6$ alkynyl, $-\text{CH}_2\text{CO}_2\text{R}^5$,
 $-\text{CO}_2\text{R}^5$ with the proviso that Y cannot be
 SO_2 , or $-\text{COR}^a$ wherein


25 R^5 and R^a are as defined above;

iv) $-\text{G-CO}_2\text{R}^5$ wherein

G is $-\text{CH}_2-$, $-\text{CH}_2\text{CH}_2-$ or $-\text{CH}=\text{CH}-$, and
 R^5 is as defined above;

- v) $-\text{CH}=\text{NOR}^a$ wherein R^a is as defined above;
vi) $-\text{CS}_2\text{R}^5$ wherein R^5 is as defined above;
vii) $-\text{COSR}^5$ wherein R^5 is as defined above;

5



n is 1 or 2,


R^a and R^b are independently hydrogen or

10

$\text{C}_1\text{-C}_6$ alkyl;

- ix) $-\text{COR}^a$ wherein R^a is defined above; and

x)



15

R^4 is hydrogen, halo, methyl or mono-, di- or tri-halomethyl.


11. A process according to claim 10 wherein

20

R^1 and R^4 are hydrogen; and

R^3 is COOR^5 .

12. A process according to claim 1 wherein said compound has the formula:



wherein R¹⁵ is a linear or branched C₃-C₆ alkyl; a C₂-C₆ alkenyl or alkynyl; a C₇-C₈ aralkyl or aryloxyalkyl; a C₁-C₈ alkoxy; a C₂-C₈ alkenyloxy or alkynyloxy; a C₁-C₈ aryloxy; C₃-C₇ cycloalkyl; C₃-C₇ cycloalkyl C₁-C₆ alkyl; C₃-C₇ cycloalkenyl unsubstituted or substituted by C₁-C₆ alkyl; a C₃-C₈ cycloalkyloxy, cycloalkylalkyloxy, cycloalkylaryloxy or alkylamino;

15 Z is O or S;

R¹ is hydrogen, halo or C₁-C₄ alkyl or C₁-C₄ alkoxy;

R² is hydrogen, halogen, C₁-C₄ alkyl, C₁-C₄ alkoxy, hydroxy, mono-, di- or tri-halomethyl, trifluoromethoxy, methylthio, nitro, cyano, acetoxy

20 or dimethylamino;

R³ is

i) - SO₂NR^aR^b wherein R^a and R^b are independently hydrogen or C₁-C₆ alkyl or together form a heterocycle wherein the heterocyclic moiety is morpholinyl, piperidinyl, pyrrolidinyl or piperazinyl;

25

ii) $-\text{CO}_2\text{R}^5$ wherein

5 R^5 is an alkyl, a C_3 - C_6 alkenyl or alkynyl, a one to six haloalkyl, an alkoxyalkyl, an alkylthioalkyl, a carboxyalkyl, an alkylcarboxyalkyl, a C_6 - C_{12} arylcarboxyalkyl, an alkylaminoalkyl or dialkylaminoalkyl, a trialkylsilylalkyl, each of the aforementioned alkyl moieties having from one to eight carbon atoms; a
10 phenyl, a naphthyl, a C_1 - C_6 alkylphenyl, a C_7 - C_{12} arylalkyl or alkarylalkyl, a C_3 - C_8 carbocyclyl, a C_1 - C_4 alkyl C_3 - C_8 carbocyclyl, or a heterocyclylalkyl, wherein the heterocyclic moiety is
15 morpholinyl, piperidinyl, pyrrolidinyl, piperazinyl, oxiranyl, oxetanyl, furanyl or tetrahydrofuranyl;

iii) $-(\text{CH}_2)_n-\text{Y}-\text{R}^d$ wherein

20 n is 0 or 1;
 Y is O, S, SO, SO_2 or NH; and
 R^d is C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, $-\text{CH}_2\text{CO}_2\text{R}^5$, $-\text{CO}_2\text{R}^5$ with the proviso that Y cannot be SO_2 , or $-\text{COR}^a$ wherein

25 R^5 and R^a are as defined above;

iv) $-\text{G}-\text{CO}_2\text{R}^5$ wherein

G is $-\text{CH}_2-$, $-\text{CH}_2\text{CH}_2-$ or $-\text{CH}=\text{CH}-$, and
 R^5 is as defined above;

-134-

- v) $-\text{CH}=\text{NOR}^a$ wherein R^a is as defined above;
 vi) $-\text{CS}_2\text{R}^5$ wherein R^5 is as defined above;
 vii) $-\text{COSR}^5$ wherein R^5 is as defined above;


- 5 viii) $-\text{O}(\text{CH}_2)_n - \text{P} \begin{matrix} \text{O} \\ \parallel \\ \text{OR}^a \\ \text{OR}^b \end{matrix}$ wherein

n is 1 or 2,

R^a and R^b are independently hydrogen or

10 $\text{C}_1\text{-C}_6$ alkyl;

- ix) $-\text{COR}^a$ wherein R^a is defined above; and



15

R^4 is hydrogen, halo, methyl or mono-, di- or tri-halomethyl.

13. A process according to claim 12 wherein

20 R^1 is hydrogen or a fluoro;

R^3 is COOR^5 ;

R^4 is hydrogen; and

R^{15} is a $\text{C}_3\text{-C}_6$ alkyl; a $\text{C}_2\text{-C}_6$ alkenyl or alkynyl; a $\text{C}_7\text{-C}_8$ phenylalkyl or phenoxyalkyl; a $\text{C}_1\text{-C}_8$ alkoxy; a


- C₂-C₈ alkenyloxy or alkynyloxy; phenoxy; C₃-C₇ cycloalkyl; C₃-C₇ cycloalkyl C₁-C₆ alkyl; C₃-C₇ cycloalkenyl unsubstituted or substituted by C₁-C₆ alkyl; C₃-C₈ cycloalkoxy or cycloalkylalkyloxy;
- 5 cycloalkylphenyloxy or alkylamino.

14. A process according to claim 13 wherein R¹⁵ is C₃-C₆ cycloalkyl or cycloalkenyl.

- 10 15. A process according to claim 14 wherein R¹ and R⁴ are hydrogen and R³ is COOR⁵.

16. A process according to claim 1 wherein said compound has the formula

15



- 20 wherein Z is O or S;

R¹ is hydrogen, halo or C₁-C₄ alkyl or C₁-C₄ alkoxy;

R² is hydrogen, halogen, C₁-C₄ alkyl, C₁-C₄ alkoxy, hydroxy, mono-, di- or tri-halomethyl,

trifluoromethoxy, methylthio, nitro, cyano, acetoxy

- 25 or dimethylamino;

R³ is

i) -SO₂NR^aR^b wherein R^a and R^b are independently hydrogen or C₁-C₆ alkyl or together form a heterocycle wherein the heterocyclic moiety is morpholinyl, piperidinyl, pyrrolidinyl or piperazinyl;

ii) -CO₂R⁵ wherein

R⁵ is an alkyl, a C₃-C₆ alkenyl or akynyl, a one to six haloalkyl, an alkoxyalkyl, an alkylthioalkyl, a carboxyalkyl, an alkylcarboxyalkyl, a C₆-C₁₂ arylcarboxyalkyl, an alkylaminoalkyl or dialkylaminoalkyl, a trialkylsilylalkyl, each of the aforementioned alkyl moieties having from one to eight carbon atoms; a phenyl, a naphthyl, a C₁-C₆ alkylphenyl, a C₇-C₁₂ arylalkyl or alkarylalkyl, a C₃-C₈ carbocyclyl, a C₁-C₄ alkyl C₃-C₈ carbocyclyl, or a heterocyclylalkyl, wherein the heterocyclic moiety is morpholinyl, piperidinyl, pyrrolidinyl, piperazinyl, oxiranyl, oxetanyl, furanyl or tetrahydrofuranyl;

iii) -(CH₂)_{n³}-Y-R^d wherein

n³ is 0 or 1;

Y is O, S, SO, SO₂ or NH; and

R^d is C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, $-CH_2CO_2R^5$, $-CO_2R^5$ with the proviso that Y cannot be SO_2 , or $-COR^a$ wherein

5

R^5 and R^a are as defined above;

iv) $-G-CO_2R^5$ wherein

G is $-CH_2-$, $-CH_2CH_2-$ or $-CH=CH-$, and

R^5 is as defined above;

v) $-CH=NOR^a$ wherein R^a is as defined above;

10

vi) $-CS_2R^5$ wherein R^5 is as defined above;

vii) $-COSR^5$ wherein R^5 is as defined above;

15

viii) $-O(CH_2)_n - \begin{matrix} O \\ || \\ P \\ / \backslash \\ OR^a \quad OR^b \end{matrix}$ wherein


n is 1 or 2,

R^a and R^b are independently hydrogen or C_1 - C_6 alkyl;

20

ix) $-COR^a$ wherein R^a is defined above; and

x)



25

R^4 is hydrogen, halo, methyl or mono-, di- or tri-halomethyl.

17. A process according to claim 16 wherein
R¹ and R⁴ are hydrogen;
R² is hydrogen or a chloro; and
R³ is a C₂-C₆ alkoxy carbonyl.

5

18. The process of claim 4, wherein said compound
is selected from the group consisting of:

- (1) 1-methylethyl 2-chloro-5-[(5,6-dihydro-2-methyl-1,4-oxathiin-3-yl)carbonyl]amino]benzoate;
- 10 (2) 1-methylethyl 2-chloro-5-[(5,6-dihydro-2-methyl-1,4-oxathiin-3-yl)carbonyl]amino-4-fluorobenzoate;
- (3) methyl 2-chloro-5-[(5,6-dihydro-2-methyl-1,4-oxathiin-3-yl)carbonyl]amino]benzoate;
- (4) propyl 2-chloro-5-[(5,6-dihydro-2-methyl-1,4-oxathiin-3-yl)carbonyl]amino]benzoate;
- 15 (5) butyl 2-chloro-5-[(5,6-dihydro-2-methyl-1,4-oxathiin-3-yl)carbonyl]amino]benzoate;
- (6) 1-methylethyl 2-chloro-5-[(2-ethyl-5,6-dihydro-1,4-oxathiin-3-yl)carbonyl]amino]benzoate;
- 20 (7) 1-methylethyl 3-[(5,6-dihydro-2-methyl-1,4-oxathiin-3-yl)-carbonyl]amino]benzoate;
- (8) ethyl 2-chloro-5-[(2-ethyl-5,6-dihydro-1,4-oxathiin-3-yl)carbonyl]amino]benzoate;
- (9) 1-methylethyl 5-[(5,6-dihydro-2-methyl-1,4-oxathiin-3-yl)carbonyl]amino]-4-fluoro-2-methylbenzoate;
- 25 (10) 1-methylethyl 3-[(5,6-dihydro-2-methyl-1,4-oxathiin-3-yl)carbonyl]amino]-4-fluorobenzoate;

- (11) ethyl 3-[[[(5,6-dihydro-2-methyl-1,4-oxathiin-3-yl)carbonyl]amino]-4-methylbenzoate;
- (12) pentyl 2-chloro-5-[[[(5,6-dihydro-2-methyl-1,4-oxathiin-3-yl)carbonyl]amino]benzoate;
- 5 (13) ethyl 2-chloro-5-[[[(5,6-dihydro-2-methyl-1,4-oxathiin-3-yl)carbonyl]amino]benzoate;
- (14) 2-methoxyethyl 2-chloro-5-[[[(5,6-dihydro-2-methyl-1,4-oxathiin-3-yl)carbonyl]amino]benzoate;
- (15) ethyl 2-chloro-5-[[[(5,6-dihydro-2-propyl-1,4-oxathiin-3-yl)carbonyl]amino]benzoate;
- 10 (16) methyl 2-chloro-5-[[[(5,6-dihydro-2-propyl-1,4-oxathiin-3-yl)carbonyl]amino]benzoate;
- (17) 1-methylethyl 5-[[[(5,6-dihydro-2-methyl-1,4-oxathiin-3-yl)carbonyl]amino]-2-fluorobenzoate;
- 15 (18) 1-methylethyl 5-[[[(5,6-dihydro-2-methyl-1,4-oxathiin-3-yl)carbonyl]amino]-2-methylbenzoate;
- (19) 2-methylpropyl 2-chloro-5-[[[(2-ethyl-5,6-dihydro-1,4-oxathiin-3-yl)carbonyl]amino]benzoate; and
- (20) 1-methylethyl 5-[[[(5,6-dihydro-2-methyl-1,4-oxathiin-3-yl)carbonyl]amino]-2,4-difluorobenzoate.
- 20

19. The process of claim 6 wherein said compound is selected from the group consisting of:

- (1) 1-methylethyl 2-chloro-5-[[[(2,4,5-trimethyl-3-furanyl)carbonyl]amino]benzoate;
- 25 (2) 1-methylethyl 2-chloro-5-[[[(3-methyl-2-furanyl)carbonyl]amino]benzoate;

- (3) 1-methylethyl 2-chloro-5-[[(2,4-dimethyl-3-furanyl)carbonyl]amino]benzoate;
- (4) 1-methylethyl 2-chloro-5-[[(2-methyl-3-furanyl)carbonyl]amino]benzoate;
- 5 (5) 1-methylethyl 2-chloro-5-[[(2,5-dimethyl-3-furanyl)carbonyl]amino]benzoate;
- (6) 1-methylethyl 2-chloro-5-[[(2,4,5-trimethyl-3-furanyl)thioxomethyl]amino]benzoate;
- (7) 1-methylethyl 2-chloro-5-[[(2-methyl-3-furanyl)thioxomethyl]amino]benzoate; and
- 10 (8) 1-methylethyl 2-chloro-5-[[(2,5-dimethyl-3-furanyl)thioxomethyl]amino]benzoate.

20. The process of claim 8 wherein said compound
15 is selected from the group consisting of:

- (1) 1-methylethyl 5-(benzoylamino)-2-chloro-4-fluorobenzoate;
- (2) 1-methylethyl 2-chloro-5-[(2-methoxybenzoyl)amino]benzoate;
- 20 (3) 1-methylethyl 2-chloro-5-[(2-methylbenzoyl)amino]benzoate;
- (4) propyl 2-chloro-5-[(2-methylbenzoyl)amino]benzoate; and
- (5) 1-methylethyl 2-chloro-5-[(2-fluorobenzoyl)amino]benzoate;
- 25 (6) 1-methylethyl 2-chloro-5-[(2-iodobenzoyl)amino]benzoate;

(7) 1-methylethyl 5-[(2-bromobenzoyl)amino]-2-chlorobenzoate;

(8) ethyl 2-chloro-5-[(2-methoxybenzoyl)amino]-benzoate;

5 (9) ethyl 5-[(2-aminobenzoyl)amino]-2-chlorobenzoate; and

(10) 1-methylethyl 5-(benzoylamino)-2-chlorobenzoate.

10 21. The process of claim 10 wherein said compound is: 1-methylethyl 2-chloro-5-[[[(5,6-dihydro-3-methyl-1,4-dioxin-2-yl)carbonyl]amino]benzoate.

22. The process of claim 12 wherein said compound
15 is (1) 1-methylethyl 2-chloro-5-[[[(1-methylethoxy)carbonyl]amino]benzoate or (2) 1-methylethyl 5-[(butoxycarbonyl)amino]-2-chlorobenzoate.

23. The process of claim 16 wherein said compound
20 is 1-methylethyl 2-chloro-5-[[[(5,6-dihydro-3-methyl-1,4-dithiin-2-yl)carbonyl]amino]benzoate.

24. The process of claim 1 wherein said compound is selected from the group consisting of:

25 (1) 1-methylethyl 2-chloro-5-[[[(1-methylethoxy)thioxomethyl]amino]benzoate;

(2) 1-methylethyl 2-chloro-5-[(ethoxythioxomethyl)amino]benzoate;

- (3) 1-methylethyl 5-[[[butoxy)thioxymethyl]amino]-
2-chlorobenzoate;
- (4) 1-methylethyl 2-chloro-5-[(propoxythio-
methyl)amino]benzoate;
- 5 (5) 1-methylethyl 2-chloro-5-[[[pentyloxy)thio-
methyl]amino]benzoate;
- (6) 1-methylethyl 2-chloro-5-[[[2-propenyloxy)thi-
oxomethyl]amino]benzoate;
- (7) 1-methylethyl 2-chloro-5-[[[2-cyclohexen-1-
10 yloxy)thioxomethyl]amino]benzoate;
- (8) 1-methylethyl 2-chloro-5-[[[cyclohexyloxy)thi-
oxomethyl]amino]benzoate;
- (9) 1-methylethyl 2-chloro-5-[[[cyclopropylme-
thoxy)thioxomethyl]amino]benzoate; and
- 15 (10) 1-methylethyl 2-chloro-5-[[[2-methoxy-
ethoxy)thioxomethyl]amino]benzoate.


25. The process of claim 1, which comprises a
compound selected from the group consisting of:

- 20 (1) 1-methylethyl 2-chloro-5-[[[3-methyl-2-
thienyl)carbonyl]amino]benzoate;
- (2) 1-methylethyl 2-chloro-5-[(phenylthio-
methyl)amino]benzoate;
- (3) cyclopentyl 2-chloro-5-[[[2-methoxyphenyl)-
25 amino]carbonyl]amino]benzoate;
- (4) 1-methylethyl 2-chloro-5-[(1-methylethoxy)-
(methylthio)methylimino]benzoate; and

(5) 1-methylethyl 2-chloro-5-[[[(1-methylethoxy)propylthio]methylene]amino]benzoate.

26. The process of claim 1, which comprises
5 administering an effective amount of said compound together with azidothymidine (AZT).

27. A compound having the formula:



wherein:

R¹ is hydrogen, halogen, C₁-C₄ alkyl or C₁-C₄ alkoxy;
15 R² is hydrogen, halogen, C₁-C₄ alkyl, C₁-C₄ alkoxy, hydroxy, mono-, di- or tri-halomethyl,

trifluoromethoxy, methylthio, nitro, cyano, acetoxy or dimethylamino;

R³ is

20 i) - SO₂NR^aR^b wherein R^a and R^b are independently hydrogen or C₁-C₆ alkyl or together form a heterocycle wherein the heterocyclic moiety is morpholinyl, piperidinyl, pyrrolidinyl or piperazinyl;

ii) $-\text{CO}_2\text{R}^5$ wherein

5 R^5 is an alkyl, a $\text{C}_3\text{-C}_6$ alkenyl or
alkynyl, a one to six haloalkyl, an
alkoxyalkyl, an alkylthioalkyl, a
carboxyalkyl, an alkylcarboxyalkyl, a
10 $\text{C}_6\text{-C}_{12}$ arylcarboxyalkyl, an alkylaminoalkyl
or dialkylaminoalkyl, a trialkylsilylalkyl,
each of the aforementioned alkyl moieties
having from one to eight carbon atoms; a
phenyl, a naphthyl, a $\text{C}_1\text{-C}_6$ alkylphenyl, a
15 $\text{C}_7\text{-C}_{12}$ arylalkyl or alkarylalkyl, a $\text{C}_3\text{-C}_8$
carbocyclyl, a $\text{C}_1\text{-C}_4$ alkyl $\text{C}_3\text{-C}_8$
carbocyclyl, or a heterocyclylalkyl,
wherein the heterocyclic moiety is
morpholinyl, piperidinyl, pyrrolidinyl,
15 piperazinyl, oxiranyl, oxetanyl, furanyl or
tetrahydrofuranyl;

iii) $-(\text{CH}_2)_{n^3}\text{-Y-R}^d$ wherein

20 n^3 is 0 or 1;
 Y is O, S, SO, SO_2 or NH; and
 R^d is $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_3\text{-C}_6$ cycloalkyl,
 $\text{C}_2\text{-C}_6$ alkenyl, $\text{C}_2\text{-C}_6$ alkynyl, $-\text{CH}_2\text{CO}_2\text{R}^5$,
 $-\text{CO}_2\text{R}^5$ with the proviso that Y cannot be
 SO_2 , or $-\text{COR}^a$ wherein


25 R^5 and R^a are as defined above;

iv) $-\text{G-CO}_2\text{R}^5$ wherein

G is $-\text{CH}_2-$, $-\text{CH}_2\text{CH}_2-$ or $-\text{CH}=\text{CH}-$, and
 R^5 is as defined above;

- v) $-\text{CH}=\text{NOR}^a$ wherein R^a is as defined above;
 vi) $-\text{CS}_2\text{R}^5$ wherein R^5 is as defined above;
 vii) $-\text{COSR}^5$ wherein R^5 is as defined above;

5



n is 1 or 2,


R^a and R^b are independently hydrogen or

10

$\text{C}_1\text{-C}_6$ alkyl;

- ix) $-\text{COR}^a$ wherein R^a is defined above; or

x)




15

R^4 is hydrogen, halo, methyl or mono-, di- or tri-halomethyl;

R is

20


i)



wherein

Y^1 is O, S, NH or NR^a wherein R^a is as defined above;


-146-



R^{18} is linear or branched $\text{C}_1\text{-C}_6$ alkyl or alkoxyalkyl wherein the alkyl groups are $\text{C}_1\text{-C}_6$, $\text{C}_3\text{-C}_8$ cycloalkyl or mono-, di- or tri-halo $\text{C}_1\text{-C}_6$ alkyl;

Y^3 is O or S; and

R^a is as defined above; or




R^a and R^b are independently hydrogen or $\text{C}_1\text{-C}_6$ alkyl; and
 Z^1 is O or S;

b) cyano;



Y^1 is as defined above;

or



wherein R^a is as defined above; and

R^A is



5

R^7 , R^8 and R^9 are


independently hydrogen or C_1-C_6

alkyl, or R^7 and R^8 together

with the N form a C_2-C_6

10

heterocyclic ring;



15

R^7 , R^8 and R^9 are independently
hydrogen or C_1-C_6 alkyl, or R^7 and R^8
together with the carbon atom form a
 C_3-C_7 carbocyclic ring;

20

- 3) a) fully unsaturated, partially or
fully reduced or substituted
oxathiinyl; furanyl; dithiinyl;
dioxinyl; thienyl; thiazolyl;
oxazolyl; isoxazolyl; thiadiazolyl;
pyrazolyl; pyrrolyl; pyranyl;
oxathiazinyl; oxadiazolyl; pyridinyl;
or indolyl; with the proviso that when

25

the oxathiinyl group is substituted by methyl or ethyl in the ortho position, R^1 and R^2 cannot both be hydrogen;

5 b) substituted or unsubstituted,
linear or branched C_1-C_8 alkyl; C_2-C_8
alkenyl; C_2-C_8 alkynyl; C_1-C_8 mono- or
di-alkylamino; C_3-C_7 cycloalkyl; C_3-C_7
cycloalkyl C_1-C_6 alkyl; C_3-C_7
cycloalkenyl unsubstituted or
10 substituted by C_1-C_6 alkyl; or C_7-C_8
phenylalkyl; or

 c) aryl, C^7-C^{10} aralkyl or
aryloxyalkyl or C_3-C_8 cycloalkyl-
aryloxy wherein the aryl moiety of
15 this group is naphthyl, phenyl or
phenyl substituted by one or more
halo, C_1-C_8 alkyl, carboxyl, C_1-C_8
haloalkyl, C_1-C_8 alkylthio, phenyl,
nitro, amino, C_1-C_8 alkylcarbonyl-
20 amino, hydroxyl, acetyl, acetyloxy,
phenoxy; C_1-C_8 alkoxy carbonyl or C_1-C_8
alkylcarbonyl;


4) R^{10} -W- wherein

 W is O, NH or NR^f wherein R^f is
25 C_1-C_4 alkyl; and
 R^{10} is

- 5
10
15
20
25
- i) a linear or branched,
unsubstituted or halo-
substituted C_1-C_8 alkyl, C_2-C_8
alkenyl, C_2-C_8 alkynyl; a C_3-C_7
cycloalkyl, C_3-C_7 cycloalkyl
 C_1-C_6 alkyl, C_3-C_7 cycloalkenyl
unsubstituted or substituted by
 C_1-C_6 alkyl; an unsubstituted
phenyl or phenyl substituted by
halo, C_1-C_6 alkyl, C_1-C_6
alkoxy, carboxyl, C_1-C_8
haloalkyl, C_3-C_7 cycloalkyl,
 C_1-C_8 alkylthio, phenyl, nitro,
amino, hydroxyl, acetyl
acetyloxy, phenoxy, C_1-C_8
alkoxycarbonyl, C_1-C_8
alkylcarbonyl, furanylalkyl,
tetrahydrofuranylalkyl,
oxetanylalkyl or oxiranylalkyl;
- ii) $R^{11}-W^1-R^e$ wherein
 R^e is a linear or
branched C_1-C_6 alkylidene;
 W^1 is O or S; and
 R^{11} is linear or branched
 C_1-C_4 alkyl;
- iii) $R^{13}R^{12}-N-R^e$ wherein
 R^e is as defined above;
and

R^{12} and R^{13} are
independently linear or
branched C_1 - C_4 alkyl;

5



wherein

10

R^e is as defined above;
 W^2 is O, S, NH, NR^{14} or
 $CR^{15}R^{16}$; wherein

15

R^{14} is linear or
branched C_1 - C_4 alkyl;
 R^{15} and R^{16} are
independently, hydrogen,
linear or branched C_1 - C_4
alkyl; and
 n^1 and m are

independently 1, 2 or 3;

20

v) $R^{17}O_2C-R^e$ wherein

R^e is as defined above;

and

25

R^{17} is linear or branched
 C_1 - C_6 alkyl, C_2 - C_6 alkenyl,
 C_2 - C_6 alkynyl or C_3 - C_7
cycloalkyl; C_3 - C_7 cycloalkyl
 C_1 - C_6 alkyl; C_3 - C_7 cyclo

alkenyl unsubstituted or
substituted by C₁-C₆ alkyl;

vi) U-R^e- wherein

R^e is as defined above;

5

U is hydroxyl, acyloxy,
aroyloxy, arylsulphonyloxy,
NO₂, CN or Si(CH₃)₃;

vii) 1-adamantyl, 2-adamantyl

or bornyl moieties;

10

viii) Ar¹-R^e- wherein

R^e is as defined above;

and


15

Ar¹ is phenyl or phenyl
substituted independently
with one to three halogen,
mono-, di- or tri-halomethyl,
nitro, C₁-C₄ alkyl, C₂-C₄
alkenyl, C₁-C₄ alkyloxy,
C₂-C₄ alkenyloxy, or C₂-C₄
alkynyloxy; or

20

5) a C₃-C₆ sugar derivative.

28. A compound having the formula:



Z is O or S;

R^A is

a) a fully unsaturated, partially or fully reduced
 10 or substituted oxathiinyl; a furanyl; a dithiinyl; a
 dioxinyl; a thienyl; a thiazolyl; an oxazolyl; an
 isoxazolyl; a thiadiazolyl; a pyrazolyl; a pyrrolyl; a
 pyranyl; an oxathiazinyl; or an oxadiazolyl; with the
 proviso that when the oxathiinyl group is substituted by
 15 methyl or ethyl in the ortho position, R¹ and R² cannot
 both be hydrogen;

(b) linear or branched C₁-C₈ alkyl; a C₂-C₈
 alkenyl; a C₂-C₈ alkynyl; a C₁-C₈ alkoxy; a C₂-C₈
 alkenyloxy; a C₂-C₈ alkynyloxy; a C₃-C₈ cycloalkyloxy; a
 20 C₃-C₈ cycloalkyl- alkoxy; a C₁-C₈ alkylamino; a C₃-C₆
 cycloalkyl; a C₃-C₆ cycloalkenyl; a C₇-C₈ phenylalkyl; a
 C₇-C₈ phenoxyalkyl or a phenoxy; or

(c) phenyl or phenyl substituted by one or more
 halo, a C₁-C₈ alkyl, a C₁-C₈ alkoxy, a carboxyl, a C₁-C₈
 25 haloalkyl, a C₁-C₈ alkylthio, a phenyl, an amino, a
 hydroxyl, an acetyl, an acetyloxy, a phenoxy; a C₁-C₈
 alkoxy carbonyl or a C₁-C₈ alkyl carbonyl;

R^1 is hydrogen, halogen, C_1 - C_4 alkyl or C_1 - C_4 alkoxy;

R^2 is hydrogen, halogen, C_1 - C_4 alkyl, C_1 - C_4 alkoxy, hydroxy, mono-, di- or tri-halomethyl, trifluoromethoxy, methylthio, nitro, cyano, acetoxy or dimethylamino;

R^3 is

i) - $SO_2NR^aR^b$ wherein R^a and R^b are independently hydrogen or C_1 - C_6 alkyl or together form a heterocycle wherein the heterocyclic moiety is morpholinyl, piperidinyl, pyrrolidinyl or piperazinyl;

ii) - CO_2R^5 wherein

R^5 is an alkyl, a C_3 - C_6 alkenyl or alkynyl, a one to six haloalkyl, an alkoxyalkyl, an alkylthioalkyl, a carboxyalkyl, an alkylcarboxyalkyl, a C_6 - C_{12} arylcarboxyalkyl, an alkylaminoalkyl or dialkylaminoalkyl, a trialkylsilylalkyl, each of the aforementioned alkyl moieties having from one to eight carbon atoms; a phenyl, a naphthyl, a C_1 - C_6 alkylphenyl, a C_7 - C_{12} arylalkyl or alkarylalkyl, a C_3 - C_8 carbocyclyl, a C_1 - C_4 alkyl C_3 - C_8 carbocyclyl, or a heterocyclylalkyl, wherein the heterocyclic moiety is morpholinyl, piperidinyl, pyrrolidinyl, piperazinyl, oxiranyl, oxetanyl, furanyl or tetrahydrofuranyl;

iii) $-(CH_2)_{n^3}-Y-R^d$ wherein

n^3 is 0 or 1;

Y is O, S, SO, SO₂ or NH; and

R^d is C₁-C₆ alkyl, C₃-C₆ cycloalkyl,

5 C₂-C₆ alkenyl, C₂-C₆ alkynyl, $-CH_2CO_2R^5$,

$-CO_2R^5$ with the proviso that Y cannot be SO₂, or $-COR^a$ wherein

R^5 and R^a are as defined above;

iv) $-G-CO_2R^5$ wherein

10 G is $-CH_2-$, $-CH_2CH_2-$ or $-CH=CH-$, and

R^5 is as defined above;

v) $-CH=NOR^a$ wherein R^a is as defined above;

vi) $-CS_2R^5$ wherein R^5 is as defined above;

vii) $-COSR^5$ wherein R^5 is as defined above;

15


viii) $-O(CH_2)_n - \begin{matrix} O \\ || \\ P \\ | \\ OR^b \end{matrix} OR^a$ wherein

n is 1 or 2,

20 R^a and R^b are independently hydrogen or

C₁-C₆ alkyl;

ix) $-\text{COR}^a$ wherein R^a is defined above; or



5

R^4 is hydrogen, halo, methyl or mono-, di- or tri-halomethyl.

29. A compound of claim 28 wherein:

10 Z is O or S;

R^A is

(a) a dihydro-3-oxathiinyl; a furanyl; a dihydro-furanyl, a thienyl, a dihydro-2-dithiinyl; or a dihydro-2-dioxinyl; which can be substituted by one to
15 three alkyl or alkoxyalkyl groups wherein the alkyl group is C_1-C_4 ; with the proviso that when the oxathiinyl group is substituted by methyl in the 2-position, R^1 and R^2 cannot both be hydrogen;


(b) a phenyl; or a phenyl substituted by a group
20 selected from a C_1-C_8 alkyl; a halogen; a C_1-C_8 haloalkyl; a C_1-C_8 alkylthio; a C_1-C_8 alkylthio; a carboxyl; an amino; a C_1-C_8 alkoxy; a C_1-C_8 alkoxy carbonyl; a hydroxyl; a C_1-C_8 alkylcarboxyl; a phenyl or a phenoxy group;

- (c) a linear or branched C₁-C₈ alkyl; a C₂-C₈ alkenyl; a C₂-C₈ alkynyl; a C₁-C₈ alkoxy; a C₂-C₈ alkenyloxy; a C₂-C₈ alkynyloxy; a C₃-C₈ cycloalkyloxy; a C₃-C₈ cycloalkylalkoxy; a C₁-C₈ alkylamino; C₃-C₇ cycloalkyl; C₃-C₇ cycloalkyl C₁-C₆ alkyl; C₃-C₇ cycloalkenyl unsubstituted or substituted by C₁-C₆ alkyl or a phenoxy group.

30. A compound of claim 27 having the formula:

10

(III)




wherein

15 Z is O or S;

 R⁶ is an alkyl or alkoxyalkyl wherein the alkyl groups are independently C₁-C₄ with the proviso that when the oxathiinyl group is substituted by methyl or ethyl in the ortho position, R¹ and R² cannot both be
20 hydrogen.

31. A compound of claim 30 having the formula:

(IV)



wherein

Z is O or S;

R¹ is a hydrogen, a fluoro or a methyl group;


10 R² is a hydrogen, a chloro, a fluoro or a methyl group;

R³ is COOR₅ wherein R₅ is an alkyl group of 1 to 6 carbon atoms;


R⁴ is hydrogen; and

15 R⁶ is a methyl, ethyl or propyl group with the proviso that when R⁶ is methyl, R¹ and R² cannot both be hydrogen.

32. A compound according to claim 27 wherein said compound has the formula:



or



wherein Z is O or S, R⁷ and R⁸ are independently a hydrogen or a methyl; R¹⁸ is hydrogen, methyl or ethyl;

R¹ is hydrogen, halo or C₁-C₄ alkyl or C₁-C₄ alkoxy;

R² is hydrogen, halogen, C₁-C₄ alkyl, C₁-C₄ alkoxy,

hydroxy, mono-, di- or tri-halomethyl, trifluoro-methoxy, methylthio, nitro, cyano, acetoxy or dimethylamino;

R³ is

i) - $\text{SO}_2\text{NR}^a\text{R}^b$ wherein R^a and R^b are independently hydrogen or $\text{C}_1\text{-C}_6$ alkyl or together form a heterocycle wherein the heterocyclic moiety is morpholinyl, piperidinyl, pyrrolidinyl or piperazinyl;

ii) $-\text{CO}_2\text{R}^5$ wherein

R^5 is an alkyl, a $\text{C}_3\text{-C}_6$ alkenyl or alkynyl, a one to six haloalkyl, an alkoxyalkyl, an alkylthioalkyl, a carboxyalkyl, an alkylcarboxyalkyl, a $\text{C}_6\text{-C}_{12}$ arylcarboxyalkyl, an alkylaminoalkyl or dialkylaminoalkyl, a trialkylsilylalkyl, each of the aforementioned alkyl moieties having from one to eight carbon atoms; a phenyl, a naphthyl, a $\text{C}_1\text{-C}_6$ alkylphenyl, a $\text{C}_7\text{-C}_{12}$ arylalkyl or alkarylalkyl, a $\text{C}_3\text{-C}_8$ carbocyclyl, a $\text{C}_1\text{-C}_4$ alkyl $\text{C}_3\text{-C}_8$ carbocyclyl, or a heterocyclylalkyl, wherein the heterocyclic moiety is morpholinyl, piperidinyl, pyrrolidinyl, piperazinyl, oxiranyl, oxetanyl, furanyl or tetrahydrofuranyl;

iii) $-(\text{CH}_2)_{n^3}-\text{Y}-\text{R}^d$ wherein

n^3 is 0 or 1;

Y is O, S, SO, SO_2 or NH; and

R^d is $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_3\text{-C}_6$ cycloalkyl, $\text{C}_2\text{-C}_6$ alkenyl, $\text{C}_2\text{-C}_6$ alkynyl, $-\text{CH}_2\text{CO}_2\text{R}^5$, $-\text{CO}_2\text{R}^5$ with the proviso that Y cannot be

SO₂, or -COR^a wherein

R⁵ and R^a are as defined above;

iv) -G-CO₂R⁵ wherein

G is -CH₂-, -CH₂CH₂- or -CH=CH-, and

5

R⁵ is as defined above;

v) -CH=NOR^a wherein R^a is as defined above;

vi) -CS₂R⁵ wherein R⁵ is as defined above;

vii) -COSR⁵ wherein R⁵ is as defined above;

10

viii) - O(CH₂)_n - $\begin{array}{c} \text{O} \\ \parallel \\ \text{P} \\ \diagup \text{OR}^a \\ \diagdown \text{OR}^b \end{array}$ wherein

n is 1 or 2,


R^a and R^b are independently hydrogen or

15

C₁-C₆ alkyl;

ix) -COR^a wherein R^a is defined above; and

x)



20

R⁴ is hydrogen, halo, methyl or mono-, di- or tri-halomethyl.


33. A compound according to claim 32 wherein

R^1 and R^4 are hydrogen;

R^2 is halo; and

R^3 is COOR^5 in which R^5 is $\text{C}_1\text{-C}_6$ alkyl.

5 34. A compound according to claim 27 wherein said compound has the formula:



wherein

Z is O or S;

R^1 is hydrogen, halo or $\text{C}_1\text{-C}_4$ alkyl or $\text{C}_1\text{-C}_4$ alkoxy;

15 R^2 is hydrogen, halogen, $\text{C}_1\text{-C}_4$ alkyl, $\text{C}_1\text{-C}_4$ alkoxy, hydroxy, mono-, di- or tri-halomethyl, trifluoromethoxy, methylthio, nitro, cyano, acetoxy or dimethylamino;

R^3 is

20 i) $-\text{SO}_2\text{NR}^a\text{R}^b$ wherein R^a and R^b are independently hydrogen or $\text{C}_1\text{-C}_6$ alkyl or together form a heterocycle wherein the heterocyclic moiety is morpholinyl, piperidinyl, pyrrolidinyl or piperazinyl;

ii) $-\text{CO}_2\text{R}^5$ wherein

5 R^5 is an alkyl, a $\text{C}_3\text{-C}_6$ alkenyl or alkynyl, a one to six haloalkyl, an alkoxyalkyl, an alkylthioalkyl, a carboxyalkyl, an alkylcarboxyalkyl, a $\text{C}_6\text{-C}_{12}$ arylcarboxyalkyl, an alkylaminoalkyl or dialkylaminoalkyl, a trialkylsilylalkyl, each of the alkyl moieties having from one to eight carbon atoms; a phenyl, a $\text{C}_1\text{-C}_6$ alkylphenyl, a naphthyl, a $\text{C}_1\text{-C}_6$ alkylphenyl, a $\text{C}_7\text{-C}_{12}$ arylalkyl or alkarylalkyl, a $\text{C}_3\text{-C}_8$ carbocyclyl, a $\text{C}_1\text{-C}_4$ alkyl $\text{C}_3\text{-C}_8$ carbocyclyl, or a heterocyclyl-alkyl, wherein the heterocyclic moiety is
10 morpholinyl, piperidinyl, pyrrolidinyl, piperazinyl, oxiranyl, oxetanyl, furanyl or tetrahydrofuranyl;

iii) $-(\text{CH}_2)_{n^3}\text{-Y-R}^d$ wherein

n^3 is 0 or 1;
20 Y is O, S, SO, SO_2 or NH; and R^d is $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_3\text{-C}_6$ cycloalkyl, $\text{C}_2\text{-C}_6$ alkenyl, $\text{C}_2\text{-C}_6$ alkynyl, $-\text{CH}_2\text{CO}_2\text{R}^5$, $-\text{CO}_2\text{R}^5$ with the proviso that Y cannot be SO_2 , or $-\text{COR}^a$ wherein


25 R^5 and R^a are as defined above;

iv) $-\text{G-CO}_2\text{R}^5$ wherein

G is $-\text{CH}_2-$, $-\text{CH}_2\text{CH}_2-$ or $-\text{CH}=\text{CH}-$, and R^5 is as defined above;

- v) $-\text{CH}=\text{NOR}^a$ wherein R^a is as defined above;
 vi) $-\text{CS}_2\text{R}^5$ wherein R^5 is as defined above;
 vii) $-\text{COSR}^5$ wherein R^5 is as defined above;

5




n is 1 or 2,

R^a and R^b are independently hydrogen or
 10 $\text{C}_1\text{-C}_6$ alkyl;

- ix) $-\text{COR}^a$ wherein R^a is defined above; and

15




R^4 is hydrogen, halo, methyl or mono-, di- or
 tri-halomethyl;

R^{10} , R^{11} , R^{12} , and R^{13} are independently hydrogen
 or halogen; and

20 $-\text{R}^{14}$ is hydrogen; a halogen; a $\text{C}_1\text{-C}_4$ alkyl; a $\text{C}_1\text{-C}_4$
 alkoxy; a $\text{C}_1\text{-C}_4$ haloalkyl; a $\text{C}_1\text{-C}_4$ alkylthio; an amino;
 $\text{C}_1\text{-C}_8$ alkylcarbonylamino, a hydroxyl; an acetyl; an
 acetyloxy; or acetylamino.

35. A compound according to claim 34 wherein R^1 is hydrogen or fluoro; R^{10} , R^{11} , R^{12} , and R^{13} are hydrogen; R^{14} is hydrogen, methyl, ethyl, a chloro, an iodo, an amino, a bromo, a fluoro, a methylthio, a methoxy, or a hydroxyl.

36. A compound according to claim 27 wherein said compound has the formula:



wherein

15 Z is O or S;
 R^1 is hydrogen, halo or C_1 - C_4 alkyl or C_1 - C_4 alkoxy;
 R^2 is hydrogen, halogen, C_1 - C_4 alkyl, C_1 - C_4 alkoxy, hydroxy, mono-, di- or tri-halomethyl, trifluoromethoxy, methylthio, nitro, cyano, acetoxy or dimethylamino;

R^3 is


20 i) $-SO_2NR^aR^b$ wherein R^a and R^b are independently hydrogen or C_1 - C_6 alkyl or together form a heterocycle wherein the heterocyclic moiety is morpholinyl, piperidinyl, pyrrolidinyl or piperazinyl;

ii) $-CO_2R^5$ wherein

R^5 is an alkyl, a C_3 - C_6 alkenyl or alkynyl, a one to six haloalkyl, an

- alkoxyalkyl, an alkylthioalkyl, a
carboxyalkyl, an alkylcarboxyalkyl, a
C₆-C₁₂ arylcarboxyalkyl, an alkylaminoalkyl
or dialkylaminoalkyl, a trialkylsilylalkyl,
5 each of the aforementioned alkyl moieties
having from one to eight carbon atoms; a
phenyl, a naphthyl, a C₁-C₆ alkylphenyl, a
C₇-C₁₂ arylalkyl or alkarylalkyl, a C₃-C₈
carbocyclyl, a C₁-C₄ alkyl C₃-C₈
10 carbocyclyl, or a heterocyclylalkyl,
wherein the heterocyclic moiety is
morpholinyl, piperidinyl, pyrrolidinyl,
piperazinyl, oxiranyl, oxetanyl, furanyl or
tetrahydrofuranyl;
- 15 iii) $-(CH_2)_{n^3}-Y-R^d$ wherein
 n^3 is 0 or 1;
 Y is O, S, SO, SO₂ or NH; and
 R^d is C₁-C₆ alkyl, C₃-C₆ cycloalkyl,
 C₂-C₆ alkenyl, C₂-C₆ alkynyl, -CH₂CO₂R⁵,
20 -CO₂R⁵ with the proviso that Y cannot be
 SO₂, or -COR^a wherein
 R⁵ and R^a are as defined above;
- iv) -G-CO₂R⁵ wherein
 G is -CH₂-, -CH₂CH₂- or -CH=CH-, and
25 R⁵ is as defined above;
- v) -CH=NOR^a wherein R^a is as defined above;
- vi) -CS₂R⁵ wherein R⁵ is as defined above;
- vii) -COSR⁵ wherein R⁵ is as defined above;

-166-



5

n is 1 or 2,


R^a and R^b are independently hydrogen or

C_1-C_6 alkyl;

ix) $-COR^a$ wherein R^a is defined above; and

10

x)



R^4 is hydrogen, halo, methyl or mono-, di- or tri-halomethyl.

15


37. A compound according to claim 36 wherein

R^1 and R^4 are hydrogen; and

R^3 is $COOR^5$.

20

38. A compound according to claim 27 wherein said compound has the formula:



5

wherein R¹⁵ is a linear or branched C₃-C₆ alkyl; a C₂-C₆ alkenyl or alkynyl; a C₇-C₈ aralkyl or aryloxyalkyl; a C₁-C₈ alkoxy; a C₂-C₈ alkenyloxy or alkynyloxy; a C₁-C₈ aryloxy; C₃-C₇ cycloalkyl; C₃-C₇ cycloalkyl C₁-C₆ alkyl; C₃-C₇ cycloalkenyl unsubstituted or substituted by C₁-C₆ alkyl; a C₃-C₈ cycloalkyloxy, cycloalkylalkyloxy, cycloalkylaryloxy or alkylamino;

Z is O or S;

R¹ is hydrogen, halo or C₁-C₄ alkyl or C₁-C₄ alkoxy;

15 R² is hydrogen, halogen, C₁-C₄ alkyl, C₁-C₄ alkoxy, hydroxy, mono-, di- or tri-halomethyl, trifluoromethoxy, methylthio, nitro, cyano, acetoxy or dimethylamino;


R³ is

20 i) - SO₂NR^aR^b wherein R^a and R^b are independently hydrogen or C₁-C₆ alkyl or together form a heterocycle wherein the heterocyclic moiety is morpholinyl, piperidinyl, pyrrolidinyl or piperazinyl;

25 ii) -CO₂R⁵ wherein


R⁵ is an alkyl, a C₃-C₆ alkenyl or alkynyl, a one to six haloalkyl, an

- alkoxyalkyl, an alkylthioalkyl, a
carboxyalkyl, an alkylcarboxyalkyl, a
C₆-C₁₂ arylcarboxyalkyl, an alkylaminoalkyl
or dialkylaminoalkyl, a trialkylsilylalkyl,
each of the aforementioned alkyl moieties
having from one to eight carbon atoms; a
phenyl, a naphthyl, a C₁-C₆ alkylphenyl, a
C₇-C₁₂ arylalkyl or alkarylalkyl, a C₃-C₈
carbocyclyl, a C₁-C₄ alkyl C₃-C₈
carbocyclyl, or a heterocyclylalkyl,
wherein the heterocyclic moiety is
morpholinyl, piperidinyl, pyrrolidinyl,
piperazinyl, oxiranyl, oxetanyl, furanyl or
tetrahydrofuranyl;
- iii) $-(CH_2)_{n^3}-Y-R^d$ wherein
 n^3 is 0 or 1;
Y is O, S, SO, SO₂ or NH; and
 R^d is C₁-C₆ alkyl, C₃-C₆ cycloalkyl,
C₂-C₆ alkenyl, C₂-C₆ alkynyl, -CH₂CO₂R⁵,
-CO₂R⁵ with the proviso that Y cannot be
SO₂, or -COR^a wherein
R⁵ and R^a are as defined above;
- iv) $-G-CO_2R^5$ wherein
G is -CH₂-, -CH₂CH₂- or -CH=CH-, and
R⁵ is as defined above;
- v) -CH=NOR^a wherein R^a is as defined above;
- vi) -CS₂R⁵ wherein R⁵ is as defined above;
- vii) -COSR⁵ wherein R⁵ is as defined above;



- 5 n is 1 or 2,
 R^a and R^b are independently hydrogen or
 $\text{C}_1\text{-C}_6$ alkyl;
 ix) $-\text{COR}^a$ wherein R^a is defined above; and

10



R^4 is hydrogen, halo, methyl or mono-, di- or
 tri-halomethyl.

15

39. A compound according to claim 38 wherein
 R^1 is hydrogen or a fluoro;
 R^3 is COOR^5 ;
 R^4 is hydrogen; and
 20 R^{15} is a $\text{C}_3\text{-C}_6$ alkyl; a $\text{C}_2\text{-C}_6$ alkenyl or alkynyl; a
 $\text{C}_7\text{-C}_8$ phenylalkyl or phenoxyalkyl; a $\text{C}_1\text{-C}_8$ alkoxy; a
 $\text{C}_2\text{-C}_8$ alkenyloxy or alkynyloxy; phenoxy; $\text{C}_3\text{-C}_7$
 cycloalkyl; $\text{C}_3\text{-C}_7$ cycloalkyl $\text{C}_1\text{-C}_6$ alkyl; $\text{C}_3\text{-C}_7$
 cycloalkenyl unsubstituted or substituted by $\text{C}_1\text{-C}_6$


-170-

alkyl; C₃-C₈ cycloalkoxy or cycloalkylalkyloxy;
cycloalkylphenyloxy or alkylamino.

40. A compound according to claim 39 wherein R¹⁵
5 is C₃-C₆ cycloalkyl or cycloalkenyl.

41. A compound according to claim 40 wherein R¹
and R⁴ are hydrogen and R³ is COOR⁵.

42. A compound according to claim 27 wherein said
10 compound has the formula



wherein

Z is O or S;

R¹ is hydrogen, halo or C₁-C₄ alkyl or C₁-C₄ alkoxy;

20 R² is hydrogen, halogen, C₁-C₄ alkyl, C₁-C₄ alkoxy,
hydroxy, mono-, di- or tri-halomethyl,
trifluoromethoxy, methylthio, nitro, cyano, acetoxy
or dimethylamino;

R³ is

25 i) - SO₂NR^aR^b wherein R^a and R^b are independently
hydrogen or C₁-C₆ alkyl or together form a

heterocycle wherein the heterocyclic moiety is morpholinyl, piperidinyl, pyrrolidinyl or piperazinyl;

ii) $-\text{CO}_2\text{R}^5$ wherein

5 R^5 is an alkyl, a $\text{C}_3\text{-C}_6$ alkenyl or alkynyl, a one to six haloalkyl, an alkoxyalkyl, an alkylthioalkyl, a carboxyalkyl, an alkylcarboxyalkyl, a $\text{C}_6\text{-C}_{12}$ arylcarboxyalkyl, an alkylaminoalkyl or dialkylaminoalkyl, a trialkylsilylalkyl, each of the aforementioned alkyl moieties having from one to eight carbon atoms; a phenyl, a naphthyl, a $\text{C}_1\text{-C}_6$ alkylphenyl, a $\text{C}_7\text{-C}_{12}$ arylalkyl or alkarylalkyl, a $\text{C}_3\text{-C}_8$ carbocyclyl, a $\text{C}_1\text{-C}_4$ alkyl $\text{C}_3\text{-C}_8$ carbocyclyl, or a heterocyclylalkyl, wherein the heterocyclic moiety is morpholinyl, piperidinyl, pyrrolidinyl, piperazinyl, oxiranyl, oxetanyl, furanyl or tetrahydrofuranyl;

10

15

20

iii) $-(\text{CH}_2)_{n^3}\text{-Y-R}^d$ wherein

n^3 is 0 or 1;

Y is O, S, SO, SO_2 or NH; and

R^d is $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_3\text{-C}_6$ cycloalkyl, $\text{C}_2\text{-C}_6$ alkenyl, $\text{C}_2\text{-C}_6$ alkynyl, $-\text{CH}_2\text{CO}_2\text{R}^5$, $-\text{CO}_2\text{R}^5$ with the proviso that Y cannot be SO_2 , or $-\text{COR}^a$ wherein

25

R^5 and R^a are as defined above;

-172-

iv) $-G-CO_2R^5$ wherein

G is $-CH_2-$, $-CH_2CH_2-$ or $-CH=CH-$, and

R^5 is as defined above;

v) $-CH=NOR^a$ wherein R^a is as defined above;

5 vi) $-CS_2R^5$ wherein R^5 is as defined above;

vii) $-COSR^5$ wherein R^5 is as defined above;

viii) $-O(CH_2)_n - \begin{matrix} O \\ || \\ P \\ \backslash \\ OR^b \end{matrix} \begin{matrix} OR^a \end{matrix}$ wherein

10


n is 1 or 2,

R^a and R^b are independently hydrogen or

C_1-C_6 alkyl;

ix) $-COR^a$ wherein R^a is defined above; and

15



R^4 is hydrogen, halo, methyl or mono-, di- or

20 tri-halomethyl.

43. A compound according to claim 42 wherein

R^1 and R^4 are hydrogen;

R^2 is hydrogen or a chloro; and

R^3 is a C_2-C_6 alkoxycarbonyl.

25

44. A compound of claim 30, wherein said compound is selected from the group consisting of:

- (1) 1-methylethyl 2-chloro-5-[(5,6-dihydro-2-methyl-1,4-oxathiin-3-yl)carbonyl]amino]benzoate;
- 5 (2) 1-methylethyl 2-chloro-5-[(5,6-dihydro-2-methyl-1,4-oxathiin-3-yl)carbonyl]amino-4-fluorobenzoate;
- (3) methyl 2-chloro-5-[(5,6-dihydro-2-methyl-1,4-oxathiin-3-yl)carbonyl]amino]benzoate;
- (4) propyl 2-chloro-5-[(5,6-dihydro-2-methyl-1,4-oxathiin-3-yl)carbonyl]amino]benzoate;
- 10 (5) butyl 2-chloro-5-[(5,6-dihydro-2-methyl-1,4-oxathiin-3-yl)carbonyl]amino]benzoate;
- (6) 1-methylethyl 2-chloro-5-[(2-ethyl-5,6-dihydro-1,4-oxathiin-3-yl)carbonyl]amino]benzoate;
- 15 (7) 1-methylethyl 3-[(5,6-dihydro-2-methyl-1,4-oxathiin-3-yl)carbonyl]amino]benzoate;
- (8) ethyl 2-chloro-5-[(2-ethyl-5,6-dihydro-1,4-oxathiin-3-yl)carbonyl]amino]benzoate;
- (9) 1-methylethyl 5-[(5,6-dihydro-2-methyl-1,4-oxathiin-3-yl)carbonyl]amino]-4-fluoro-2-methylbenzoate;
- 20 (10) 1-methylethyl 3-[(5,6-dihydro-2-methyl-1,4-oxathiin-3-yl)carbonyl]amino]-4-fluorobenzoate;
- (11) ethyl 3-[(5,6-dihydro-2-methyl-1,4-oxathiin-3-yl)carbonyl]amino]-4-methylbenzoate;
- 25 (12) pentyl 2-chloro-5-[(5,6-dihydro-2-methyl-1,4-oxathiin-3-yl)carbonyl]amino]benzoate; and
- (13) ethyl 2-chloro-5-[(5,6-dihydro-2-methyl-1,4-oxathiin-3-yl)carbonyl]amino]benzoate;

(14) 2-methoxyethyl 2-chloro-5-[[5,6-dihydro-2-methyl-1,4-oxathiin-3-yl)carbonyl]amino]benzoate;

(15) ethyl 2-chloro-5-[[5,6-dihydro-2-propyl-1,4-oxathiin-3-yl)carbonyl]amino]benzoate;

5 (16) methyl 2-chloro-5-[[5,6-dihydro-2-propyl-1,4-oxathiin-3-yl)carbonyl]amino]benzoate;

(17) 1-methylethyl 5-[[5,6-dihydro-2-methyl-1,4-oxathiin-3-yl)carbonyl]amino]-2-fluorobenzoate;

10 (18) 1-methylethyl 5-[[5,6-dihydro-2-methyl-1,4-oxathiin-3-yl)carbonyl]amino]-2-methylbenzoate;

(19) 2-methylpropyl 2-chloro-5-[[2-ethyl-5,6-dihydro-1,4-oxathiin-3-yl)carbonyl]amino]benzoate; and

(20) 1-methylethyl 5[[5,6-dihydro-2-methyl-1,4-oxathiin-3-yl)carbonyl]amino]-2,4-difluorobenzoate.

15 45. A compound of claim 32 wherein said compound is selected from the group consisting of:

(1) 1-methylethyl 2-chloro-5-[[2,4,5-trimethyl-3-furanyl)carbonyl]amino]benzoate; and

20 (2) 1-methylethyl 2-chloro-5-[[3-methyl-2-furanyl)carbonyl]amino]benzoate;

(3) 1-methylethyl 2-chloro-5-[[2,4-dimethyl-3-furanyl)carbonyl]amino]benzoate;

(4) 1-methylethyl 2-chloro-5-[[2-methyl-3-furanyl)carbonyl]amino]benzoate;

25 (5) 1-methylethyl 2-chloro-5-[[2,5-dimethyl-3-furanyl)carbonyl]amino]benzoate;

(6) 1-methylethyl 2-chloro-5-[[2,4,5-trimethyl-3-furanyl)thioxomethyl]amino]benzoate;

(7) 1-methylethyl 2-chloro-5-[[[2-methyl-3-furanyl)thioxomethyl]amino]benzoate; and

(8) 1-methylethyl 2-chloro-5-[[[2,5-dimethyl-3-furanyl)thioxomethyl]amino]benzoate.

5

46. A compound of claim 34 wherein said compound is selected from the group consisting of:

(1) 1-methylethyl 5-(benzoylamino)-2-chloro-4-fluorobenzoate;

10 (2) 1-methylethyl 2-chloro-5-[(2-methoxybenzoyl)amino]benzoate;

(3) 1-methylethyl 2-chloro-5-[(2-methylbenzoyl)amino]benzoate;

(4) propyl 2-chloro-5-[(2-methylbenzoyl)amino]benzoate;

(5) 1-methylethyl 2-chloro-5-[(2-fluorobenzoyl)amino]benzoate;

(6) 1-methylethyl 2-chloro-5-[(2-iodobenzoyl)amino]benzoate;

20 (7) 1-methylethyl 5-[(2-bromobenzoyl)amino]-2-chlorobenzoate;

(8) ethyl 2-chloro-5-[(2-methoxybenzoyl)amino]benzoate;

(9) ethyl 5-[(2-aminobenzoyl)amino]-2-chlorobenzoate; and

25 (10) 1-methylethyl 5-(benzoylamino)-2-chlorobenzoate.

47. A compound of claim 36 wherein said compound is: 1-methylethyl 2-chloro-5-[[[(5,6-dihydro-3-methyl-1,4-dioxin-2-yl)carbonyl]amino]benzoate.

5 48. A compound of claim 38 wherein said compound is (1) 1-methylethyl 2-chloro-5-[[[(1-methylethoxy)carbonyl]amino]benzoate or (2) 1-methylethyl 5-[(butoxycarbonyl)amino]-2-chlorobenzoate.

10 49. A compound of claim 42 wherein said compound is 1-methylethyl 2-chloro-5-[[[(5,6-dihydro-3-methyl-1,4-dithiin-2-yl)carbonyl]amino]benzoate.

15 50. A compound of claim 27 wherein said compound is selected from the group consisting of:

(1) 1-methylethyl 2-chloro-5-[[[(1-methylethoxy)thioxomethyl]amino]benzoate;

(2) 1-methylethyl 2-chloro-5-[(ethoxythioxomethyl)amino]benzoate;

20 (3) 1-methylethyl 5-[(butoxythioxymethyl)amino]-2-chlorobenzoate;

(4) 1-methylethyl 2-chloro-5-[(propoxythioxomethyl)amino]benzoate;

25 (5) 1-methylethyl 2-chloro-5-[[[(pentyloxy)thioxomethyl]amino]benzoate;

(6) 1-methylethyl 2-chloro-5-[[[(2-propenyloxy)thioxomethyl]amino]benzoate;

(7) 1-methylethyl 2-chloro-5-[[[(2-cyclohexen-1-yloxy)thioxomethyl]amino]benzoate;

(8) 1-methylethyl 2-chloro-5-[[[(cyclohexyloxy)thioxomethyl]amino]benzoate;

5 (9) 1-methylethyl 2-chloro-5-[[[(cyclopropylmethoxy)thioxomethyl]amino]benzoate; and

(10) 1-methylethyl 2-chloro-5-[[[(2-methoxyethoxy)thioxomethyl]amino]benzoate.

10 51. A compound of claim 27, which comprises a compound selected from the group consisting of:

(1) 1-methylethyl 2-chloro-5-[(3-methyl-2-thienylcarbonyl)amino]benzoate;

(2) 1-methylethyl 2-chloro-5-[(phenylthio-
15 methyl)amino]benzoate;

(3) cyclopentyl 2-chloro-5-[[[(2-methoxyphenyl)-amino]carbonyl]amino]benzoate;

(4) 1-methylethyl
2-chloro-5-[[[(1-methylethoxy)methylthio]methylene]amino]
20 benzoate; and

(5) 1-methylethyl 2-chloro-5-[[[(1-methylethoxy)propylthio]methylene]amino]benzoate.

52. The intermediate compound 2-chloro-5-[[[(1-methylethoxy)thioxomethyl]amino]benzoic acid.
25

53. A pharmaceutical formulation for inhibiting the growth or replication of HIV which comprises an effective amount of the compound of claim 27 in a pharmaceutically acceptable carrier.






FIG.-1

FIG.-2FIG.-3

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 90/05760

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁸ According to International Patent Classification (IPC) or to both National Classification and IPC C 07 C 233/81; IPC ⁵ : C 07 D 327/06, 319/12, 339/08, 307/68, C 07 C 333/08; 275/34, C 07 D 333/38, C 07 F 9/24, A 61 K 31/38																				
II. FIELDS SEARCHED <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black;">Minimum Documentation Searched ⁷</div> <table style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 20%; text-align: left; border-bottom: 1px solid black;">Classification System</th> <th style="text-align: left; border-bottom: 1px solid black;">Classification Symbols</th> </tr> <tr> <td style="vertical-align: top; border-right: 1px solid black; padding: 5px;">IPC⁵</td> <td style="padding: 5px;">C 07 D 327/00, 319/00, 339/00, 307/00, C 07 C 233/00, 333/00, 275/00, C 07 D 333/00, C 07 F 9/00, C 7 D 263/00</td> </tr> </table> <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black;">Documentation Searched other than Minimum Documentation to the Extent that such Documents are included in the Fields Searched ⁸</div>			Classification System	Classification Symbols	IPC ⁵	C 07 D 327/00, 319/00, 339/00, 307/00, C 07 C 233/00, 333/00, 275/00, C 07 D 333/00, C 07 F 9/00, C 7 D 263/00														
Classification System	Classification Symbols																			
IPC ⁵	C 07 D 327/00, 319/00, 339/00, 307/00, C 07 C 233/00, 333/00, 275/00, C 07 D 333/00, C 07 F 9/00, C 7 D 263/00																			
III. DOCUMENTS CONSIDERED TO BE RELEVANT ⁹ <table style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 10%; text-align: left; border-bottom: 1px solid black;">Category ⁹</th> <th style="text-align: left; border-bottom: 1px solid black;">Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²</th> <th style="width: 15%; text-align: left; border-bottom: 1px solid black;">Relevant to Claim No. ¹³</th> </tr> <tr> <td style="text-align: center; vertical-align: top; border-right: 1px solid black; padding: 5px;">X</td> <td style="padding: 5px;">EP, A, 0099822 (CARPIBEM) 1 February 1984 see pages 2,3,18-20 <div style="text-align: center;">---</div></td> <td style="vertical-align: top; border-right: 1px solid black; padding: 5px;">27-29,53</td> </tr> <tr> <td style="text-align: center; vertical-align: top; border-right: 1px solid black; padding: 5px;">X</td> <td style="padding: 5px;">EP, A, 0104070 (SUMITOMO) 28 March 1984 see claims <div style="text-align: center;">---</div></td> <td style="vertical-align: top; border-right: 1px solid black; padding: 5px;">27,38</td> </tr> <tr> <td style="text-align: center; vertical-align: top; border-right: 1px solid black; padding: 5px;">X</td> <td style="padding: 5px;">GB, A, 1451299 (BAYER AKTIENGESELLSCHAFT) 29 September 1976 see pages 6-23 <div style="text-align: center;">---</div></td> <td style="vertical-align: top; border-right: 1px solid black; padding: 5px;">27,38</td> </tr> <tr> <td style="text-align: center; vertical-align: top; border-right: 1px solid black; padding: 5px;">A</td> <td style="padding: 5px;">FR, A, 2143577 (UGINE KUHLMANN) 9 February 1973 see pages 1-7 <div style="text-align: center;">---</div></td> <td style="vertical-align: top; border-right: 1px solid black; padding: 5px;">34,53</td> </tr> <tr> <td style="text-align: center; vertical-align: top; border-right: 1px solid black; padding: 5px;">A</td> <td style="padding: 5px;">Chemical Abstracts, Volume 90, 1979, (Columbus, Ohio, US), G.A. White et al.: "Oxathiin ./. <div style="text-align: center;">---</div></td> <td style="vertical-align: top; border-right: 1px solid black; padding: 5px;">27-31,53</td> </tr> </table>			Category ⁹	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³	X	EP, A, 0099822 (CARPIBEM) 1 February 1984 see pages 2,3,18-20 <div style="text-align: center;">---</div>	27-29,53	X	EP, A, 0104070 (SUMITOMO) 28 March 1984 see claims <div style="text-align: center;">---</div>	27,38	X	GB, A, 1451299 (BAYER AKTIENGESELLSCHAFT) 29 September 1976 see pages 6-23 <div style="text-align: center;">---</div>	27,38	A	FR, A, 2143577 (UGINE KUHLMANN) 9 February 1973 see pages 1-7 <div style="text-align: center;">---</div>	34,53	A	Chemical Abstracts, Volume 90, 1979, (Columbus, Ohio, US), G.A. White et al.: "Oxathiin ./. <div style="text-align: center;">---</div>	27-31,53
Category ⁹	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³																		
X	EP, A, 0099822 (CARPIBEM) 1 February 1984 see pages 2,3,18-20 <div style="text-align: center;">---</div>	27-29,53																		
X	EP, A, 0104070 (SUMITOMO) 28 March 1984 see claims <div style="text-align: center;">---</div>	27,38																		
X	GB, A, 1451299 (BAYER AKTIENGESELLSCHAFT) 29 September 1976 see pages 6-23 <div style="text-align: center;">---</div>	27,38																		
A	FR, A, 2143577 (UGINE KUHLMANN) 9 February 1973 see pages 1-7 <div style="text-align: center;">---</div>	34,53																		
A	Chemical Abstracts, Volume 90, 1979, (Columbus, Ohio, US), G.A. White et al.: "Oxathiin ./. <div style="text-align: center;">---</div>	27-31,53																		
<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; vertical-align: top; padding: 5px;"> ¹⁰ Special categories of cited documents: ¹⁰ "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed </td> <td style="width: 50%; vertical-align: top; padding: 5px;"> "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "A" document member of the same patent family </td> </tr> </table>			¹⁰ Special categories of cited documents: ¹⁰ "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "A" document member of the same patent family																
¹⁰ Special categories of cited documents: ¹⁰ "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "A" document member of the same patent family																			
IV. CERTIFICATION <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; border-bottom: 1px solid black; padding: 5px;">Date of the Actual Completion of the International Search</td> <td style="width: 50%; border-bottom: 1px solid black; padding: 5px;">Date of Mailing of this International Search Report</td> </tr> <tr> <td style="text-align: center; padding: 5px;">25th January 1991</td> <td style="text-align: center; padding: 5px;">14. 02. 91</td> </tr> <tr> <td style="border-bottom: 1px solid black; padding: 5px;">International Searching Authority</td> <td style="border-bottom: 1px solid black; padding: 5px;">Signature of Authorized Officer</td> </tr> <tr> <td style="text-align: center; padding: 5px;">EUROPEAN PATENT OFFICE</td> <td style="padding: 5px;"> <div style="border: 1px solid black; display: inline-block; padding: 2px;">M. PEIS</div> M. Peis </td> </tr> </table>			Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	25th January 1991	14. 02. 91	International Searching Authority	Signature of Authorized Officer	EUROPEAN PATENT OFFICE	<div style="border: 1px solid black; display: inline-block; padding: 2px;">M. PEIS</div> M. Peis										
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report																			
25th January 1991	14. 02. 91																			
International Searching Authority	Signature of Authorized Officer																			
EUROPEAN PATENT OFFICE	<div style="border: 1px solid black; display: inline-block; padding: 2px;">M. PEIS</div> M. Peis																			

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET PCT/ISA 10 (2)

carboxamides highly active against
carboxin-resistant succinic
dehydrogenase complexes from carboxin-
selected mutants of *ustilago maydis* and
aspergillus nidulans",
see page 170, abstract 17500u,
& Pestic. Biochem. Physiol. 1978, 9(2),
165-82

A FR, A, 2555179 (CARPIBEM)
24 May 1985
see pages 1-5; Claims

27,28,32,53

incompletely

V. ☒ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE¹

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☒ Claim numbers XX, because they relate to subject matter not required to be searched by this Authority, namely:

xx Claims 1 - 26

Pls. see Rule 39.1 (iv) - PCT:

Method for treatment of the human or animal body by surgery or therapy
as well as diagnostic methods.

2. ☒ Claim numbers XX, because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

xx Claims 27 - 29, 38 - 41 searched incompletely

Pls. see attached sheet ./.

3. ☐ Claim numbers, because they are dependent claims and are not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. ☐ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING²

This international Searching Authority found multiple inventions in this international application as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.
2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:
3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:
4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the international Searching Authority did not invite payment of any additional fee.

Remark on Protest

- ☐ The additional search fees were accompanied by applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM FORM PCT/ISA/210 (supplemental sheet (2))

The application does not comply with the requirements of Art. 6 - PCT : "... claims shall be clear and concise.". Indeed the only common structure is a phenyl group and the very long list of substituents with their often numerous significances with some disclaimers makes that the present application hardly meets the requirements of Art. 6. Therefore and for economical reasons, the search was based on the examples.

ANNEX TO THE INTERNATIONAL SEARCH REPORT ON INTERNATIONAL PATENT APPLICATION NO.

US 9005760

SA 41172

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 11/02/91. The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A- 0099822	01-02-84	FR-A, B 2530245	20-01-84
		FR-A, B 2546890	07-12-84
		AU-B- 566089	08-10-87
		AU-A- 1686883	19-01-84
		CA-A- 1205478	03-06-86
		JP-A, B 59073582	25-04-84
		US-A- 4668801	26-05-87
EP-A- 0104070	28-03-84	AU-B- 559739	19-03-87
		AU-A- 1919283	22-03-84
		CA-A- 1230884	29-12-87
		JP-A- 59073564	25-04-84
		JP-A- 59073506	25-04-84
		JP-A- 59051258	24-03-84
		JP-A- 59051208	24-03-84
GB-A- 1451299	29-09-76	DE-A- 2413258	02-10-75
		DE-A- 2445529	01-04-76
		AU-A- 7915675	23-09-76
		BE-A- 826851	19-09-75
		FR-A, B 2264804	17-10-75
		JP-A- 50126637	04-10-75
		JP-A- 50126828	06-10-75
		LU-A- 72082	04-02-76
FR-A- 2143577	09-02-73	NL-A- 7503351	23-09-75
		US-A- 3877926	15-04-75
		US-A- 3877927	15-04-75
		BE-A- 784792	02-10-72
		DE-A- 2229014	21-12-72
		FR-A- 2143717	09-02-73
		GB-A- 1394891	21-05-75
		LU-A- 65509	20-10-72
		NL-A- 7208197	19-12-72
		OA-A- 4106	15-11-79
		DE-A- 2229036	21-12-72
		NL-A- 7208194	19-12-72
		AT-B- 320338	10-02-75
		AU-B- 466717	20-12-73

ANNEX TO THE INTERNATIONAL SEARCH REPORT ON INTERNATIONAL PATENT APPLICATION NO.

US 9005760

SA 41172

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 11/02/91
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
FR-A- 2143577		AU-A- 4333172	20-12-73
		CA-A- 980360	23-12-75
		DE-A- 2229013	30-05-73
		JP-A- 48058132	15-08-73
		NL-A- 7208199	28-05-73
		US-A- 3962307	08-06-76
		US-A- 4013704	22-03-77
		US-I- B573991	30-03-76
<hr/>			
FR-A- 2555179	24-05-85	None	
<hr/>			

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☐ BLACK BORDERS

☒ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES

☐ FADED TEXT OR DRAWING

☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING

☐ SKEWED/SLANTED IMAGES

☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS

☐ GRAY SCALE DOCUMENTS

☒ LINES OR MARKS ON ORIGINAL DOCUMENT

☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.